

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 9

September 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	viii
1.7 Cumulative Supplement Legend	ix
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 9
September 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS) (ABBOTT)	ABBVIE INC (ABBVIE) (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ABRAXIX PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)

APP PHARMACEUTICALS (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
APP PHARMACEUTICALS LLC (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
NEXUS PHARMACEUTICALS (NEXUS PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)
ROSS LABORATORIES DIV ABBOTT LABORATORIES (ROSS LABS)	ABBVIE INC (ABBVIE)
SOLVAY PHARMACEUTICALS (SOLVAY)	ABBVIE INC (ABBVIE)
UNIMED PHARMACEUTICALS INC (UNIMED PHARMS)	ABBVIE INC (ABBVIE)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001

SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834	15160	
SINGLE SOURCE	2451	2446	2428	2429	
	(16.9%)	(16.6%)	(16.4%)	(16.0%)	
MULTISOURCE	11953	12187	12328	12653	
	(82.5%)	(82.8%)	(83.1%)	(83.5%)	
THERAPEUTICALLY EQUIVALENT	11792	12037	12187	12509	
	(81.4%)	(81.8%)	(82.2%)	(82.5%)	
NOT THERAPEUTICALLY EQUIVALENT	161	150	141	144	
	(1.1%)	(1.0%)	(1.0%)	(0.9%)	
EXCEPTIONS ¹	76	78	78	78	
	(0.5%)	(0.5%)	(0.5%)	(0.5%)	
NEW MOLECULAR ENTITIES					
APPROVED	6	8	7	9	
NUMBER OF APPLICANTS	810	826	826	836	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
----	------------------	---------------	-------------	--------------	-----	------

ZIAGEN

AB	+ VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG
----	-----------------	---------------	-------------	--------------	-----	------

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
----	-------------------	------	-------------	--------------	-----	------

AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
----	--	------	-------------	--------------	-----	------

AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

+	MIKART	325MG;50MG	A089987 001	Oct 26, 1992	Jun	CRLD
---	--------	------------	-------------	--------------	-----	------

PHRENILIN

@	VALEANT	325MG;50MG	A087811 001	Jun 19, 1985	Jun	DISC
---	---------	------------	-------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	LANNETT HOLDINGS INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012	Aug	NEWA
----	----------------------	-----------------	-------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012	Jul	NEWA
--	-------------------	----------------------	-------------	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
----	---------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

CAPITAL AND CODEINE

+	VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
---	---------	--------------------	-------------	--	-----	------

+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001		Jun	CAHN
---	--------------------	--------------------	-------------	--	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002	Jun	DISC
--	-----------------	-----------------------	-------------	--------------	-----	------

AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
----	------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
----	---------------------	-----------	-------------	--------------	-----	------

AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
----	--	-------------	-------------	--------------	-----	------

AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA
----	--	------------	-------------	--------------	-----	------

>D>	@ ENDO PHARMS	500MG;5MG	A040281 001	Sep 30, 1998	Sep	CAHN
-----	---------------	-----------	-------------	--------------	-----	------

>D>	@	500MG;7.5MG	A040280 001	Sep 30, 1998	Sep	CAHN
-----	---	-------------	-------------	--------------	-----	------

>D>	@	650MG;7.5MG	A040280 002	Sep 30, 1998	Sep	CAHN
-----	---	-------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>		@ ENDO PHARMS	650MG;10MG	A040280	003	Sep 30,	1998	Sep	CAHN
>D>		@	750MG;7.5MG	A040281	002	Sep 30,	1998	Sep	CAHN
>A>		@ VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30,	1998	Sep	CAHN
>A>		@	500MG;7.5MG	A040280	001	Sep 30,	1998	Sep	CAHN
>A>		@	650MG;7.5MG	A040280	002	Sep 30,	1998	Sep	CAHN
>A>		@	650MG;10MG	A040280	003	Sep 30,	1998	Sep	CAHN
>A>		@	750MG;7.5MG	A040281	002	Sep 30,	1998	Sep	CAHN

VICODIN

>D>	AA	+	ABBOTT	500MG;5MG	A088058	001	Jan 07,	1983	Sep	CAHN
>A>	AA	+	ABBVIE	500MG;5MG	A088058	001	Jan 07,	1983	Sep	CAHN

VICODIN ES

>D>	AA	+	ABBOTT	750MG;7.5MG	A089736	001	Dec 09,	1988	Sep	CAHN
>A>	AA	+	ABBVIE	750MG;7.5MG	A089736	001	Dec 09,	1988	Sep	CAHN

VICODIN HP

>D>	AA		ABBOTT	660MG;10MG	A040117	001	Sep 23,	1996	Sep	CAHN
>A>	AA		ABBVIE	660MG;10MG	A040117	001	Sep 23,	1996	Sep	CAHN

ZYDONE

>D>		+	ENDO PHARMS	400MG;5MG	A040288	001	Nov 27,	1998	Sep	CAHN
>D>		+		400MG;7.5MG	A040288	002	Nov 27,	1998	Sep	CAHN
>D>		+		400MG;10MG	A040288	003	Nov 27,	1998	Sep	CAHN
>A>		+	VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27,	1998	Sep	CAHN
>A>		+		400MG;7.5MG	A040288	002	Nov 27,	1998	Sep	CAHN
>A>		+		400MG;10MG	A040288	003	Nov 27,	1998	Sep	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>		@ ENDO PHARMS	500MG;5MG	A040303	001	Dec 30,	1999	Sep	CAHN
>A>		@ VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30,	1999	Sep	CAHN

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

	AA		ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03,	2012	Mar	NEWA
	AA			325MG;10MG	A040800	002	Apr 03,	2012	Mar	NEWA
	AA		ALVOGEN INC	325MG;7.5MG	A202677	001	Jul 26,	2012	Jul	NEWA
	AA			325MG;10MG	A202677	002	Jul 26,	2012	Jul	NEWA

PERCOCET

>D>	AA	+	ENDO PHARMS	325MG;2.5MG	A040330	001	Jun 25,	1999	Sep	CAHN
>D>		@		325MG;5MG	A085106	002			Sep	CAHN
>D>	AA	+		325MG;5MG	A040330	002	Jun 25,	1999	Sep	CAHN
>D>	AA	+		325MG;7.5MG	A040434	001	Nov 23,	2001	Sep	CAHN
>D>	AA	+		325MG;10MG	A040434	002	Nov 23,	2001	Sep	CAHN
>D>	AA	+		500MG;7.5MG	A040341	001	Jul 26,	1999	Sep	CAHN
>D>	AA	+		650MG;10MG	A040341	002	Jul 26,	1999	Sep	CAHN
>A>	AA	+	VINTAGE PHARMS LLC	325MG;2.5MG	A040330	001	Jun 25,	1999	Sep	CAHN
>A>		@		325MG;5MG	A085106	002			Sep	CAHN
>A>	AA	+		325MG;5MG	A040330	002	Jun 25,	1999	Sep	CAHN
>A>	AA	+		325MG;7.5MG	A040434	001	Nov 23,	2001	Sep	CAHN
>A>	AA	+		325MG;10MG	A040434	002	Nov 23,	2001	Sep	CAHN
>A>	AA	+		500MG;7.5MG	A040341	001	Jul 26,	1999	Sep	CAHN
>A>	AA	+		650MG;10MG	A040341	002	Jul 26,	1999	Sep	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Mar	NEWA
AB	ZYDUS PHARMS USA INC	325MG;37.5MG	A090460	001	Sep 06, 2012	Aug	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Apr	NEWA
AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD
	DIAMOX						
	@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990	Apr	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA INC	20%	A203853	001	Jun 21, 2012	Jun	NEWA
----	----------------	-----	---------	-----	--------------	-----	------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

	+ FOREST LABS INC	0.375MG/INH	N202450	001	Jul 23, 2012	Jul	NEWA
--	-------------------	-------------	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC 200MG

A074889 001 Oct 31, 1997 May CAHN

TABLET; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC 400MG

A074891 001 Oct 31, 1997 May CAHN

@ 800MG

A074891 002 Oct 31, 1997 May CAHN

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB	TOLMAR	0.3%	A200298	001	Jun 14, 2012	Jun	NEWA
----	--------	------	---------	-----	--------------	-----	------

DIFFERIN

AB	+ GALDERMA LABS LP	0.3%	N021753	001	Jun 19, 2007	Jun	CFTG
----	--------------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

	+ GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	Apr	CAHN
--	--------------------	------	---------	-----	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@ TEVA PARENTERAL 3MG/ML

A078676 001 Jul 31, 2008 Mar DISC

@ 3MG/ML

A076564 001 Jun 16, 2004 Jan DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	AN	TEVA PARENTERAL	EQ 0.083% BASE	A075343 001	Nov 09, 1999	Sep	CAHN
>A>	AN	TEVA PHARMS	EQ 0.083% BASE	A075343 001	Nov 09, 1999	Sep	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>A>	AN	RITEDOSE CORP	EQ 0.083% BASE;0.017%	A202496 001	Oct 01, 2012	Sep	NEWA
		@ SANDOZ INC	EQ 0.083% BASE;0.017%	A076867 001	Dec 21, 2006	Apr	DISC
>D>	AN	TEVA PARENTERAL	EQ 0.083% BASE;0.017%	A076724 001	Dec 31, 2007	Sep	CAHN
>A>	AN	TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724 001	Dec 31, 2007	Sep	CAHN

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076973 001	Jul 12, 2005	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076884 001	Jul 18, 2005	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+		MISSION PHARMA	EQ 70MG BASE	N202344 001	Mar 12, 2012	Mar	NEWA
---	--	----------------	--------------	-------------	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	10MG	A079060 001	Aug 30, 2012	Aug	NEWA
AB		INVAGEN PHARMS	10MG	A090284 001	Jan 17, 2012	Jan	NEWA
AB		WOCKHARDT LTD	10MG	A090221 001	Aug 10, 2012	Jul	NEWA

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@		GENZYME	80 UNITS/ML	N020057 003	Apr 05, 1991	Mar	DISC
---	--	---------	-------------	-------------	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>D>	AB	ALPHAPHARM	0.25MG	A074046 001	Oct 19, 1993	Sep	CAHN
>D>	AB		0.5MG	A074046 002	Oct 19, 1993	Sep	CAHN
>D>	AB		1MG	A074046 003	Oct 19, 1993	Sep	CAHN
>D>	AB		2MG	A074046 004	May 07, 1997	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	0.25MG	A074046 001	Oct 19, 1993	Sep	CAHN
>A>	AB		0.5MG	A074046 002	Oct 19, 1993	Sep	CAHN
>A>	AB		1MG	A074046 003	Oct 19, 1993	Sep	CAHN
>A>	AB		2MG	A074046 004	May 07, 1997	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@		SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006	Mar	DISC
@			1MG	A077777 002	Jun 30, 2006	Mar	DISC
@			2MG	A077777 003	Jun 30, 2006	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC	3MG	A077777 004	Jun 30, 2006	Mar	DISC
@ VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007	Jul	DISC
@	1MG	A078442 002	Oct 15, 2007	Jul	DISC
@	2MG	A078442 003	Oct 15, 2007	Jul	DISC
@	3MG	A078442 004	Oct 15, 2007	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726 001	Jan 19, 2005	Jan	CAHN
AB		0.5MG	N021726 002	Jan 19, 2005	Jan	CAHN
AB	+	1MG	N021726 003	Jan 19, 2005	Jan	CAHN
AB		2MG	N021726 004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+	CUBIST PHARMS	12MG	N021775 001	May 20, 2008	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065 001	May 15, 2003	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

AMCINONIDE

+	FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096 001	Nov 19, 2002	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@	HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC
---	---------	-----------------	-------------	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15%(150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA
	15%(300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER					
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
NOVAMINE 15%					
@ HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@	CLOVER PHARMS	250MG/ML	N015229 002		Mar	CAHN
---	---------------	----------	-------------	--	-----	------

SYRUP; ORAL

AMICAR

AA	+	CLOVER PHARMS	1.25GM/5ML	N015230 002		Mar	CAHN
----	---	---------------	------------	-------------	--	-----	------

TABLET; ORAL

AMICAR

AB		CLOVER PHARMS	500MG	N015197 001		Mar	CAHN
+			1GM	N015197 002	Jun 24, 2004	Mar	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ BEDFORD 50MG/ML

A076018 001 Oct 15, 2002 Jun DISC

@ BEDFORD LABS 50MG/ML

A076299 001 Oct 24, 2002 Jun DISC

@ TEVA PARENTERAL 50MG/ML

A076163 001 Sep 05, 2003 Jan DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MURTY PHARMS 200MG

A077069 001 Apr 08, 2005 May CAHN

AB 400MG

A077069 002 Apr 08, 2005 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB CARACO 10MG

A040816 002 Jun 27, 2008 Apr NEWA

AB 50MG

A040816 003 Jun 27, 2008 Apr NEWA

AB 75MG

A040816 004 Jun 27, 2008 Apr NEWA

AB 100MG

A040816 005 Jun 27, 2008 Apr NEWA

AB 150MG

A040816 006 Jun 27, 2008 Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC EQ 12.5MG BASE;5MG

A071297 002 Dec 10, 1986 Feb CTEC

+ EQ 25MG BASE;10MG

A071297 001 Dec 10, 1986 Feb CRLD

LIMBITROL

@ VALEANT PHARM INTL EQ 12.5MG BASE;5MG

N016949 001 Feb DISC

LIMBITROL DS

@ VALEANT PHARM INTL EQ 25MG BASE;10MG

N016949 002 Feb DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB MACLEODS PHARMS LTD EQ 5MG BASE

A201380 001 Apr 13, 2012 Mar NEWA

AB EQ 10MG BASE

A201380 002 Apr 13, 2012 Mar NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 2.5MG BASE;10MG

A202239 001 Sep 05, 2012 Aug NEWA

AB EQ 5MG BASE;10MG

A202239 002 Sep 05, 2012 Aug NEWA

AB EQ 5MG BASE;20MG

A202239 003 Sep 05, 2012 Aug NEWA

AB EQ 5MG BASE;40MG

A202239 004 Sep 05, 2012 Aug NEWA

AB EQ 10MG BASE;20MG

A202239 005 Sep 05, 2012 Aug NEWA

AB EQ 10MG BASE;40MG

A202239 006 Sep 05, 2012 Aug NEWA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

>D> NOVARTIS 5MG;12.5MG;160MG

N022314 001 Apr 30, 2009 Sep CFTG

>A> AB 5MG;12.5MG;160MG

N022314 001 Apr 30, 2009 Sep CFTG

>D> 5MG;25MG;160MG

N022314 002 Apr 30, 2009 Sep CFTG

>A> AB 5MG;25MG;160MG

N022314 002 Apr 30, 2009 Sep CFTG

>D> 10MG;12.5MG;160MG

N022314 003 Apr 30, 2009 Sep CFTG

>A> AB 10MG;12.5MG;160MG

N022314 003 Apr 30, 2009 Sep CFTG

TABLET; ORAL
EXFORGE HCT

>D>		NOVARTIS	10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
>A>	AB		10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
>D>		+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG
>A>	AB	+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

>A>		AMLODIPINE,VALSARTAN AND HYDROCHLOROTHIAZIDE					
>A>	AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435 001	Sep 25, 2012	Sep	NEWA
>A>	AB		5MG;25MG;160MG	A200435 002	Sep 25, 2012	Sep	NEWA
>A>	AB		10MG;12.5MG;160MG	A200435 005	Sep 25, 2012	Sep	NEWA
>A>	AB		10MG;25MG;160MG	A200435 003	Sep 25, 2012	Sep	NEWA
>A>	AB		10MG;25MG;320MG	A200435 004	Sep 25, 2012	Sep	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL
DISPERMOX

@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
----	-------	-------------------------	-------------	--------------	-----	------

ADDERALL XR 15

AB	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 20

AB	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
----	-------	-----------------	-------------	--------------	-----	------

ADDERALL XR 25

AB	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 30

AB	+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
----	---	-------	-------------------------	-------------	--------------	-----	------

ADDERALL XR 5

AB	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA
----	-------------------	-------------------------	-------------	--------------	-----	------

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

INDEPENDENCE PHARMS

5MG

A200166 001 Aug 09, 2012 Jul NEWA

+

10MG

A200166 002 Aug 09, 2012 Jul NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+ ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996 May CAHN

+

100MG/VIAL

N050729 002 Nov 22, 1996 May CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP ANTIBIOTICE

EQ 250MG BASE/VIAL

A090354 001 Dec 28, 2009 Aug CAHN

AP

EQ 500MG BASE/VIAL

A090354 002 Dec 28, 2009 Aug CAHN

AP

EQ 1GM BASE/VIAL

A090354 003 Dec 28, 2009 Aug CAHN

AP

EQ 2GM BASE/VIAL

A090354 004 Dec 28, 2009 Aug CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB SHIRE LLC

EQ 0.5MG BASE

N020333 001 Mar 14, 1997 Jan CAHN

ANAGRELIDE HYDROCHLORIDE

>D> AB ALPHAPHARM

EQ 0.5MG BASE

A077613 001 Jun 27, 2006 Sep CAHN

>D> AB

EQ 1MG BASE

A077613 002 Jun 27, 2006 Sep CAHN

>A> AB

MYLAN PHARMS INC

EQ 0.5MG BASE

A077613 001 Jun 27, 2006 Sep CAHN

>A> AB

EQ 1MG BASE

A077613 002 Jun 27, 2006 Sep CAHN

@ SANDOZ INC

EQ 0.5MG BASE

A076683 001 Apr 18, 2005 Mar DISC

@

EQ 1MG BASE

A076683 002 Apr 18, 2005 Mar DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB APOTEX INC

1MG

A200654 001 May 11, 2012 Apr NEWA

AB

IMPAX LABS INC

1MG

A091242 001 May 31, 2012 May NEWA

APREPITANT

CAPSULE; ORAL

APREPITANT

>A>

SANDOZ

40MG

A090999 001 Sep 24, 2012 Sep NEWA

>A> AB

80MG

A090999 002 Sep 24, 2012 Sep NEWA

>A> AB

125MG

A090999 003 Sep 24, 2012 Sep NEWA

EMEND

>D>

MERCK

40MG

N021549 003 Jun 30, 2006 Sep CFTG

>A> AB

40MG

N021549 003 Jun 30, 2006 Sep CFTG

>D>

80MG

N021549 001 Mar 26, 2003 Sep CFTG

>A> AB

80MG

N021549 001 Mar 26, 2003 Sep CFTG

>D>

+

125MG

N021549 002 Mar 26, 2003 Sep CFTG

>A> AB

+

125MG

N021549 002 Mar 26, 2003 Sep CFTG

APROTININ

INJECTABLE; INJECTION

TRASYLOL

@ BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993 May DISC

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP + PFIZER

250MG/2.5ML (100MG/ML)

N020883 001 Jun 30, 2000 Jan CTNA

ARGATROBAN

AP HIKMA PHARM CO LTD

250MG/2.5ML (100MG/ML)

N203049 001 Jan 05, 2012 Jan NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012 May NEWA

AB

150MG

A200043 002 Jun 01, 2012 May NEWA

AB

250MG

A200043 003 Jun 01, 2012 May NEWA

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012 Aug NEWA

200MG

A200156 004 Aug 29, 2012 Aug NEWA

NUVIGIL

AB CEPHALON

50MG

N021875 001 Jun 15, 2007 May CFTG

AB

150MG

N021875 003 Jun 15, 2007 May CFTG

AB +

250MG

N021875 004 Jun 15, 2007 May CFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA NOVEL LABS INC

4.7GM;100GM;1.015GM;5.9GM;2.691GM
;7.5GM

A090145 001 Jan 25, 2012 Jan NEWA

MOVIPREP

AA + SALIX PHARMS

4.7GM;100GM;1.015GM;5.9GM;2.691GM
;7.5GM

N021881 001 Aug 02, 2006 Jan CFTG

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

ORGANON SUB MERCK

EQ 5MG BASE

N022117 001 Aug 13, 2009 Jul CAHN

+

EQ 10MG BASE

N022117 002 Aug 13, 2009 Jul CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>D> @ ENDO PHARMS

325MG;50MG;40MG;30MG

A075351 001 Mar 05, 1999 Sep CAHN

>A>

@ VINTAGE PHARMS LLC

325MG;50MG;40MG;30MG

A075351 001 Mar 05, 1999 Sep CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB PROSAM LABS

325MG;200MG

A040252 001 Dec 10, 1997 Feb CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	-------------	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@ ZYDUS PHARMS USA INC 18MG

A079017 001 Sep 17, 2010 Jun DISC

@ 25MG

A079017 002 Sep 17, 2010 Jun DISC

@ 40MG

A079017 003 Sep 17, 2010 Jun DISC

@ 60MG

A079017 004 Sep 17, 2010 Jun DISC

@ 80MG

A079017 005 Sep 17, 2010 Jun DISC

@ 100MG

A079017 006 Sep 17, 2010 Jun DISC

STRATTERA

LILLY 10MG

N021411 002 Nov 26, 2002 Jun CTEC

18MG

N021411 003 Nov 26, 2002 Jun CTEC

25MG

N021411 004 Nov 26, 2002 Jun CTEC

40MG

N021411 005 Nov 26, 2002 Jun CTEC

+ 60MG

N021411 006 Nov 26, 2002 Jun CTEC

80MG

N021411 007 Feb 14, 2005 Jun CTEC

100MG

N021411 008 Feb 14, 2005 Jun CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB APOTEX INC EQ 10MG BASE

A090548 001 May 29, 2012 May NEWA

AB EQ 20MG BASE

A090548 002 May 29, 2012 May NEWA

AB EQ 40MG BASE

A090548 003 May 29, 2012 May NEWA

AB EQ 80MG BASE

A090548 004 May 29, 2012 May NEWA

AB DR REDDYS LABS LTD EQ 10MG BASE

A091650 001 Jul 17, 2012 Jul NEWA

AB EQ 20MG BASE

A091650 002 Jul 17, 2012 Jul NEWA

AB EQ 40MG BASE

A091650 003 Jul 17, 2012 Jul NEWA

AB EQ 80MG BASE

A202357 001 Jul 17, 2012 Jul NEWA

AB MYLAN PHARMS INC EQ 10MG BASE

A091226 001 May 29, 2012 May NEWA

AB EQ 20MG BASE

A091226 002 May 29, 2012 May NEWA

AB EQ 40MG BASE

A091226 003 May 29, 2012 May NEWA

AB EQ 80MG BASE

A091226 004 May 29, 2012 May NEWA

AB SANDOZ INC EQ 10MG BASE

A077575 001 May 29, 2012 May NEWA

AB EQ 20MG BASE

A077575 002 May 29, 2012 May NEWA

AB EQ 40MG BASE

A077575 003 May 29, 2012 May NEWA

AB EQ 80MG BASE

A077575 004 May 29, 2012 May NEWA

AB TEVA PHARMS EQ 10MG BASE

A078773 001 May 29, 2012 May NEWA

AB EQ 20MG BASE

A078773 002 May 29, 2012 May NEWA

AB EQ 40MG BASE

A078773 003 May 29, 2012 May NEWA

AB EQ 80MG BASE

A078773 004 May 29, 2012 May NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP + BEDFORD 10MG/ML

A074901 001 Jul 18, 1997 Feb CTEC

AP SAGENT PHARMS 10MG/ML

A091489 001 Feb 17, 2012 Feb NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP + BEDFORD 10MG/ML

A074900 001 Jul 18, 1997 Feb CTEC

AP SAGENT PHARMS 10MG/ML

A091488 001 Feb 17, 2012 Feb NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

+

50MG
100MG
200MG

N202276 001	Apr 27, 2012	Apr	NEWA
N202276 002	Apr 27, 2012	Apr	NEWA
N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

+

1MG
5MG

N202324 001	Jan 27, 2012	Jan	NEWA
N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

+

BAYER HLTHCARE

15%

N021470 001	Dec 24, 2002	Jun	CAHN
-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT

ALCON PHARMA

0.05%

A202305 001	May 31, 2012	May	NEWA
-------------	--------------	-----	------

SPRAY, METERED; NASAL

ASTEPRO

AB

+

MEDA PHARMS

EQ 0.1876MG BASE/SPRAY

N022371 001	Aug 31, 2009	Aug	CFTG
-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

AB

APOTEX INC

EQ 0.1876MG BASE/SPRAY

A201846 001	Aug 31, 2012	Aug	NEWA
-------------	--------------	-----	------

AB

SUN PHARMA GLOBAL

EQ 0.125MG BASE/SPRAY

A090423 001	May 23, 2012	May	NEWA
-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+

MEDA PHARMS

EQ 0.125MG
BASE/SPRAY;0.05MG/SPRAY

N202236 001	May 01, 2012	May	NEWA
-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS USA

EQ 40MG MEDOXOMIL

N200796 001	Feb 25, 2011	Apr	CAHN
-------------	--------------	-----	------

+

EQ 80MG MEDOXOMIL

N200796 002	Feb 25, 2011	Apr	CAHN
-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

TAKEDA PHARMS USA

EQ 40MG MEDOXOMIL;12.5MG

N202331 001	Dec 20, 2011	Apr	CAHN
-------------	--------------	-----	------

+

EQ 40MG MEDOXOMIL;25MG

N202331 002	Dec 20, 2011	Apr	CAHN
-------------	--------------	-----	------

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

@ PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007	Jul	DISC
@ TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
@	EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA	
AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

CNS THERAPS INC 1MG/ML

N022462 004 Jun 22, 2012 Jun NEWA

TABLET; ORAL

BACLOFEN

>D>	AB	MATRIX LABS LTD	10MG	A090334 001	Feb 18, 2010	Sep	CAHN
>D>	AB		20MG	A090334 002	Feb 18, 2010	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	10MG	A090334 001	Feb 18, 2010	Sep	CAHN
>A>	AB		20MG	A090334 002	Feb 18, 2010	Sep	CAHN
	AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
	AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@ UCB INC 10MG

N021589 001 Oct 30, 2003 Jan CAHN

@ 20MG

N021589 002 Oct 30, 2003 Jan CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+ SALIX PHARMS 1.1GM

N022205 001 Feb 03, 2012 Feb NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

>D>	+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Sep	CPOT
>A>	+		0.08MG/ACTUATION	N202813 001	Mar 23, 2012	Sep	CPOT
	+		0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar	NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

>D>	AB	NOVARTIS	5MG	N019851 001	Jun 25, 1991	Sep	CAHN
>D>	AB		10MG	N019851 002	Jun 25, 1991	Sep	CAHN
>D>	AB		20MG	N019851 003	Jun 25, 1991	Sep	CAHN
>D>	AB	+	40MG	N019851 004	Jun 25, 1991	Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	5MG	N019851 001	Jun 25, 1991	Sep	CAHN
>A>	AB		10MG	N019851 002	Jun 25, 1991	Sep	CAHN
>A>	AB		20MG	N019851 003	Jun 25, 1991	Sep	CAHN
>A>	AB	+	40MG	N019851 004	Jun 25, 1991	Sep	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

LOTENSIN HCT

>D>	AB	NOVARTIS	5MG;6.25MG	N020033 001	May 19, 1992	Sep	CAHN
>D>	AB		10MG;12.5MG	N020033 002	May 19, 1992	Sep	CAHN
>D>	AB		20MG;12.5MG	N020033 004	May 19, 1992	Sep	CAHN
>D>	AB	+	20MG;25MG	N020033 003	May 19, 1992	Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	5MG;6.25MG	N020033 001	May 19, 1992	Sep	CAHN
>A>	AB		10MG;12.5MG	N020033 002	May 19, 1992	Sep	CAHN
>A>	AB		20MG;12.5MG	N020033 004	May 19, 1992	Sep	CAHN
>A>	AB	+	20MG;25MG	N020033 003	May 19, 1992	Sep	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@ NESHER PHARMS

100MG

A040795 001 Oct 31, 2007 Jun DISC

@

200MG

A040795 002 Oct 31, 2007 Jun DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB VALEANT INTL 5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Apr CAHN

BT + 5%;EQ 1% BASE

N050756 002 Apr 20, 2007 Apr CAHN

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D> AB DOW PHARM SCIENCES 5%;EQ 1% BASE

A065443 001 Aug 11, 2009 Sep CAHN

>A> AB MYLAN PHARMS INC 5%;EQ 1% BASE

A065443 001 Aug 11, 2009 Sep CAHN

AB PERRIGO ISRAEL 5%;1.2%

A090979 001 Jun 26, 2012 Jun NEWA

DUAC

AB + STIEFEL 5%;1.2%

N050741 001 Aug 26, 2002 Jun CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB + VALEANT INTL 5%;3%

N050557 001 Oct 26, 1984 Jan CAHN

BENZAMYCIN PAK

+ VALEANT INTL 5%;3%

N050769 001 Nov 27, 2000 Jun CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA EMCURE PHARMS LTD 50MG

A202061 001 Jan 27, 2012 Jan NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP APP PHARMS LLC 1MG/ML

A090233 001 Jul 28, 2009 May CAHN

COGENTIN

AP + OAK PHARMS AKORN 1MG/ML

N012015 001 Feb CAHN

TABLET; ORAL

BENZTROPINE MESYLATE

@ LANNETT HOLDINGS INC 0.5MG

A088877 001 Apr 11, 1985 Jan DISC

@

1MG

A088894 001 Apr 11, 1985 Jan DISC

@

2MG

A088895 001 Apr 11, 1985 Jan DISC

AA PROSAM LABS 0.5MG

A040699 001 Feb 14, 2008 Feb CMFD

AA 1MG

A040705 001 Feb 14, 2008 Feb CMFD

TABLET; ORAL

BENZTROPINE MESYLATE

AA		PROSAM LABS	2MG	A040706	001	Feb 14, 2008	Feb	CMFD
AA	+	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103	002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103	003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ SCHERING

0.6MG/5ML

N014215 002

May DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN
----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN
----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN
----	---	---------------	------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ STIEFEL EQ 0.12% BASE

N020934 001 Feb 28, 1999 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
----	--	-------------	-----	---------	-----	--------------	-----	------

AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN
----	---	--	------	---------	-----	--------------	-----	------

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ MERCK SHARP DOHME 200MG

N202258 001 May 13, 2011 Mar CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL

N021602 001 May 13, 2003 Jan CDJR

BOSENTAN

TABLET; ORAL

TRACLEER

+ ACTELION PHARMS LTD 62.5MG

N021290 001 Nov 20, 2001 May CAHN

+ 125MG

N021290 002 Nov 20, 2001 May CAHN

>A> BOSUTINIB MONOHYDRATE

>A> TABLET; ORAL

>A> BOSULIF

>A> WYETH PHARMS INC EQ 100MG BASE

N203341 001 Sep 04, 2012 Sep NEWA

>A> + EQ 500MG BASE

N203341 002 Sep 04, 2012 Sep NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

PARLODEL

>D> AB + NOVARTIS EQ 5MG BASE

N017962 002 Mar 01, 1982 Sep CAHN

>A> AB + US PHARMS HOLDINGS I EQ 5MG BASE

N017962 002 Mar 01, 1982 Sep CAHN

TABLET; ORAL

PARLODEL

>D> AB + NOVARTIS EQ 2.5MG BASE

N017962 001 Sep CAHN

>A> AB + US PHARMS HOLDINGS I EQ 2.5MG BASE

N017962 001 Sep CAHN

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT

@ ASTRAZENECA 0.16MG/INH

N020441 002 Jun 24, 1997 Jun DISC

SUSPENSION; INHALATION

BUDESONIDE

>D> AN TEVA PARENTERAL 0.25MG/2ML

A077519 001 Nov 18, 2008 Sep CAHN

>D> AN 0.5MG/2ML

A077519 002 Nov 18, 2008 Sep CAHN

>A> AN TEVA PHARMS 0.25MG/2ML

A077519 001 Nov 18, 2008 Sep CAHN

>A> AN 0.5MG/2ML

A077519 002 Nov 18, 2008 Sep CAHN

AN WATSON LABS INC 0.25MG/2ML

A078404 001 Jul 31, 2012 Jul NEWA

AN 0.5MG/2ML

A078404 002 Jul 31, 2012 Jul NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA 0.08MG/INH;0.0045MG/INH

N021929 001 Jul 21, 2006 Jan CDJR

+ 0.16MG/INH;0.0045MG/INH

N021929 002 Jul 21, 2006 Jan CDJR

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

@ PACIRA PHARMS INC 133MG/10ML (13.3MG/ML)

N022496 001 Oct 28, 2011 Jul DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB + ROXANE EQ 8MG BASE

A078633 002 Oct 08, 2009 Aug CRLD

TABLET; SUBLINGUAL

SUBUTEX

@ RECKITT BENCKISER

EQ 2MG BASE

N020732 002 Oct 08, 2002 Aug DISC

@

EQ 8MG BASE

N020732 003 Oct 08, 2002 Aug DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER

EQ 2MG BASE;EQ 0.5MG BASE

N022410 001 Aug 30, 2010 Apr CAIN

EQ 4MG BASE;EQ 1MG BASE

N022410 003 Aug 10, 2012 Aug NEWA

+

EQ 8MG BASE;EQ 2MG BASE

N022410 002 Aug 30, 2010 Apr CAIN

EQ 12MG BASE;EQ 3MG BASE

N022410 004 Aug 10, 2012 Aug NEWA

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER

EQ 2MG BASE;EQ 0.5MG BASE

N020733 001 Oct 08, 2002 Apr CPOT

+

EQ 8MG BASE;EQ 2MG BASE

N020733 002 Oct 08, 2002 Apr CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D> AB3 IMPAX LABS 300MG

A077415 002 Dec 15, 2006 Sep CTEC

>A> BX 300MG

A077415 002 Dec 15, 2006 Sep CTEC

AB1 WOCKHARDT LTD 100MG

A201331 001 Aug 30, 2012 Aug NEWA

AB1 150MG

A201331 002 Aug 30, 2012 Aug NEWA

AB1 200MG

A201331 003 Aug 30, 2012 Aug NEWA

FORFIVO XL

+ EDMONT PHARMS LLC 450MG

N022497 001 Nov 10, 2011 Mar CAHN

WELLBUTRIN SR

>D> AB1 + GLAXOSMITHKLINE 150MG

N020358 003 Oct 04, 1996 Sep CRLD

>A> AB1 150MG

N020358 003 Oct 04, 1996 Sep CRLD

>D> AB1 200MG

N020358 004 Jun 14, 2002 Sep CRLD

>A> AB1 + 200MG

N020358 004 Jun 14, 2002 Sep CRLD

WELLBUTRIN XL

>D> AB3 + VALEANT INTL 150MG

N021515 001 Aug 28, 2003 Sep CRLD

>A> AB3 150MG

N021515 001 Aug 28, 2003 Sep CRLD

>D> AB3 300MG

N021515 002 Aug 28, 2003 Sep CRLD

>A> AB3 + 300MG

N021515 002 Aug 28, 2003 Sep CRLD

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@ APOTEX

5MG

A075521 001 Apr 05, 2002 Mar DISC

@

10MG

A075521 002 Apr 05, 2002 Mar DISC

@

15MG

A075521 003 Apr 05, 2002 Mar DISC

@ EGIS

5MG

A075119 001 Mar 14, 2002 Mar DISC

@

10MG

A075119 002 Mar 14, 2002 Mar DISC

@

15MG

A075119 003 Jan 23, 2003 Mar DISC

@ NESHER PHARMS

5MG

A075572 001 Feb 27, 2002 Jun DISC

@

10MG

A075572 002 Feb 27, 2002 Jun DISC

@

15MG

A075572 003 Feb 27, 2002 Jun DISC

@ PROSAM LABS

5MG

A075388 001 May 09, 2002 Mar DISC

AB 5MG

A075388 001 May 09, 2002 Feb CMFD

@

10MG

A075388 002 May 09, 2002 Mar DISC

AB 10MG

A075388 002 May 09, 2002 Feb CMFD

@

15MG

A075388 003 May 09, 2002 Mar DISC

AB 15MG

A075388 003 May 09, 2002 Feb CMFD

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	PROSAM LABS	30MG	A078302 001	Dec 17, 2007	Feb	CMFD
----	-------------	------	-------------	--------------	-----	------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

@ PERRIGO ISRAEL 2%

A200923 001	May 18, 2012	Apr	NEWA
-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012	Aug	NEWA
----	---------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012	Aug	NEWA
----	---------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
----	--------	--------	-------------	--------------	-----	------

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
----	-----------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
----	-------------	------------------	-------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>D>	@ ENDO LABS	12.5MG	A074418 001	Feb 13, 1996	Sep	CAHN
>D>	@	25MG	A074418 002	Feb 13, 1996	Sep	CAHN
>D>	@	50MG	A074418 003	Feb 13, 1996	Sep	CAHN
>D>	@	100MG	A074418 004	Feb 13, 1996	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	12.5MG	A074418 001	Feb 13, 1996	Sep	CAHN
>A>	@	25MG	A074418 002	Feb 13, 1996	Sep	CAHN
>A>	@	50MG	A074418 003	Feb 13, 1996	Sep	CAHN
>A>	@	100MG	A074418 004	Feb 13, 1996	Sep	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

>D>	@ ENDO LABS	25MG; 15MG	A074788 001	Dec 29, 1997	Sep	CAHN
>D>	@	25MG; 25MG	A074788 002	Dec 29, 1997	Sep	CAHN

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
>D>	@ ENDO LABS	50MG;15MG	A074788	004	Dec 29, 1997	Sep	CAHN
>D>	@	50MG;25MG	A074788	003	Dec 29, 1997	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	25MG;15MG	A074788	001	Dec 29, 1997	Sep	CAHN
>A>	@	25MG;25MG	A074788	002	Dec 29, 1997	Sep	CAHN
>A>	@	50MG;15MG	A074788	004	Dec 29, 1997	Sep	CAHN
>A>	@	50MG;25MG	A074788	003	Dec 29, 1997	Sep	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A>	AB	TEVA PHARMS	100MG	A078592	001	Sep 20, 2012	Sep	NEWA
>A>	AB		200MG	A078592	002	Sep 20, 2012	Sep	NEWA
>A>	AB		300MG	A078592	003	Sep 20, 2012	Sep	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085	001	May 10, 2012	Apr	NEWA
AB			37.5MG;200MG;150MG	A079085	002	May 10, 2012	Apr	NEWA
AB		STALEVO 100						
AB		ORION PHARMA	25MG;200MG;100MG	N021485	002	Jun 11, 2003	Apr	CFTG
AB		STALEVO 150						
AB		ORION PHARMA	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003	Apr	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB		UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Jan	CAHN
AB			25MG;100MG	A076699	002	Aug 27, 2004	Jan	CAHN
AB	+		25MG;250MG	A076699	003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP		CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	Mar	CAHN
AP			150MG/VIAL	A077383	002	Jan 27, 2006	Mar	CAHN
AP			450MG/VIAL	A077383	003	Jan 27, 2006	Mar	CAHN
AP		ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May	NEWA
AP			150MG/VIAL	A091510	002	May 29, 2012	May	NEWA
AP			450MG/VIAL	A091510	003	May 29, 2012	May	NEWA

PARAPLATIN

@ CORDEN PHARMA

@

@

			50MG/VIAL	N019880	001	Mar 03, 1989	Feb	CAHN
			150MG/VIAL	N019880	002	Mar 03, 1989	Feb	CAHN
			450MG/VIAL	N019880	003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP		ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Jan	NEWA
AP			600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Jan	NEWA
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Mar	CAHN
AP			150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Mar	CAHN
AP			450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Mar	CAHN
AP			600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Mar	CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS

60MG/VIAL

N202714 001 Jul 20, 2012 Jul NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA PROSAM LABS

350MG

A040188 001 Mar 07, 1997 Feb CAHN

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997 Apr DISC

@

EQ 500MG BASE

A064156 002 Aug 28, 1997 Apr DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997 Apr DISC

AB +

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997 Feb CTEC

@

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997 Apr DISC

AB +

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997 Feb CTEC

@

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997 Apr DISC

AB +

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997 Feb CTEC

@

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997 Apr DISC

AB +

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997 Feb CTEC

AB YUNG SHIN PHARM

EQ 125MG BASE/5ML

A065412 001 Feb 17, 2012 Feb NEWA

AB

EQ 187MG BASE/5ML

A065412 002 Feb 17, 2012 Feb NEWA

AB

EQ 250MG BASE/5ML

A065412 003 Feb 17, 2012 Feb NEWA

AB

EQ 375MG BASE/5ML

A065412 004 Feb 17, 2012 Feb NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003 Apr DISC

@

EQ 187MG BASE

A065092 002 Dec 22, 2003 Apr DISC

@

EQ 250MG BASE

A065092 003 Dec 22, 2003 Apr DISC

@

EQ 375MG BASE

A065092 004 Dec 22, 2003 Apr DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD

EQ 500MG BASE

A065015 001 Jun 22, 1999 Apr DISC

TABLET; ORAL

CEFADROXIL

@ RANBAXY

EQ 1GM BASE

A065018 001 Apr 23, 1999 Apr DISC

+ TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987 Aug CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 2GM BASE/VIAL

N050779 003 Jan 13, 2012 May NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSSEN PHARMA

200MG

N021222 001 Aug 29, 2001 Mar CAHN

+

400MG

N021222 002 Jul 21, 2008 Mar CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA

CEFIXIME

CAPSULE; ORAL

SUPRAX

+	LUPIN LTD	400MG	N203195 001	Jun 01, 2012	Jun	NEWA
---	-----------	-------	-------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

@	RANBAXY LABS LTD	250MG	A065198 001	Dec 13, 2006	Apr	DISC
@		500MG	A065198 002	Dec 13, 2006	Apr	DISC

CEFZIL

@	CORDEN PHARMA	250MG	N050664 001	Dec 23, 1991	Feb	CAHN
@		500MG	N050664 002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@	COVIS PHARMA	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
+		EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
+		EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012	Aug	NEWA
AP	+ SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+	EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ RANBAXY LABS LTD

@

@

EQ 125MG BASE

EQ 250MG BASE

EQ 500MG BASE

A065043 003 Feb 15, 2002 Apr DISC

A065043 002 Feb 15, 2002 Apr DISC

A065043 001 Feb 15, 2002 Apr DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

AB	+ COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZINACEF

AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

AP	+	EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
----	---	--------------------	-------------	--------------	-----	------

ZINACEF IN PLASTIC CONTAINER

+ COVIS PHARMA

+

EQ 15MG BASE/ML

EQ 30MG BASE/ML

N050643 001 Apr 28, 1989 Apr CAHN

N050643 002 Apr 28, 1989 Apr CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

@ SHIONOGI INC

@

@

EQ 100MG BASE/ML

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

N050406 003 Jul CAHN

N050406 001 Jul CAHN

N050406 002 Jul CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ RANBAXY LABS LTD

AA

SILARX

5MG/5ML

5MG/5ML

A077472 001 Jun 18, 2008 Jul DISC

A078876 001 May 11, 2012 Apr NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+ ASPEN GLOBAL INC

2MG

N010669 002 May CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--------------------	---	-------------	--------------	-----	------

>A> CHOLINE C-11

>A> INJECTABLE; INTRAVENOUS

>A> CHOLINE C-11

>A>	+	MCPRF	4-33.1mCi	N203155 001	Sep 12, 2012	Sep	NEWA
-----	---	-------	-----------	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
+		0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
AB	GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501 001	Jul 26, 2012	Jul	NEWA
AP	MYLAN LLC	EQ 75MG BASE/ML	A201276 001	Jun 27, 2012	Jun	NEWA

VISTIDE

AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996	Jun	CFTG
----	---	---------------------	-----------------	-------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>D>	AB	ALPHAPHARM	50MG	A077019 001	Nov 23, 2004	Sep	CAHN
>D>	AB		100MG	A077019 002	Nov 23, 2004	Sep	CAHN
>A>	AB	BIOKEY	50MG	A077722 001	Sep 24, 2012	Sep	NEWA
>A>	AB		100MG	A077831 001	Sep 24, 2012	Sep	NEWA
>A>	AB	MYLAN PHARMS INC	50MG	A077019 001	Nov 23, 2004	Sep	CAHN
>A>	AB		100MG	A077019 002	Nov 23, 2004	Sep	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	@	ENDO PHARMS	200MG	A074281 001	May 17, 1994	Sep	CAHN
>D>	@		300MG	A074281 002	May 17, 1994	Sep	CAHN
>D>	@		400MG	A074281 003	May 17, 1994	Sep	CAHN
>D>	@		800MG	A074329 001	May 17, 1994	Sep	CAHN

TABLET; ORAL

CIMETIDINE

>A>	@ VINTAGE PHARMS LLC	200MG	A074281 001	May 17, 1994	Sep	CAHN
>A>	@	300MG	A074281 002	May 17, 1994	Sep	CAHN
>A>	@	400MG	A074281 003	May 17, 1994	Sep	CAHN
>A>	@	800MG	A074329 001	May 17, 1994	Sep	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

>D>	@ ENDO PHARMS	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994	Sep	CAHN
	@ HOSPIRA	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995	Jun	DISC
	@	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995	Jun	DISC
>A>	@ VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994	Sep	CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

>D>	@ ENDO PHARMS	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994	Sep	CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

	@ TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
	@	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008	Jun	DISC
	@	400MG/200ML	A077888 002	Mar 18, 2008	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

	@ PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
	@	EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
	@	EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
	@	EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
	NIMBEX					
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
	NIMBEX PRESERVATIVE FREE					
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062	001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

>D>	ALPHAPHARM	EQ 10MG BASE	A077668	001	Feb 28, 2007	Sep	CAHN
>D>		EQ 20MG BASE	A077668	002	Feb 28, 2007	Sep	CAHN
>D>	+	EQ 40MG BASE	A077668	003	Feb 28, 2007	Sep	CAHN
>A>	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Sep	CAHN
>A>		EQ 20MG BASE	A077668	002	Feb 28, 2007	Sep	CAHN
>A>	+	EQ 40MG BASE	A077668	003	Feb 28, 2007	Sep	CAHN

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	ALPHAPHARM	EQ 10MG BASE	A077037	001	Nov 05, 2004	Sep	CAHN
>D>	AB		EQ 20MG BASE	A077037	002	Nov 05, 2004	Sep	CAHN
>D>	AB		EQ 40MG BASE	A077037	003	Nov 05, 2004	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	Sep	CAHN
>A>	AB		EQ 20MG BASE	A077037	002	Nov 05, 2004	Sep	CAHN
>A>	AB		EQ 40MG BASE	A077037	003	Nov 05, 2004	Sep	CAHN
		@ SANDOZ	EQ 10MG BASE	A077035	001	Oct 28, 2004	Aug	DISC
		@	EQ 20MG BASE	A077035	002	Oct 28, 2004	Aug	DISC
		@	EQ 40MG BASE	A077035	003	Oct 28, 2004	Aug	DISC
	AB	TEVA PHARMS	EQ 10MG BASE	A077048	001	Nov 16, 2004	Aug	CAHN
	AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Aug	CAHN
	AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC KET	N202535	001	Jul 16, 2012	Jul	NEWA
---	-------------------	---------------------------------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489	001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489	002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

@	SANDOZ	500MG	A065250	001	Aug 25, 2005	Aug	DISC
---	--------	-------	---------	-----	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

>D>	AB	MATRIX LABS LTD	EQ 75MG BASE	A091225	001	May 31, 2011	Sep	CAHN
>D>	AB		EQ 150MG BASE	A091225	002	May 31, 2011	Sep	CAHN
>D>	AB		EQ 300MG BASE	A091225	003	May 31, 2011	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	Sep	CAHN
>A>	AB		EQ 150MG BASE	A091225	002	May 31, 2011	Sep	CAHN
>A>	AB		EQ 300MG BASE	A091225	003	May 31, 2011	Sep	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012	Aug	NEWA
----	------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
----	---	----------------------	----------------	-------------	--------------	-----	------

AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
----	---	--	-----------------	-------------	--------------	-----	------

AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG
----	---	--	-----------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
----	--	------------	----------------	-------------	--------------	-----	------

AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA
----	--	--	-----------------	-------------	--------------	-----	------

AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA
----	--	--	-----------------	-------------	--------------	-----	------

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	@	COREPHARMA	EQ 1% BASE	A064108 001	Sep 27, 1996	Sep	CAHN
-----	---	------------	------------	-------------	--------------	-----	------

AT		FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006	Jan	CAHN
----	--	----------------	------------	-------------	--------------	-----	------

>A>	@	RENAISSANCE PHARMA	EQ 1% BASE	A064108 001	Sep 27, 1996	Sep	CAHN
-----	---	--------------------	------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010	May	CRLD
----	---	-------------	-------------	-------------	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC

5MG

N202067 001	Oct 21, 2011	Mar	CAHN
-------------	--------------	-----	------

10MG

N202067 002	Oct 21, 2011	Mar	CAHN
-------------	--------------	-----	------

+

20MG

N202067 003	Oct 21, 2011	Mar	CAHN
-------------	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		PERRIGO ISRAEL	0.05%	A077763 001	Mar 10, 2008	Jul	CTEC
-----	--	----------------	-------	-------------	--------------	-----	------

AB2			0.05%	A201402 001	Aug 14, 2012	Jul	NEWA
-----	--	--	-------	-------------	--------------	-----	------

OLUX

AB1	+	STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	Jul	CTEC
-----	---	------------------	-------	-------------	--------------	-----	------

OLUX E

AB2	+	STIEFEL LABS INC	0.05%	N022013 001	Jan 12, 2007	Jul	CFTG
-----	---	------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ G AND W LABS INC

0.05%

A074139 001	Aug 03, 1994	Jun	CAHN
-------------	--------------	-----	------

@ RENAISSANCE PHARMA

0.05%

A075338 001	Feb 09, 2001	Aug	CAHN
-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
	@ RENAISSANCE PHARMA	0.05%	A075733 001	Aug 22, 2001	Aug	CAHN

TEMOVATE

AB1	+ FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985	Jan	CAHN
-----	------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB	TARO	0.05%	A200302 001	Jul 02, 2012	Jun	NEWA
----	------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A074407 001	Feb 23, 1996	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

@ RENAISSANCE PHARMA

		0.05%	A075057 001	Aug 12, 1998	Aug	CAHN
--	--	-------	-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012	Jul	NEWA
----	----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

@ G AND W LABS INC

		0.05%	A074331 001	Dec 15, 1995	Jun	CAHN
--	--	-------	-------------	--------------	-----	------

TEMOVATE

AT	+ FOUGERA PHARMS	0.05%	N019966 001	Feb 22, 1990	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>D>	AB	ALPHAPHARM	0.5MG	A074940 001	Oct 30, 1997	Sep	CAHN
>D>	AB		1MG	A074940 002	Oct 30, 1997	Sep	CAHN
>D>	AB		2MG	A074940 003	Oct 30, 1997	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	0.5MG	A074940 001	Oct 30, 1997	Sep	CAHN
>A>	AB		1MG	A074940 002	Oct 30, 1997	Sep	CAHN
>A>	AB		2MG	A074940 003	Oct 30, 1997	Sep	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615 001	Oct 02, 1996	Feb	CAHN
----	---------------------	------------------------	-------------	--------------	-----	------

AP	+	5 MG/10 ML (0.5 MG/ML)	N020615 002	Apr 27, 1999	Feb	CAHN
----	---	------------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

	SHIONOGI INC	0.2MG	N022331 004	Sep 28, 2010	May	CMFD
--	--------------	-------	-------------	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 75MG BASE	A076274 001	May 17, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540 001	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273 001	Jan 14, 2008	Mar	CMFD
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023 001	May 17, 2012	Apr	NEWA

TABLET; ORAL

CLOPIDOGREL BISULFATE

	AB	GATE PHARMS	EQ 300MG BASE	A091216 001	May 17, 2012	Apr	NEWA
	AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012	Apr	NEWA
	AB		EQ 300MG BASE	A077665 002	May 17, 2012	Apr	NEWA
	AB	ROXANE	EQ 75MG BASE	A078004 001	May 17, 2012	Apr	NEWA
	AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr	NEWA
	AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr	NEWA
	AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr	NEWA
	AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr	NEWA
	AB	WOCKHARDT LTD	EQ 75MG BASE	A202266 001	Aug 14, 2012	Jul	NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686 001	Oct 10, 2012	Sep	NEWA

PLAVIX

AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar	CTEC
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@	LUNDBECK LLC	3.75MG	N017105 001		Mar	CAHN
@		7.5MG	N017105 002		Mar	CAHN
@		15MG	N017105 003		Mar	CAHN

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105 006		Mar	CAHN
AB		7.5MG	N017105 007		Mar	CAHN
AB	+	15MG	N017105 008		Mar	CAHN
	TRANXENE SD					
@	LUNDBECK LLC	11.25MG	N017105 005		Mar	CAHN
@		22.5MG	N017105 004		Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

	JAZZ	12.5MG	N021590 004	May 30, 2007	Apr	CAHN
		25MG	N021590 001	Feb 10, 2004	Apr	CAHN
@		50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+		100MG	N021590 002	Feb 10, 2004	Apr	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
@		50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+		100MG	N021590 002	Feb 10, 2004	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100 001	Aug 27, 2012	Aug	NEWA
---	---------------------	-------------------------	-------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386 001	Jun 29, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

>A>	AP	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359 001	Sep 28, 2012	Sep	NEWA
-----	----	-------------------	--------------------	-------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984	May	CAHN
---	-------------	--------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

>D>	AP	INNOPHARMA INC	0.25MG/VIAL	A202147 001	Jun 29, 2012	Sep	CAHN
	AP		0.25MG/VIAL	A202147 001	Jun 29, 2012	Jun	NEWA
>A>	AP	SANDOZ	0.25MG/VIAL	A202147 001	Jun 29, 2012	Sep	CAHN

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@ KING PFIZER 0.8MG/INH

N018887 001	Dec 05, 1985	Jun	DISC
-------------	--------------	-----	------

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN
----	---	----------------------	-----------	-------------	--------------	-----	------

AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479 001	Feb 29, 1996	Jun	CAHN
----	---	------------------	-----------	-------------	--------------	-----	------

SOLUTION; INHALATION

CROMOLYN SODIUM

>D>	AN	+	TEVA PARENTERAL	10MG/ML	A075271 001	Jan 18, 2000	Sep	CAHN
-----	----	---	-----------------	---------	-------------	--------------	-----	------

>A>	AN	+	TEVA PHARMS	10MG/ML	A075271 001	Jan 18, 2000	Sep	CAHN
-----	----	---	-------------	---------	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A073144 002	Feb 03, 2006	Jul	CRLD
----	------------------	-----	-------------	--------------	-----	------

AB	+	10MG	A073144 001	May 30, 1991	Jul	CRLD
----	---	------	-------------	--------------	-----	------

AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
----	-------------	-----	-------------	--------------	-----	------

AB		10MG	A077209 001	Oct 04, 2005	Feb	CAHN
----	--	------	-------------	--------------	-----	------

FLEXERIL

@ JANSSEN RES AND DEV 5MG

N017821 001		Jul	DISC
-------------	--	-----	------

@ 10MG

N017821 002		Jul	DISC
-------------	--	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003		Apr	CRLD
----	---	-----------------	------------	-------------	--	-----	------

AP	+	1GM/VIAL	N012142 004	Aug 30, 1982	Apr	CRLD
----	---	----------	-------------	--------------	-----	------

AP	+	2GM/VIAL	N012142 005	Aug 30, 1982	Apr	CRLD
----	---	----------	-------------	--------------	-----	------

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	WATSON LABS INC	25MG	A065044 002	Dec 20, 2000	May	CAHN
AB1		100MG	A065044 001	Dec 20, 2000	May	CAHN

SOLUTION; ORAL

CYCLOSPORINE

>D>	AB1	ABBOTT	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN
>A>	AB1	ABBVIE	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	ONCO THERAPIES LTD	100MG/ML	A201784 001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------	-------------	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		Mar	CAHN
----	---	--------------	------------	-------------	--	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

@	MIKAH PHARMA	25MG
@		50MG
@		100MG

A076686 001	Oct 24, 2005	Jul	CAHN
A076686 002	Oct 24, 2005	Jul	CAHN
A076686 003	Oct 24, 2005	Jul	CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

@ FERA PHARMS 0.5%

N019849 001	Dec 31, 1990	Jul	CTNA
-------------	--------------	-----	------

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011	Feb	CAHN
---	---------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

PREZISTA

	JANSSEN PRODS	EQ 75MG BASE	N021976 004	Dec 18, 2008	Feb	CAHN
		EQ 150MG BASE	N021976 005	Dec 18, 2008	Feb	CAHN
@		EQ 300MG BASE	N021976 001	Jun 23, 2006	Feb	CAHN
		EQ 400MG BASE	N021976 003	Oct 21, 2008	Feb	CAHN
+		EQ 600MG BASE	N021976 002	Feb 25, 2008	Feb	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECMOMYCIN

@	COREPHARMA	150MG
@		300MG

N050261 002		Jul	DISC
N050261 003		Jul	DISC

DEMECLOCYCLINE HYDROCHLORIDE

AB	+	AMNEAL PHARM	300MG	A065425 002	Feb 27, 2008	Jul	CRLD
----	---	--------------	-------	-------------	--------------	-----	------

DESFLURANE

LIQUID; INHALATION

SUPRANE

	+	BAXTER HLTHCARE	99.9%	N020118 001	Sep 18, 1992	Jul	CAHN
--	---	-----------------	-------	-------------	--------------	-----	------

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB		BELCHER PHARMS	5MG	A078355 001	Apr 19, 2012	Apr	NEWA
----	--	----------------	-----	-------------	--------------	-----	------

AB		MYLAN PHARMS INC	5MG	A078351 001	Feb 10, 2012	Jan	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

DESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB	+	SANOFI AVENTIS US	0.01%	N017922 001		Mar	CFTG
----	---	-------------------	-------	-------------	--	-----	------

DESMOPRESSIN ACETATE

AB		SUN PHARM INDS	0.01%	A077212 001	Apr 12, 2012	Mar	NEWA
----	--	----------------	-------	-------------	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

>D>	AB	VINTAGE	0.15MG;0.03MG	A076675 001	Feb 25, 2011	Sep	CAHN
-----	----	---------	---------------	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675 001	Feb 25, 2011	Sep	CAHN
-----	----	--------------------	---------------	-------------	--------------	-----	------

MIRCETTE

AB	+	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG	N020713 001	Apr 22, 1998	Jun	CAHN
----	---	--------------------	--------------------------	-------------	--------------	-----	------

VIORELE

AB		GLENMARK GENERICS	0.15MG,N/A;0.02MG,0.01MG	A091346 001	Apr 02, 2012	Mar	NEWA
----	--	-------------------	--------------------------	-------------	--------------	-----	------

DESONIDE

LOTION; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075860 001	Mar 19, 2002	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075751 001	Mar 12, 2001	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB		FOUGERA PHARMS	0.25%	A078369 001	Jun 29, 2010	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

TOPICORT

	+	TARO	0.05%	A073210 001	Nov 30, 1990	Apr	CTNA
--	---	------	-------	-------------	--------------	-----	------

>D>		+	0.25%	A073193 001	Nov 30, 1990	Sep	CTEC
-----	--	---	-------	-------------	--------------	-----	------

>A>	AB	+	0.25%	A073193 001	Nov 30, 1990	Sep	CTEC
-----	----	---	-------	-------------	--------------	-----	------

	+		0.25%	A073193 001	Nov 30, 1990	Apr	CTNA
--	---	--	-------	-------------	--------------	-----	------

	@	TARO PHARMS NORTH	0.25%	N017856 001		Apr	DISC
--	---	-------------------	-------	-------------	--	-----	------

TOPICORT LP

	@	TARO PHARMS NORTH	0.05%	N018309 001		Apr	DISC
--	---	-------------------	-------	-------------	--	-----	------

GEL; TOPICAL

TOPICORT

AB	+	TARO	0.05%	A074904 001	Jul 14, 1998	Apr	CTNA
----	---	------	-------	-------------	--------------	-----	------

	@	TARO PHARMS NORTH	0.05%	N018586 001	Mar 29, 1982	Apr	DISC
--	---	-------------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESOXIMETASONE

>A>							
-----	--	--	--	--	--	--	--

>A>	AB	FOUGERA PHARMS	0.25%	A078657 001	Sep 28, 2012	Sep	NEWA
-----	----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL
 >A> DESOXIMETASONE
 AB + TARO 0.25% A074286 001 Jun 07, 1996 Mar CRLD
 TOPICORT
 >D> + TARO 0.25% A074286 001 Jun 07, 1996 Sep CTEC
 >A> AB + 0.25% A074286 001 Jun 07, 1996 Sep CTEC
 + 0.25% A074286 001 Jun 07, 1996 Apr CTNA
 @ TARO PHARMS NORTH 0.25% N018763 001 Sep 30, 1983 Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 DEXAMETHASONE SODIUM PHOSPHATE
 AP + APP PHARMS LLC EQ 10MG PHOSPHATE/ML A040572 001 Apr 22, 2005 Feb CRLD

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
 TOTECT
 + APRICUS PHARMS EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Jun CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
 DEXTROAMPHETAMINE SULFATE
 >D> @ ENDO PHARMS 5MG A040299 001 May 13, 1999 Sep CAHN
 >A> @ VINTAGE PHARMS LLC 5MG A040299 001 May 13, 1999 Sep CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
 AA TRIS PHARMA INC 15MG/5ML;6.25MG/5ML A091687 001 Jun 28, 2012 Jun NEWA

DIAZEPAM

INJECTABLE; INJECTION
 DIAZEPAM
 @ HIKMA MAPLE 5MG/ML A070312 001 Dec 16, 1985 Jul CAHN
 @ 5MG/ML A070311 001 Dec 16, 1985 Jul CAHN
 @ 5MG/ML A070313 001 Dec 16, 1985 Jul CAHN
 @ 5MG/ML A071309 001 Jul 17, 1987 Jul CAHN
 @ 5MG/ML A071310 001 Jul 17, 1987 Jul CAHN
 @ 5MG/ML A071308 001 Jul 17, 1987 Jul CAHN
 @ HOSPIRA 5MG/ML A071584 001 Oct 13, 1987 Apr DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL
 ZIPSOR
 + DEPOMED INC 25MG N022202 001 Jun 16, 2009 Jun CAHN

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
 DICLOFENAC SODIUM
 >D> AB ALPHAPHARM 50MG A075281 002 Feb 12, 2002 Sep CAHN
 >D> AB 75MG A075281 003 Feb 12, 2002 Sep CAHN
 >A> AB MYLAN PHARMS INC 50MG A075281 002 Feb 12, 2002 Sep CAHN
 >A> AB 75MG A075281 003 Feb 12, 2002 Sep CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB GD SEARLE LLC 50MG;0.2MG

N020607 001 Dec 24, 1997 Jun CFTG

AB + 75MG;0.2MG

N020607 002 Dec 24, 1997 Jun CFTG

DICLOFENAC SODIUM AND MISOPROSTOL

AB WATSON LABS INC 50MG;0.2MG

A201089 001 Jul 09, 2012 Jun NEWA

AB 75MG;0.2MG

A201089 002 Jul 09, 2012 Jun NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

>D> AB MATRIX LABS LTD 125MG

A090788 001 Apr 08, 2010 Sep CAHN

>D> AB 200MG

A090788 002 Apr 08, 2010 Sep CAHN

>D> AB 250MG

A090788 003 Apr 08, 2010 Sep CAHN

>D> AB 400MG

A090788 004 Apr 08, 2010 Sep CAHN

>A> AB MYLAN PHARMS INC 125MG

A090788 001 Apr 08, 2010 Sep CAHN

>A> AB 200MG

A090788 002 Apr 08, 2010 Sep CAHN

>A> AB 250MG

A090788 003 Apr 08, 2010 Sep CAHN

>A> AB 400MG

A090788 004 Apr 08, 2010 Sep CAHN

TABLET, CHEWABLE; ORAL

DIDANOSINE

AUROBINDO 100MG

A077275 001 Aug 14, 2012 Jul NEWA

150MG

A077275 002 Aug 14, 2012 Jul NEWA

200MG

A077275 003 Aug 14, 2012 Jul NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX + FOUGERA PHARMS 0.05%

A076263 001 Dec 20, 2002 Jan CAHN

AB1 + 0.05%

A075187 001 Mar 30, 1998 Jan CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB FOUGERA PHARMS 0.05%

A075374 001 Apr 27, 1999 Jan CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB EMCURE PHARMS USA 500MG

A202845 001 Mar 08, 2012 Feb NEWA

AB + TEVA 500MG

A073673 001 Jul 31, 1992 Feb CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP HIKMA MAPLE 0.25MG/ML

A083391 001 Jul CAHN

@ HOSPIRA 0.25MG/ML

A040093 001 May 16, 1996 Jun DISC

TABLET; ORAL

DIGOXIN

@ MYLAN PHARMS INC 0.125MG

A040282 001 Dec 23, 1999 Jul CAHN

@ 0.25MG

A040282 002 Dec 23, 1999 Jul CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A> AB4 ACTAVIS ELIZABETH 120MG

A091022 001 Sep 28, 2012 Sep NEWA

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB4	ACTAVIS ELIZABETH	180MG	A091022 002	Sep 28, 2012	Sep	NEWA
>A>	AB4		240MG	A091022 003	Sep 28, 2012	Sep	NEWA
>A>	AB4		300MG	A091022 004	Sep 28, 2012	Sep	NEWA
>A>	AB4		360MG	A091022 005	Sep 28, 2012	Sep	NEWA
>A>	AB4		420MG	A091022 006	Sep 28, 2012	Sep	NEWA

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>A>	AP	AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999	Sep	CAHN
>D>	AP	APOTEX INC	5MG/ML	A075375 001	Sep 30, 1999	Sep	CAHN
	AP	HIKMA FARMACEUTICA	5MG/ML	A202651 001	Aug 09, 2012	Jul	NEWA
	AP	HIKMA MAPLE	5MG/ML	A078538 001	Dec 17, 2008	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Jan	DISC

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	FERRING CONTROLLED	10MG	N020411 001	Mar 30, 1995	Jul	CAHN
---	--------------------	------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

@	MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC
---	-------------	---------	-------------	--	-----	------

BENADRYL PRESERVATIVE FREE

@	MCNEIL CONS	50MG/ML	N009486 001		Mar	DISC
---	-------------	---------	-------------	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	BAXTER HLTHCARE	50MG/ML	A080817 002		Apr	CRLD
		@ HIKMA MAPLE	50MG/ML	A083183 001		Jul	CAHN
AP	+		50MG/ML	A080817 002		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP		HIKMA MAPLE	5MG/ML	A074521 001	Oct 18, 1996	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@	NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
---	---------------	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB		REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
TAXOTERE						
AP	+ SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+	80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

	AB	INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012	Jul	NEWA
	AB		10MG	A201634 002	Jun 13, 2012	Jul	NEWA
	AB	MACLEODS PHARMS LTD	5MG	A201146 001	Aug 17, 2012	Aug	NEWA
	AB		10MG	A201146 002	Aug 17, 2012	Aug	NEWA
>D>	AB	MATRIX LABS LTD	5MG	A090521 001	May 31, 2011	Sep	CAHN
>D>	AB		10MG	A090521 002	May 31, 2011	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	5MG	A090521 001	May 31, 2011	Sep	CAHN
>A>	AB		10MG	A090521 002	May 31, 2011	Sep	CAHN
	AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
	AB		10MG	A200292 002	May 31, 2011	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

	+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE							
>D>	AT	TEVA PARNTL	EQ 2% BASE;EQ 0.5% BASE	A078704 001	Sep 28, 2009	Sep	CAHN
>A>	AT	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704 001	Sep 28, 2009	Sep	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	NESHER PHARMS	EQ 1MG BASE
@		EQ 2MG BASE
@		EQ 4MG BASE
@		EQ 8MG BASE

A075609 001	Oct 18, 2000	Feb	DISC
A075609 002	Oct 18, 2000	Feb	DISC
A075609 003	Oct 18, 2000	Feb	DISC
A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
---	----------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP	SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012	Jul	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC
	MONODOX					
AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

@	SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
@		EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
@		EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul	CAHN
@		EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul	CAHN
AP	PFIZER	EQ 100MG BASE/VIAL	A091406 001	Aug 21, 2012	Aug	NEWA
	DOXYCYCLINE HYCLATE					
@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul	CAHN
@		EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
	TABLET, DELAYED RELEASE; ORAL					
	DORYX					
AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan
		DOXYCYCLINE HYCLATE				
AB	MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123 001	Aug 10, 2011	Apr	CAIN
---	---------------------	--------------------------	-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@ SANDOZ INC	2.5MG	A075621 001	Aug 22, 2000	Feb	DISC
@	2.5MG	A075496 001	Aug 22, 2000	Jan	DISC
@	5MG	A075621 002	Aug 22, 2000	Feb	DISC
@	5MG	A075496 002	Aug 22, 2000	Jan	DISC
@	10MG	A075621 003	Aug 22, 2000	Feb	DISC
@	10MG	A075459 001	Aug 22, 2000	Jan	DISC
@	20MG	A075621 004	Aug 22, 2000	Feb	DISC
@	20MG	A075459 002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ SANDOZ INC	5MG;12.5MG	A076116 001	Sep 19, 2001	Mar	DISC
@	10MG;25MG	A076116 002	Sep 19, 2001	Mar	DISC

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN + BAXTER HLTHCARE	99.9%	N017087 001		Jul	CAHN
----------------------	-------	-------------	--	-----	------

ENTACAPONE

TABLET; ORAL

COMTAN

AB + ORION PHARMA	200MG	N020796 001	Oct 19, 1999	Jul	CFTG
+	200MG	N020796 001	Oct 19, 1999	May	CAHN

ENTACAPONE

AB SUN PHARMA GLOBAL	200MG	A090690 001	Jul 16, 2012	Jul	NEWA
AB WOCKHARDT LTD	200MG	A078941 001	Aug 16, 2012	Jul	NEWA

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

>A> + ASTELLAS	40MG	N203415 001	Aug 31, 2012	Sep	CAHN
>D> + MEDIVATION	40MG	N203415 001	Aug 31, 2012	Sep	CAHN
+	40MG	N203415 001	Aug 31, 2012	Aug	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT LUITPOLD	0.05%	A090951 001	Oct 31, 2011	Mar	CAHN
-------------	-------	-------------	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALCLICK

BX + COREPHARMA	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009	Mar	CAHN
BX +	EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009	Mar	CAHN

AUVI-Q

BX + INTELLIJECT	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012	Aug	NEWA
BX	EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012	Aug	NEWA

TWINJECT 0.15

BX + COREPHARMA	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004	Mar	CAHN
-----------------	--------------------	-------------	--------------	-----	------

INJECTABLE; IM-SC

TWINJECT 0.3

BX	+	COREPHARMA	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Mar	CAHN
----	---	------------	-------------------	-------------	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D>		@ ELKINS SINN	0.01MG/ML;1%	A080406 001		Sep	CAHN
-----	--	---------------	--------------	-------------	--	-----	------

>D>		@	0.01MG/ML;2%	A080406 002		Sep	CAHN
-----	--	---	--------------	-------------	--	-----	------

>A>		@ HIKMA MAPLE	0.01MG/ML;1%	A080406 001		Sep	CAHN
-----	--	---------------	--------------	-------------	--	-----	------

>A>		@	0.01MG/ML;2%	A080406 002		Sep	CAHN
-----	--	---	--------------	-------------	--	-----	------

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048 001		May	CRLD
----	---	-----------	--------------	-------------	--	-----	------

XYLOCAINE DENTAL WITH EPINEPHRINE

		@ DENTSPLY PHARM	0.01MG/ML;2%	N021381 001		May	DISC
--	--	------------------	--------------	-------------	--	-----	------

		@	0.02MG/ML;2%	N021381 002		May	DISC
--	--	---	--------------	-------------	--	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	200MG/100ML (2MG/ML)	A065361 002	Oct 22, 2007	Mar	CAHN
----	--	-----------	----------------------	-------------	--------------	-----	------

AP			50MG/25ML (2MG/ML)	A065361 001	Oct 22, 2007	Mar	CAHN
----	--	--	--------------------	-------------	--------------	-----	------

AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	CAHN
----	--	----------------------	--------------------	-------------	--------------	-----	------

AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	CAHN
----	--	--	----------------------	-------------	--------------	-----	------

AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012	Mar	NEWA
----	--	--------------------	--------------------	-------------	--------------	-----	------

AP			200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012	Mar	NEWA
----	--	--	----------------------	-------------	--------------	-----	------

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

ACTELION PHARMS LTD EQ 0.5MG BASE/VIAL

N022260 002	Jun 28, 2012	Jun	NEWA
-------------	--------------	-----	------

+ EQ 1.5MG BASE/VIAL

N022260 001	Jun 27, 2008	May	CAHN
-------------	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB		WARNER CHILCOTT LLC	250MG	A062338 001		Jun	CAHN
----	--	---------------------	-------	-------------	--	-----	------

GEL; TOPICAL

E-GLADES

@ COREPHARMA	2%	A065009 001	Mar 18, 2002	Jul	DISC
--------------	----	-------------	--------------	-----	------

@ RENAISSANCE PHARMA	2%	A065009 001	Mar 18, 2002	Aug	CAHN
----------------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

@ RENAISSANCE PHARMA	2%	A064127 001	Feb 14, 1997	Aug	CAHN
----------------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYCETTE

@ JOHNSON AND JOHNSON	2%	N050594 001	Feb 15, 1985	Apr	CAHN
-----------------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

>D>		@ COREPHARMA	2%	A064128 001	Jul 03, 1996	Sep	CAHN
-----	--	--------------	----	-------------	--------------	-----	------

AT	+	FOUGERA PHARMS	2%	A065320 001	Jul 25, 2006	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

>A>		@ RENAISSANCE PHARMA	2%	A064128 001	Jul 03, 1996	Sep	CAHN
-----	--	----------------------	----	-------------	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA
AA	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	May	NEWA
AA	TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA

LEXAPRO

AA	+ FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG
----	---------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	ACCORD HLTHCARE	EQ 5MG BASE	A202389	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202389	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202389	003	Sep 11, 2012	Aug	NEWA
AB	APOTEX INC	EQ 5MG BASE	A078777	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Aug	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A090432	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090432	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090432	003	Sep 11, 2012	Aug	NEWA
AB	HIKMA PHARMS	EQ 5MG BASE	A078766	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078766	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078766	003	Sep 11, 2012	Aug	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A078604	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078604	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078604	003	Sep 11, 2012	Aug	NEWA
AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	NEWA
AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	NEWA
AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	NEWA
AB	JUBILANT ORGANOSYS	EQ 5MG BASE	A202280	001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	Aug	NEWA
AB	LUPIN LTD	EQ 5MG BASE	A078169	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078169	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078169	003	Sep 11, 2012	Aug	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202210	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202210	003	Sep 11, 2012	Aug	NEWA
AB	STI PHARMA LLC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077512	002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077512	003	Sep 12, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE	A090939	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090939	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090939	003	Sep 11, 2012	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734	001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Aug	NEWA

LEXAPRO

AB	FOREST LABS	EQ 5MG BASE	N021323	001	Aug 14, 2002	Feb	CFTG
AB		EQ 10MG BASE	N021323	002	Aug 14, 2002	Feb	CFTG
AB	+	EQ 20MG BASE	N021323	003	Aug 14, 2002	Feb	CFTG

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

AP	+	BAXTER HLTHCARE	10MG/ML	N019386	006	Feb 25, 2003	Jun	CAHN
		@	10MG/ML	N019386	003	Aug 15, 1988	Jun	CAHN
		@	20MG/ML	N019386	007	May 28, 2003	Jun	CAHN
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jun	CAHN
		BREVIBLOC IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jun	CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA

EQ 2.5MG BASE/PACKET

N021957 003 Dec 15, 2011 Jun NEWA

EQ 5MG BASE/PACKET

N021957 004 Dec 15, 2011 Jun NEWA

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT US	0.01%	A086069	001	Jan 31, 1984	Jun	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

GEL, METERED; TRANSDERMAL

ELESTRIN

>D>	+	JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Sep	CAHN
	+		0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Jun	CAHN
>A>	+	JAZZ PHARMS II	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Sep	CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

WARNER IRELAND

EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003 May CAHN

+			EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May	CAHN
---	--	--	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT LLC

0.45MG

N021633 001 Aug 20, 2004 Jun CAHN

0.9MG

N021633 002 Aug 20, 2004 Jun CAHN

+			1.8MG	N021633	003	Aug 20, 2004	Jun	CAHN
---	--	--	-------	---------	-----	--------------	-----	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB TEVA PHARMS USA

0.5MG;0.1MG

A200747 001 Mar 08, 2012 Feb NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM

0.3MG

N020992 001 Jun 21, 2002 Jun CAHN

0.45MG

N020992 005 Feb 05, 2004 Jun CAHN

0.625MG

N020992 002 Mar 24, 1999 Jun CAHN

0.9MG

N020992 003 Mar 24, 1999 Jun CAHN

+			1.25MG	N020992	004	Mar 13, 2000	Jun	CAHN
---	--	--	--------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD
		LOSEASONIQUE						
AB		TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Jun	CAHN
		LYBREL						
		@ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC
		PREVEN EMERGENCY CONTRACEPTIVE KIT						
		@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN
		SEASONALE						
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN
		SEASONIQUE						
AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN
		TABLET; ORAL-21						
		NORDETTE-21						
		@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982	Jun	CAHN
		TABLET; ORAL-28						
		FALMINA						
AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA
		MARLISSA						
AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA
		MYZILRA						
>D>	AB	VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	Sep	CAHN
	AB		0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	May	CDFR
>A>	AB	VINTAGE PHARMS LLC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	Sep	CAHN
		NORDETTE-28						
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Jun	CAHN
		ORSYTHIA						
>D>	AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Sep	CAHN
>A>	AB1	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011	Sep	CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

	+	JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001	Jun	CPOT
--	---	----------------	------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB		GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA
		ALYACEN 7/7/7						
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA
		CYCLAFEM 1/35						
>D>	AB	VINTAGE	0.035MG;1MG	A076337	001	Nov 12, 2010	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010	Sep	CAHN
		CYCLAFEM 7/7/7						
>D>	AB	VINTAGE	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A076338	001	Nov 16, 2010	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A076338	001	Nov 16, 2010	Sep	CAHN
		OVCON-35						
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jun	CAHN

TABLET; ORAL-28

OVCON-50

	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576 001		Jun	CAHN
		WERA					
AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204 001	Mar 27, 2012	Mar	NEWA
		TABLET, CHEWABLE; ORAL					
		FEMCON FE					
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490 001	Nov 14, 2003	Jun	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065 001	Jan 14, 2005	Jun	CAHN
AB	+		0.005MG;1MG	N021065 002	Oct 15, 1999	Jun	CAHN
		LO LOESTRIN FE					
	+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN

TABLET; ORAL-21

ESTROSTEP 21

		@ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
		LOESTRIN 21 1.5/30					
AB		WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875 001		Jun	CAHN
		LOESTRIN 21 1/20					
AB		WARNER CHILCOTT LLC	0.02MG;1MG	N017876 001		Jun	CAHN

TABLET; ORAL-28

ESTROSTEP FE

AB	+	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
		GILDESS FE 1.5/30					
>D>	AB	VINTAGE	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Sep	CAHN
		GILDESS FE 1/20					
>D>	AB	VINTAGE	0.02MG;1MG	A077077 001	May 20, 2005	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077 001	May 20, 2005	Sep	CAHN
		LOESTRIN FE 1.5/30					
AB	+	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

AB		NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
		NORGESTIMATE AND ETHINYL ESTRADIOL					
AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
AB		LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
		PREVIFEM					
>D>	AB	VINTAGE	0.035MG;0.25MG	A076334 001	Jan 09, 2004	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334 001	Jan 09, 2004	Sep	CAHN
		TRI-LINYAH					
AB		NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
		TRI-PREVIFEM					
>D>	AB	VINTAGE	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004	Sep	CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105	001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	---------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

>A>	AB	ZYDUS PHARMS USA INC	250MG	A200892	001	Sep 25, 2012	Sep	NEWA
-----	----	----------------------	-------	---------	-----	--------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+	LUNDBECK LLC	250MG	N010841	001		Aug	CAHN
---	--------------	-------	---------	-----	--	-----	------

@		500MG	N010841	003		Aug	CAHN
---	--	-------	---------	-----	--	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

>D>	@	ENDO PHARMS	200MG	A074842	001	Jul 17, 1997	Sep	CAHN
-----	---	-------------	-------	---------	-----	--------------	-----	------

>D>	@		300MG	A074842	002	Jul 17, 1997	Sep	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

>A>	@	VINTAGE PHARMS LLC	200MG	A074842	001	Jul 17, 1997	Sep	CAHN
-----	---	--------------------	-------	---------	-----	--------------	-----	------

>A>	@		300MG	A074842	002	Jul 17, 1997	Sep	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

ETODOLAC

>D>	@	ENDO PHARMS	400MG	A074841	001	Jun 27, 1997	Sep	CAHN
-----	---	-------------	-------	---------	-----	--------------	-----	------

AB	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Feb	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

AB		500MG	A074819	002	Apr 28, 1998	Feb	CMFD
----	--	-------	---------	-----	--------------	-----	------

>A>	@	VINTAGE PHARMS LLC	400MG	A074841	001	Jun 27, 1997	Sep	CAHN
-----	---	--------------------	-------	---------	-----	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	MYLAN INSTITUTIONAL	2MG/ML	A091297	001	Jun 20, 2012	Jun	NEWA
----	---------------------	--------	---------	-----	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

@	CORDEN PHARMA	50MG	N019557	001	Dec 30, 1986	Feb	CAHN
---	---------------	------	---------	-----	--------------	-----	------

@		100MG	N019557	002	Dec 30, 1986	Feb	CAHN
---	--	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

ETOPOSIDE

AP	+	APP PHARMS LLC	20MG/ML	A074983	001	Sep 30, 1998	Mar	CRLD
----	---	----------------	---------	---------	-----	--------------	-----	------

AP		BEDFORD	20MG/ML	A074290	001	Jul 17, 1995	Mar	CRLD
----	--	---------	---------	---------	-----	--------------	-----	------

VEPESID

@	CORDEN PHARMA	20MG/ML	N018768	001	Nov 10, 1983	Feb	CAHN
---	---------------	---------	---------	-----	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012	Mar	NEWA
-----------------	------	---------	-----	--------------	-----	------

	100MG	N022187	001	Jan 18, 2008	Feb	CAHN
--	-------	---------	-----	--------------	-----	------

+	200MG	N022187	002	Dec 22, 2010	Feb	CAHN
---	-------	---------	-----	--------------	-----	------

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS 7.5MG

N022334 004 Mar 30, 2012 Apr NEWA

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM 2MG

N203985 001 Aug 29, 2012 Aug NEWA

3MG

N203985 002 Aug 29, 2012 Aug NEWA

+ 5MG

N203985 003 Aug 29, 2012 Aug NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ AMYLIN 2MG/VIAL

N022200 001 Jan 27, 2012 Jan NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH 10MG

N021445 001 Oct 25, 2002 Feb CAHN

+ MSP SINGAPORE 10MG

N021445 001 Oct 25, 2002 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL 10MG;10MG

N021687 001 Jul 23, 2004 Jan CAHN

10MG;20MG

N021687 002 Jul 23, 2004 Jan CAHN

10MG;40MG

N021687 003 Jul 23, 2004 Jan CAHN

+ 10MG;80MG

N021687 004 Jul 23, 2004 Jan CAHN

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE 50MG

N022345 001 Jun 10, 2011 May CAHN

200MG

N022345 002 Jun 10, 2011 May CAHN

300MG

N022345 003 Jun 10, 2011 May CAHN

+ 400MG

N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB MACLEODS PHARMS LTD 125MG

A201022 001 Jan 12, 2012 Jan NEWA

AB 250MG

A201022 002 Jan 12, 2012 Jan NEWA

AB 500MG

A201022 003 Jan 12, 2012 Jan NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP + HIKMA MAPLE 10MG/ML

A075488 001 Apr 16, 2001 Jul CAHN

AP + 10MG/ML

A075799 001 Apr 30, 2002 Jul CAHN

FAMOTIDINE PRESERVATIVE FREE

AP + HIKMA MAPLE 10MG/ML

A075789 001 Apr 30, 2002 Jul CAHN

AP + 10MG/ML

A075486 001 Apr 16, 2001 Jul CAHN

TABLET; ORAL

PEPCID

AB MARATHON PHARMS 20MG

N019462 001 Oct 15, 1986 Jan CAHN

TABLET; ORAL

PEPCID

AB	+	MARATHON PHARMS	40MG	N019462	002	Oct 15, 1986	Jan	CAHN
----	---	-----------------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	@	UCB INC	20MG	N021712	001	Sep 24, 2004	Jan	CAHN
--	---	---------	------	---------	-----	--------------	-----	------

	@		40MG	N021712	002	Sep 24, 2004	Jan	CAHN
--	---	--	------	---------	-----	--------------	-----	------

FEBUXOSTAT

TABLET; ORAL

ULORIC

		TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Apr	CAHN
--	--	-------------------	------	---------	-----	--------------	-----	------

+			80MG	N021856	002	Feb 13, 2009	Apr	CAHN
---	--	--	------	---------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>D>	AB	ENDO PHARMS	2.5MG	A200815	001	Oct 28, 2011	Sep	CAHN
-----	----	-------------	-------	---------	-----	--------------	-----	------

>D>	AB		5MG	A200815	002	Oct 28, 2011	Sep	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		10MG	A200815	003	Oct 28, 2011	Sep	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	2.5MG	A200815	001	Oct 28, 2011	Sep	CAHN
-----	----	--------------------	-------	---------	-----	--------------	-----	------

>A>	AB		5MG	A200815	002	Oct 28, 2011	Sep	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	AB		10MG	A200815	003	Oct 28, 2011	Sep	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

	AB	WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012	Jul	NEWA
--	----	---------------	-------	---------	-----	--------------	-----	------

	AB		5MG	A091484	002	Aug 15, 2012	Jul	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

	AB		10MG	A091484	003	Aug 15, 2012	Jul	NEWA
--	----	--	------	---------	-----	--------------	-----	------

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB		LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Feb	CFTG
----	--	----------------	------	---------	-----	--------------	-----	------

AB	+		130MG	N021695	003	Nov 30, 2004	Feb	CFTG
----	---	--	-------	---------	-----	--------------	-----	------

FENOFIBRATE (MICRONIZED)

AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

AB			130MG	A090859	002	Mar 01, 2012	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

FENOFIBRATE

AB		IMPAX LABS	160MG	A076509	002	Mar 26, 2008	May	CRLD
----	--	------------	-------	---------	-----	--------------	-----	------

AB	+		160MG	A076509	002	Mar 26, 2008	Mar	CRLD
----	---	--	-------	---------	-----	--------------	-----	------

AB		TEVA	54MG	A076433	001	May 13, 2005	May	CMFD
----	--	------	------	---------	-----	--------------	-----	------

	@		54MG	A076433	001	May 13, 2005	Mar	DISC
--	---	--	------	---------	-----	--------------	-----	------

AB	+		160MG	A076433	002	May 13, 2005	May	CMFD
----	---	--	-------	---------	-----	--------------	-----	------

	@		160MG	A076433	002	May 13, 2005	Mar	DISC
--	---	--	-------	---------	-----	--------------	-----	------

AB		VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

AB			145MG	A090715	002	Apr 05, 2012	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+	XSPIRE	EQ 200MG BASE	N017604	003			Aug	CAHN
---	--------	---------------	---------	-----	--	--	-----	------

	@	EQ 300MG BASE	N017604	002			Aug	CAHN
--	---	---------------	---------	-----	--	--	-----	------

		EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug	CAHN
--	--	---------------	---------	-----	--------------	-----	------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100							
AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jun	CAHN
FENTANYL-25							
AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jun	CAHN
FENTANYL-50							
AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jun	CAHN
FENTANYL-75							
AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jun	CAHN

SPRAY; SUBLINGUAL
SUBSYS

INSYS THERAP		0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA
		0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATESPRAY, METERED; NASAL
LAZANDA

ARCHIMEDES		EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE							
AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

@ AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996	Jun	DISC
-------------------	-------------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG
		FEXOFENADINE HYDROCHLORIDE						
AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Jun	CPOT
+		10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012	Apr	NEWA
+		10-50ML (13.5-51CMI/ML)	N202008	003	Apr 06, 2012	Apr	NEWA

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012	Apr	NEWA
---	----------------------	----------------------	---------	-----	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug	CAHN
	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Jul	CAHN
AB		100MG	A078423	002	Mar 07, 2011	Jul	CAHN
AB		150MG	A078423	003	Mar 07, 2011	Jul	CAHN
AB		200MG	A078423	004	Mar 07, 2011	Jul	CAHN
	@ PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC
	@	100MG	A076424	002	Jul 29, 2004	Feb	DISC
	@	150MG	A076424	003	Jul 29, 2004	Feb	DISC
	@	200MG	A076424	004	Jul 29, 2004	Feb	DISC
	@ RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004	Apr	DISC
	@	100MG	A076386	002	Jul 29, 2004	Apr	DISC
	@	150MG	A076386	003	Jul 29, 2004	Apr	DISC
	@	200MG	A076386	004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@	GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC
---	--------------	-----------	---------	-----	--------------	-----	------

FLUDARABINE PHOSPHATE

AP	+	HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD
----	---	---------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

OFORTA

@	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	May	DISC
---	-------------------	------	---------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jul	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jul	CAHN
AP	SAGENT PHARMS	0.5MG/5ML (0.1MG/ML)	A090584	001	Aug 28, 2012	Aug	NEWA
AP		1MG/10ML (0.1MG/ML)	A090584	002	Aug 28, 2012	Aug	NEWA
	@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC
	@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Jul	CPOT
---	--------------	------------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

FLUNISOLIDE

AB	HI TECH PHARMA CO	0.025MG/SPRAY	A077704 001	Aug 03, 2006	Aug	CAHN
----	-------------------	---------------	-------------	--------------	-----	------

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

>D>	AB1	ACTAVIS MID ATLANTIC	0.05%	A073085 001	Feb 14, 1992	Sep	CAHN
-----	-----	----------------------	-------	-------------	--------------	-----	------

>A>	AB1	G AND W LABS INC	0.05%	A073085 001	Feb 14, 1992	Sep	CAHN
-----	-----	------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE EMULSIFIED BASE

AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

	@ G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995	May	CAHN
--	--------------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

FLUOCINONIDE

>D>	AT	ACTAVIS MID ATLANTIC	0.05%	A071535 001	Dec 02, 1988	Sep	CAHN
-----	----	----------------------	-------	-------------	--------------	-----	------

>A>	AT	G AND W LABS INC	0.05%	A071535 001	Dec 02, 1988	Sep	CAHN
-----	----	------------------	-------	-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

CARAC

+	VALEANT INTL	0.5%	N020985 001	Oct 27, 2000	Jul	CAHN
---	--------------	------	-------------	--------------	-----	------

FLUOROPLEX

+	AQUA PHARMS	1%	N016988 001		Jan	CAHN
---	-------------	----	-------------	--	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668 001	Jul 17, 2012	Jul	NEWA
----	--------------------	----------------------	-------------	--------------	-----	------

AP		1GM/20ML (50MG/ML)	A202668 002	Jul 17, 2012	Jul	NEWA
----	--	--------------------	-------------	--------------	-----	------

AP		2.5GM/50ML (50MG/ML)	A202669 001	Jul 17, 2012	Jul	NEWA
----	--	----------------------	-------------	--------------	-----	------

AP		5GM/100ML (50MG/ML)	A202669 002	Jul 17, 2012	Jul	NEWA
----	--	---------------------	-------------	--------------	-----	------

>A>	@ SPECTRUM PHARMS	50MG/ML	A087792 001	Oct 13, 1982	Sep	CAHN
-----	-------------------	---------	-------------	--------------	-----	------

>D>	@ WATSON LABS	50MG/ML	A087792 001	Oct 13, 1982	Sep	CAHN
-----	---------------	---------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	ALPHAPHARM	EQ 10MG BASE	A075577 001	Jan 29, 2002	Sep	CAHN
-----	-----	------------	--------------	-------------	--------------	-----	------

>D>	AB1		EQ 20MG BASE	A075577 002	Jan 29, 2002	Sep	CAHN
-----	-----	--	--------------	-------------	--------------	-----	------

>A>	AB1	HERITAGE PHARMS INC	EQ 10MG BASE	A201336 001	Oct 01, 2012	Sep	NEWA
-----	-----	---------------------	--------------	-------------	--------------	-----	------

>A>	AB1		EQ 20MG BASE	A201336 002	Oct 01, 2012	Sep	NEWA
-----	-----	--	--------------	-------------	--------------	-----	------

>A>	AB		EQ 40MG BASE	A201336 003	Oct 01, 2012	Sep	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

>A>	AB1	MYLAN PHARMS INC	EQ 10MG BASE	A075577 001	Jan 29, 2002	Sep	CAHN
-----	-----	------------------	--------------	-------------	--------------	-----	------

>A>	AB1		EQ 20MG BASE	A075577 002	Jan 29, 2002	Sep	CAHN
-----	-----	--	--------------	-------------	--------------	-----	------

PROZAC

AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
-----	------------------	--------------	-------------	--------------	-----	------

AB1		EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
-----	--	--------------	-------------	--------------	-----	------

AB	+	EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
----	---	--------------	-------------	--------------	-----	------

	@	EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN
--	---	--------------	-------------	--------------	-----	------

CAPSULE; ORAL

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
AB2	+	EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
		EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
+		EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
AB		EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA

SYMBYAX

AB	LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806 003		Aug	CRLD
		0.025%	N012806 003		Jul	CAHN
+		0.05%	N012806 002		Aug	CRLD
		0.05%	N012806 002		Jul	CAHN
	WATSON PHARMS	0.05%	N012806 002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
---	-------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@	AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
@		0.05%	N012806 001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
AB		SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD
>D>	AB	WATSON LABS	125MG	A075820 001	Sep 18, 2001	Sep	CAHN
>A>	AB	WATSON LABS INC FL	125MG	A075820 001	Sep 18, 2001	Sep	CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
		FLUTICASONE PROPIONATE					
AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
	@	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
----	------------------	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
----	--	--------------	-------------	--------------	-----	------

AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
----	-------------	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

LESCOL

AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
----	----------	--------------	-------------	--------------	-----	------

AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG
----	---	--------------	-------------	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
--	-------------	-------	-------------	--------------	-----	------

+		150MG	N022033 002	Feb 28, 2008	Jun	CAHN
---	--	-------	-------------	--------------	-----	------

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

>A>	AP	MYLAN LLC	1.5GM/1.5ML (1GM/ML)	A078639 001	Mar 03, 2008	Sep	CAHN
-----	----	-----------	----------------------	-------------	--------------	-----	------

>D>	AP	SYNERX PHARMA	1.5GM/1.5ML (1GM/ML)	A078639 001	Mar 03, 2008	Sep	CAHN
-----	----	---------------	----------------------	-------------	--------------	-----	------

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFOROMIST

>D>	+	DEY PHARMA	0.02MG/2ML	N022007 001	May 11, 2007	Sep	CAHN
-----	---	------------	------------	-------------	--------------	-----	------

>A>	+	MYLAN SPECLT	0.02MG/2ML	N022007 001	May 11, 2007	Sep	CAHN
-----	---	--------------	------------	-------------	--------------	-----	------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
---	-------------------	-----------------------	-------------	--------------	-----	------

+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN
---	--	-----------------------	-------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
---	------------------	------	-------------	--------------	-----	------

@		20MG	A076580 002	Apr 23, 2004	Apr	DISC
---	--	------	-------------	--------------	-----	------

@		40MG	A076580 003	Apr 23, 2004	Apr	DISC
---	--	------	-------------	--------------	-----	------

MONOPRIL

@	BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
---	----------------------	------	-------------	--------------	-----	------

@		20MG	N019915 003	May 16, 1991	Mar	DISC
---	--	------	-------------	--------------	-----	------

@		40MG	N019915 004	Mar 28, 1995	Mar	DISC
---	--	------	-------------	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
----	-------------	-------------------------	-------------	--------------	-----	------

@	TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC
---	-----------------	-------------------------	-------------	--------------	-----	------

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

@ EISAI INC

1050MG/30ML (35MG/ML)

N022244 001 Dec 12, 2008 Jul DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>D> @ BAXTER HLTHCARE

10MG/ML

A071439 001 Sep 14, 1990 Sep CAHN

>D> @

10MG/ML

N018267 001 Sep CAHN

>A> @ HIKMA MAPLE

10MG/ML

A071439 001 Sep 14, 1990 Sep CAHN

>A> @

10MG/ML

N018267 001 Sep CAHN

@ HOSPIRA

10MG/ML

A070578 001 Jul 08, 1987 Jun DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA ACELLA PHARMS LLC

250MG/5ML

A076403 001 May 01, 2012 Jun CAHN

AA AMNEAL PHARMS

250MG/5ML

A202024 001 Mar 23, 2012 Mar NEWA

AA KIEL

250MG/5ML

A076403 001 May 01, 2012 Apr NEWA

TABLET; ORAL

GABAPENTIN

>D> AB MATRIX LABS LTD

600MG

A090335 001 Jun 01, 2010 Sep CAHN

>D> AB

800MG

A090335 002 Jun 01, 2010 Sep CAHN

>A> AB MYLAN PHARMS INC

600MG

A090335 001 Jun 01, 2010 Sep CAHN

>A> AB

800MG

A090335 002 Jun 01, 2010 Sep CAHN

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD

250MG

A076457 001 Jun 27, 2003 Apr DISC

@

500MG

A076457 002 Jun 27, 2003 Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP EMCURE PHARMS LTD

EQ 200MG BASE/VIAL

A202063 001 Sep 11, 2012 Aug NEWA

AP

EQ 1GM BASE/VIAL

A202063 002 Sep 11, 2012 Aug NEWA

AP HAMELN RDS GMBH

EQ 200MG BASE/VIAL

A090663 001 Sep 10, 2012 Aug NEWA

AP

EQ 1GM BASE/VIAL

A090663 002 Sep 10, 2012 Aug NEWA

+ HOSPIRA INC

200MG/5.26ML (38MG/ML)

N200795 001 Aug 04, 2011 Apr CTNA

+

1GM/26.3ML (38MG/ML)

N200795 002 Aug 04, 2011 Apr CTNA

+

2GM/52.6ML (38MG/ML)

N200795 003 Aug 04, 2011 Apr CTNA

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

>D> @ BAXTER HLTHCARE

EQ 10MG BASE/ML

A062251 002 Sep CAHN

>D> @

EQ 40MG BASE/ML

A062251 001 Sep CAHN

>A> @ HIKMA MAPLE

EQ 10MG BASE/ML

A062251 002 Sep CAHN

>A> @

EQ 40MG BASE/ML

A062251 001 Sep CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
	@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
	@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
	@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
	@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+	TAKEDA PHARMS USA	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
		4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>D>	@ ENDO PHARMS	5MG	A074378 001	Nov 28, 1994	Sep	CAHN
>D>	@	10MG	A074378 002	Nov 28, 1994	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994	Sep	CAHN
>A>	@	10MG	A074378 002	Nov 28, 1994	Sep	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	DR REDDYS LABS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
>D>	AB		2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
>D>	AB		5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN
>A>	AB	HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
>A>	AB		2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
>A>	AB		5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

+	MERZ PHARMS	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN
---	-------------	---------	-------------	--------------	-----	------

TABLET; ORAL

GLYCOPYRROLATE

>A>	AA	EXCELLIUM	1MG	A090195 001	Sep 21, 2012	Sep	NEWA
>A>	AA		2MG	A090195 002	Sep 21, 2012	Sep	NEWA
	AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007	Sep	CAHN
-----	----	-----------------	----------------------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
>A>	HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007	Sep	CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
TABLET; ORAL						
		GRIFULVIN V				
	@ VALEANT INTL	125MG	A062279 001		Jul	CAHN
	@	250MG	A062279 002		Jul	CAHN
	+	500MG	A062279 003		Jul	CAHN

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

>A>	AB	ACTAVIS	ELIZABETH	EQ 1MG	BASE	A200881	001	Oct 05,	2012	Sep	NEWA
>A>	AB			EQ 2MG	BASE	A200881	002	Oct 05,	2012	Sep	NEWA
>A>	AB			EQ 3MG	BASE	A200881	003	Oct 05,	2012	Sep	NEWA
>A>	AB			EQ 4MG	BASE	A200881	004	Oct 05,	2012	Sep	NEWA
		INTUNIV									
>D>		SHIRE		EQ 1MG	BASE	N022037	001	Sep 02,	2009	Sep	CFTG
>A>	AB			EQ 1MG	BASE	N022037	001	Sep 02,	2009	Sep	CFTG
>D>				EQ 2MG	BASE	N022037	002	Sep 02,	2009	Sep	CFTG
>A>	AB			EQ 2MG	BASE	N022037	002	Sep 02,	2009	Sep	CFTG
>D>				EQ 3MG	BASE	N022037	003	Sep 02,	2009	Sep	CFTG
>A>	AB			EQ 3MG	BASE	N022037	003	Sep 02,	2009	Sep	CFTG
>D>		+		EQ 4MG	BASE	N022037	004	Sep 02,	2009	Sep	CFTG
>A>	AB	+		EQ 4MG	BASE	N022037	004	Sep 02,	2009	Sep	CFTG

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
OINTMENT; TOPICAL						
		HALOBETASOL PROPIONATE				
AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD
----	---	---------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

	@		10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
--	---	--	--------------------	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
----	---	---------	-------------------	-------------	--------------	-----	------

AP	+		10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD
----	---	--	--------------------	-------------	--------------	-----	------

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

@	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jun	DISC
---	-----------	--------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	--	----------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	ACCORD HLTHCARE	12.5MG	A202556 001	Sep 24, 2012	Sep	NEWA
-----	----	-----------------	--------	-------------	--------------	-----	------

>A>	AB		25MG	A202556 002	Sep 24, 2012	Sep	NEWA
-----	----	--	------	-------------	--------------	-----	------

>A>	AB		50MG	A202556 003	Sep 24, 2012	Sep	NEWA
-----	----	--	------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar	CFTG
----	---	----------------	--------------	-------------	--------------	-----	------

AB	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Mar	CFTG
----	---	--	--------------	-------------	--------------	-----	------

	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Feb	CRLD
--	---	--	--------------	-------------	--------------	-----	------

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	DR REDDYS LABS LTD	12.5MG;150MG	A203500 001	Sep 27, 2012	Sep	NEWA
-----	----	--------------------	--------------	-------------	--------------	-----	------

>A>	AB		12.5MG;300MG	A203500 002	Sep 27, 2012	Sep	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

>A>	AB	MACLEODS PHARMS LTD	12.5MG;150MG	A202414 001	Sep 27, 2012	Sep	NEWA
-----	----	---------------------	--------------	-------------	--------------	-----	------

>A>	AB		12.5MG;300MG	A202414 002	Sep 27, 2012	Sep	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

>A>	AB	MYLAN PHARMS INC	12.5MG;150MG	A077969 001	Sep 27, 2012	Sep	NEWA
-----	----	------------------	--------------	-------------	--------------	-----	------

>A>	AB		12.5MG;300MG	A077969 002	Sep 27, 2012	Sep	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

>A>	AB	SANDOZ	12.5MG;150MG	A077446 001	Sep 27, 2012	Sep	NEWA
-----	----	--------	--------------	-------------	--------------	-----	------

>A>	AB		12.5MG;300MG	A077446 002	Sep 27, 2012	Sep	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

AB		TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
----	--	------	--------------	-------------	--------------	-----	------

AB			12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

@			25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC
---	--	--	------------	-------------	--------------	-----	------

			25MG;300MG	A077369 003	Mar 30, 2012	Mar	NEWA
--	--	--	------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Sep	CAHN
-----	----	-------------	-------------	-------------	--------------	-----	------

AB			12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
----	--	--	-------------	-------------	--------------	-----	------

>D>	AB		12.5MG;100MG	A091617 002	Feb 17, 2012	Sep	CAHN
-----	----	--	--------------	-------------	--------------	-----	------

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;100MG	A091617	002	Feb 17, 2012	Feb	NEWA
>D>	AB	25MG;100MG	A091617	003	Feb 17, 2012	Sep	CAHN
	AB	25MG;100MG	A091617	003	Feb 17, 2012	Feb	NEWA
>A>	AB	ALEMBIC PHARMS LTD 12.5MG;50MG	A091617	001	Feb 17, 2012	Sep	CAHN
>A>	AB	12.5MG;100MG	A091617	002	Feb 17, 2012	Sep	CAHN
>A>	AB	25MG;100MG	A091617	003	Feb 17, 2012	Sep	CAHN
>A>	AB	CADISTA PHARMS 12.5MG;50MG	A201845	001	Sep 18, 2012	Sep	NEWA
>A>	AB	12.5MG;100MG	A201845	002	Sep 18, 2012	Sep	NEWA
>A>	AB	25MG;100MG	A201845	003	Sep 18, 2012	Sep	NEWA
	AB	MACLEODS PHARMS LTD 12.5MG;50MG	A202289	001	Aug 09, 2012	Jul	NEWA
	AB	12.5MG;100MG	A202289	002	Aug 09, 2012	Jul	NEWA
	AB	25MG;100MG	A202289	003	Aug 09, 2012	Jul	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jan	CMFD
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jan	CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Apr	CRLD
		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

>D>	AB	NOVARTIS	25MG;50MG	N018303	001	Dec 31, 1984	Sep	CAHN
>D>	AB	+	25MG;100MG	N018303	002	Dec 31, 1984	Sep	CAHN
>D>		@	50MG;100MG	N018303	003	Dec 31, 1984	Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	25MG;50MG	N018303	001	Dec 31, 1984	Sep	CAHN
>A>	AB	+	25MG;100MG	N018303	002	Dec 31, 1984	Sep	CAHN
>A>		@	50MG;100MG	N018303	003	Dec 31, 1984	Sep	CAHN

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654	002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654	003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Jan	DISC
@		12.5MG;15MG	A090096	002	Sep 25, 2008	Jan	DISC
@		25MG;15MG	A090096	003	Sep 25, 2008	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

>D>		NOVARTIS	12.5MG;80MG	N020818	001	Mar 06, 1998	Sep	CFTG
>A>	AB		12.5MG;80MG	N020818	001	Mar 06, 1998	Sep	CFTG
>D>			12.5MG;160MG	N020818	002	Mar 06, 1998	Sep	CFTG
>A>	AB		12.5MG;160MG	N020818	002	Mar 06, 1998	Sep	CFTG
>D>			12.5MG;320MG	N020818	004	Apr 28, 2006	Sep	CFTG
>A>	AB		12.5MG;320MG	N020818	004	Apr 28, 2006	Sep	CFTG
>D>			25MG;160MG	N020818	003	Jan 17, 2002	Sep	CFTG
>A>	AB		25MG;160MG	N020818	003	Jan 17, 2002	Sep	CFTG

TABLET; ORAL

DIOVAN HCT

>D>	+	NOVARTIS	25MG;320MG	N020818 005	Apr 28, 2006	Sep	CFTG
>A>	AB	+	25MG;320MG	N020818 005	Apr 28, 2006	Sep	CFTG
>A>		VALSARTAN AND HYDROCHLOROTHIAZIDE					
>A>	AB	MYLAN PHARMS INC	12.5MG;80MG	A078020 001	Sep 21, 2012	Sep	NEWA
>A>	AB		12.5MG;160MG	A078020 002	Sep 21, 2012	Sep	NEWA
>A>	AB		12.5MG;320MG	A078020 004	Sep 21, 2012	Sep	NEWA
>A>	AB		25MG;160MG	A078020 003	Sep 21, 2012	Sep	NEWA
>A>	AB		25MG;320MG	A078020 005	Sep 21, 2012	Sep	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYTONE

>D>		@ SANOFI AVENTIS US	1%	A080472 003		Sep	CAHN
>D>		@	2.5%	A080472 004		Sep	CAHN
>A>		@ VALEANT INTL	1%	A080472 003		Sep	CAHN
>A>		@	2.5%	A080472 004		Sep	CAHN
		NUTRACORT					
		@ DOW PHARM	0.5%	A080442 002		Jun	CAHN
		@	1%	A080442 003		Jun	CAHN

LOTION; TOPICAL

CETACORT

@ DOW PHARM

@

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000	Jan	CAHN
		HYTONE					
>D>		@ SANOFI AVENTIS US	1%	A080473 003		Sep	CAHN
>D>		@	2.5%	A080473 004	Nov 30, 1982	Sep	CAHN
>A>		@ VALEANT INTL	1%	A080473 003		Sep	CAHN
>A>		@	2.5%	A080473 004	Nov 30, 1982	Sep	CAHN
		NUTRACORT					
		@ DOW PHARM	0.5%	A080443 002		Jun	CAHN
AT			1%	A080443 003		Jun	CAHN
AT			2.5%	A087644 001	Aug 24, 1982	Jun	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692 001		Jan	CAHN
----	---	----------------	----	-------------	--	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505 001		Jan	CAHN
----	--	----------------	--------	-------------	--	-----	------

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

AB	+	PRECISION DERMAT	0.1%	N018514 001	Mar 31, 1982	Jun	CAHN
		LOCOID LIPOCREAM					
	+	PRECISION DERMAT	0.1%	N020769 001	Sep 08, 1997	Jun	CAHN
		LOTION; TOPICAL					
		LOCOID					
	+	PRECISION DERMAT	0.1%	N022076 001	May 18, 2007	May	CAHN

OINTMENT; TOPICAL

LOCOID

AB	+	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	May	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

LOCOID

AT	+	PRECISION DERMAT	0.1%	N019116	001	Feb 25, 1987	Jun	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB	+	TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
----	---	------	------	---------	-----	--------------	-----	------

WESTCORT

@ RANBAXY

0.2%

N017950	001		Mar	DISC
---------	-----	--	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>D>	AT	ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Sep	CAHN
-----	----	-------	-------------------------------------	---------	-----	--------------	-----	------

>A>	AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Sep	CAHN
-----	----	------------------	-------------------------------------	---------	-----	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN
----	---	-----------	------	---------	-----	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ NESHER PHARMS

2MG

A077311	001	Nov 09, 2005	Jun	DISC
---------	-----	--------------	-----	------

@

4MG

A077311	002	Nov 09, 2005	Jun	DISC
---------	-----	--------------	-----	------

@

8MG

A077311	003	Nov 09, 2005	Jun	DISC
---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC

32MG

N021217	004	Aug 24, 2012	Aug	NEWA
---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC

10MG/5ML

A086880	001		Feb	CAHN
---------	-----	--	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ MIKAH PHARMA

10MG

A040600	001	Dec 28, 2004	Jul	CAHN
---------	-----	--------------	-----	------

@

25MG

A040602	001	Dec 28, 2004	Jul	CAHN
---------	-----	--------------	-----	------

@

50MG

A040604	001	Dec 28, 2004	Jul	CAHN
---------	-----	--------------	-----	------

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

@ PFIZER

EQ 25MG HCL/5ML

N011795	001		Jul	DISC
---------	-----	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
IBANDRONATE SODIUM							
AB		APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
AB		MUTUAL PHARM CO INC	EQ 150MG BASE	A078996 001	Aug 15, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	@	NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
	@		600MG	A078132 002	Sep 10, 2007	Jun	DISC
	@		800MG	A078132 003	Sep 10, 2007	Jun	DISC
	@	OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
---	--------------	------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+	AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
---	-------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>A>	AP	ONCO THERAPIES LTD	1MG/ML	A200144 001	Oct 11, 2012	Sep	NEWA
	@	TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
	@		10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
	@		20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB		PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB			25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB			50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB		APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB		FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB		GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

>D>	AB	ALPHAPHARM	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
>D>	AB		2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
>A>	AB		2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>A>	AB	HETERO LABS LTD III	75MG	A201807 001	Sep 28, 2012	Sep	NEWA
-----	----	---------------------	------	-------------	--------------	-----	------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

		LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
	+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

@ LILLY

50 UNITS/ML;50 UNITS/ML

N021018 003	Dec 22, 1999	Jun	DISC
-------------	--------------	-----	------

HUMALOG MIX 75/25 PEN

@ LILLY

75 UNITS/ML;25 UNITS/ML

N021017 003	Dec 22, 1999	Jun	DISC
-------------	--------------	-----	------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

@ LILLY

100 UNITS/ML

N020563 002	Aug 06, 1998	Jun	DISC
-------------	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN	TEVA PARENTERAL	0.02%	A075313 001	Feb 07, 2000	Sep	CAHN
>A>	AN	TEVA PHARMS	0.02%	A075313 001	Feb 07, 2000	Sep	CAHN

IRBESARTAN

TABLET; ORAL

AVAPRO

AB		SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
AB			150MG	N020757 002	Sep 30, 1997	Mar	CFTG
AB	+		300MG	N020757 003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

>A>	AB	AUROBINDO PHARMA LTD	75MG	A203081 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A203081 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A203081 003	Sep 27, 2012	Sep	NEWA
>A>	AB	DR REDDYS LABS LTD	75MG	A203161 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A203161 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A203161 003	Sep 27, 2012	Sep	NEWA

TABLET; ORAL

IRBESARTAN

>A>	AB	HETERO LABS LTD V	75MG	A202910 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A202910 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A202910 003	Sep 27, 2012	Sep	NEWA
>A>	AB	MACLEODS PHARMS LTD	75MG	A202254 001	Oct 03, 2012	Sep	NEWA
>A>	AB		150MG	A202254 002	Oct 03, 2012	Sep	NEWA
>A>	AB		300MG	A202254 003	Oct 03, 2012	Sep	NEWA
>A>	AB	MYLAN PHARMS INC	75MG	A200461 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A200461 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A200461 003	Sep 27, 2012	Sep	NEWA
>A>	AB	PRINSTON INC	75MG	A203071 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A203071 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A203071 003	Sep 27, 2012	Sep	NEWA
>A>	AB	SANDOZ	75MG	A077466 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A077466 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A077466 003	Sep 27, 2012	Sep	NEWA
	AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
	AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
	AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA
>A>	AB	WATSON LABS INC	75MG	A090720 001	Oct 12, 2012	Sep	NEWA
>A>	AB		150MG	A090720 002	Oct 12, 2012	Sep	NEWA
>A>	AB		300MG	A090720 003	Oct 12, 2012	Sep	NEWA
>A>	AB	ZYDUS PHARMS USA INC	75MG	A079213 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A079213 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A079213 003	Sep 27, 2012	Sep	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP		CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP			100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP		EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP			100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP		HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP			100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP		TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP			100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP			500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
		@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

AN	+	BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
----	---	-----------------	-------	-------------	--	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB		ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Jun	CAHN
		@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

>D>		CIPHER	10MG	N021951 001	May 25, 2012	Sep	CTEC
-----	--	--------	------	-------------	--------------	-----	------

CAPSULE; ORAL									
ABSORICA									
>A>	BX	CIPHER	10MG	N021951	001	May 25, 2012	Sep	CTEC	
			10MG	N021951	001	May 25, 2012	May	NEWA	
>D>			20MG	N021951	002	May 25, 2012	Sep	CTEC	
>A>	BX		20MG	N021951	002	May 25, 2012	Sep	CTEC	
			20MG	N021951	002	May 25, 2012	May	NEWA	
>D>			30MG	N021951	003	May 25, 2012	Sep	CTEC	
>A>	BX		30MG	N021951	003	May 25, 2012	Sep	CTEC	
			30MG	N021951	003	May 25, 2012	May	NEWA	
>D>			40MG	N021951	004	May 25, 2012	Sep	CTEC	
>A>	BX		40MG	N021951	004	May 25, 2012	Sep	CTEC	
			40MG	N021951	004	May 25, 2012	May	NEWA	
MYORISAN									
AB		DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Jan	NEWA	
AB			20MG	A076485	002	Jan 19, 2012	Jan	NEWA	
AB			40MG	A076485	003	Jan 19, 2012	Jan	NEWA	
ITRACONAZOLE									
CAPSULE; ORAL									
ITRACONAZOLE									
AB		MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012	Jul	NEWA	
IVACAFTOR									
TABLET; ORAL									
KALYDECO									
+		VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012	Jan	NEWA	
IVERMECTIN									
LOTION; TOPICAL									
SKLICE									
+		SANOFI PASTEUR	0.5%	N202736	001	Feb 07, 2012	Feb	NEWA	
KANAMYCIN SULFATE									
INJECTABLE; INJECTION									
KANAMYCIN									
>D>		@ BAXTER HLTHCARE	EQ 75MG BASE/2ML	A062324	001		Sep	CAHN	
>D>		@	EQ 500MG BASE/2ML	A062324	002		Sep	CAHN	
>D>		@	EQ 1GM BASE/3ML	A062324	003		Sep	CAHN	
>A>		@ HIKMA MAPLE	EQ 75MG BASE/2ML	A062324	001		Sep	CAHN	
>A>		@	EQ 500MG BASE/2ML	A062324	002		Sep	CAHN	
>A>		@	EQ 1GM BASE/3ML	A062324	003		Sep	CAHN	
KETOCONAZOLE									
CREAM; TOPICAL									
KETOCONAZOLE									
AB		FOUGERA PHARMS	2%	A076294	001	Apr 28, 2004	Jan	CAHN	
KETOPROFEN									
CAPSULE; ORAL									
KETOPROFEN									
		DORADO PHARMA	25MG	A074014	001	Jan 29, 1993	Jul	CAHN	
AB			50MG	A074014	002	Jan 29, 1993	Jul	CAHN	
AB			75MG	A074014	003	Jan 29, 1993	Jul	CAHN	

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB	ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997	Jun	CAHN
----	----------------------	-------	-------------	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>D>	AP	BAXTER HLTHCARE	15MG/ML	A075772 001	Jul 21, 2004	Sep	CAHN
>D>	AP		30MG/ML	A075772 002	Jul 21, 2004	Sep	CAHN
>D>	AP	BAXTER HLTHCARE CORP	15MG/ML	A075299 001	Nov 03, 1999	Sep	CAHN
>D>	AP		30MG/ML	A075299 002	Nov 03, 1999	Sep	CAHN
>A>	AP	HIKMA MAPLE	15MG/ML	A075772 001	Jul 21, 2004	Sep	CAHN
>A>	AP		15MG/ML	A075299 001	Nov 03, 1999	Sep	CAHN
>A>	AP		30MG/ML	A075299 002	Nov 03, 1999	Sep	CAHN
>A>	AP		30MG/ML	A075772 002	Jul 21, 2004	Sep	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908 001	Jul 10, 2012	Jun	NEWA
AB		200MG	A200908 002	Jul 10, 2012	Jun	NEWA
AB		300MG	A200908 003	Jul 10, 2012	Jun	NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
AB		200MG	A090169 004	May 12, 2012	Apr	NEWA
BX	UPSHER SMITH	25MG	A078310 001	Feb 04, 2009	Aug	CTEC
BX		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
BX		150MG	A078310 003	Feb 04, 2009	Aug	CTEC
BX		200MG	A078310 004	Feb 04, 2009	Aug	CTEC

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>D>	AB	MATRIX LABS LTD	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
>D>	AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
>A>	AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
	AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
	AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@	TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
@		30MG	A078730 002	Oct 15, 2010	Mar	DISC

PREVACID

	TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
+		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

@	SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
		EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
		EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

>A>	AT	AKORN	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN
>D>	AT	PADDOCK LLC	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

>D>	+	CELGENE	15MG	N021880 003	Jun 29, 2006	Sep	CRLD
>A>			15MG	N021880 003	Jun 29, 2006	Sep	CRLD

LETROZOLE

TABLET; ORAL

LETROZOLE

	AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
>D>	AB	ENDO PHARMS	2.5MG	A090789 001	Jun 03, 2011	Sep	CAHN

TABLET; ORAL

LETROZOLE

>A>	AB	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Sep	CAHN
-----	----	--------------------	-------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ TEVA PARENTERAL

EQ 50MG BASE/VIAL

A081278 001 Sep 28, 1993 Mar DISC

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A200753	001	Sep 06, 2012	Aug	NEWA
AP		EQ 100MG BASE/VIAL	A200753	002	Sep 06, 2012	Aug	NEWA
AP		EQ 200MG BASE/VIAL	A200753	003	Sep 06, 2012	Aug	NEWA
AP		EQ 350MG BASE/VIAL	A200855	001	Sep 06, 2012	Aug	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011	001	Oct 22, 1990	May	CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	May	CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	May	CAHN
AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869	001	Apr 06, 2012	Mar	NEWA
AP	LUITPOLD	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Aug	CAHN
AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Jan	NEWA
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	LOTUS PHARM CO LTD	500MG	A090906	001	Nov 05, 2010	Jul	CAHN
AB	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797	003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797	004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	BOCA PHARMA	500MG	A201464	001	May 25, 2012	May	NEWA
AB		750MG	A201464	002	May 25, 2012	May	NEWA
AB	ROUSES POINT PHARMS	500MG	A202524	001	Aug 27, 2012	Aug	NEWA
AB		750MG	A202524	002	Aug 27, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012	May	NEWA
AB		750MG	A091338	002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264	001	Jun 29, 2012	Jun	NEWA
----	---------------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA
AB	ZYDUS PHARMS USA INC	250MG	A077652 001	Sep 07, 2012	Aug	NEWA
AB		500MG	A077652 002	Sep 07, 2012	Aug	NEWA
AB		750MG	A077652 003	Sep 07, 2012	Aug	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS

EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)

N020140 003 Apr 29, 2011 Jun DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB	WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA
	PLAN B					
AB	+ TEVA BRANDED PHARM	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
	@	0.75MG	N021045 001	Jul 28, 1999	May	CAHN
	PLAN B ONE-STEP					
AB	+ DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

AB	WATSON LABS INC	5%	A200675 001	Aug 23, 2012	Aug	NEWA
	LIDODERM					
AB	+ TEIKOKU PHARMA USA	5%	N020612 001	Mar 19, 1999	Aug	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	@ BAXTER HLTHCARE	1%	A080407 001		Sep	CAHN
>D>	@	2%	A080407 002		Sep	CAHN
>A>	@ HIKMA MAPLE	1%	A080407 001		Sep	CAHN
>A>	@	2%	A080407 002		Sep	CAHN
>A>	AP PFIZER	0.5%	A091058 001	Sep 30, 2010	Sep	CAHN
>A>	AP	0.5%	A091056 001	Dec 08, 2010	Sep	CAHN
>A>	AP	1%	A091056 002	Dec 08, 2010	Sep	CAHN
>A>	AP	1%	A091058 002	Sep 30, 2010	Sep	CAHN
>D>	AP STRIDES ARCOLAB LTD	0.5%	A091056 001	Dec 08, 2010	Sep	CAHN
>D>	AP	0.5%	A091058 001	Sep 30, 2010	Sep	CAHN
>D>	AP	1%	A091056 002	Dec 08, 2010	Sep	CAHN
>D>	AP	1%	A091058 002	Sep 30, 2010	Sep	CAHN

INJECTABLE; INJECTION

	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE				
>D>	@ BAXTER HLTHCARE	1%	A084625 001	Sep	CAHN	
>D>	@	2%	A084625 002	Sep	CAHN	
>A>	@ HIKMA MAPLE	1%	A084625 001	Sep	CAHN	
>A>	@	2%	A084625 002	Sep	CAHN	
>A>	AP PFIZER	2%	A090665 001	Sep 27, 2010	Sep	CAHN
>D>	AP STRIDES ARCOLAB LTD	2%	A090665 001	Sep 27, 2010	Sep	CAHN
	XYLOCAINE DENTAL					
	@ DENTSPLY PHARM	2%	N021380 001	May	DISC	

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003	Jan	CAHN
----	----------------	-----------	-------------	--------------	-----	------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+	GALDERMA LABS LP	7%;7%	N021717 001	Jun 29, 2006	Jun	CTNA
---	------------------	-------	-------------	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

	FOREST LABS INC	145MCG	N202811 001	Aug 30, 2012	Aug	NEWA
+		290MCG	N202811 002	Aug 30, 2012	Aug	NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan	NEWA
		2.5MG;850MG	N201281 002	Jan 30, 2012	Jan	NEWA
+		2.5MG;1GM	N201281 003	Jan 30, 2012	Jan	NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun	NEWA
	ZYVOX					
AP	+ PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun	CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun	NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul	NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588 001		Jun	CMFD
	@	10MG	N017588 001		May	DISC
		40MG	N017588 002		Jun	CMFD
	@	40MG	N017588 002		May	DISC
+		100MG	N017588 003		Jun	CMFD
	@	100MG	N017588 003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Jan	NEWA
----	-------------------	--------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

LORAZEPAM

>D>	@ BAXTER HLTHCARE	2MG/ML	A074496	001	Sep 28, 1998	Sep	CAHN
>D>	@	4MG/ML	A074496	002	Sep 28, 1998	Sep	CAHN
	@ BEDFORD	2MG/ML	A077076	001	Jul 13, 2005	Jun	DISC
	@	4MG/ML	A077076	002	Jul 13, 2005	Jun	DISC
>A>	@ HIKMA MAPLE	2MG/ML	A074496	001	Sep 28, 1998	Sep	CAHN
>A>	@	4MG/ML	A074496	002	Sep 28, 1998	Sep	CAHN
	@ HOSPIRA	2MG/ML	A074300	001	Apr 12, 1994	Jun	DISC

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+	ARENA PHARMS INC	10MG	N022529	001	Jun 27, 2012	Jun	NEWA
+	EISAI INC	10MG	N022529	001	Jun 27, 2012	Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

>A>	AB	CADISTA PHARMS	25MG	A201170	001	Sep 18, 2012	Sep	NEWA
>A>	AB		50MG	A201170	002	Sep 18, 2012	Sep	NEWA
>A>	AB		100MG	A201170	003	Sep 18, 2012	Sep	NEWA
	AB	MACLEODS PHARMS LTD	25MG	A202230	001	May 30, 2012	May	NEWA
	AB		50MG	A202230	002	May 30, 2012	May	NEWA
	AB		100MG	A202230	003	May 30, 2012	May	NEWA
>A>	AB	MICRO LABS LTD INDIA	25MG	A091541	001	Sep 24, 2012	Sep	NEWA
>A>	AB		50MG	A091541	002	Sep 24, 2012	Sep	NEWA
>A>	AB		100MG	A091541	003	Sep 24, 2012	Sep	NEWA

LOTEPREDNOL ETABONATE

>A>	GEL; OPHTHALMIC							
>A>	LOTEMAX							
>A>	+	BAUSCH AND LOMB	0.5%	N202872	001	Sep 28, 2012	Sep	NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

@	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	Jul	CAHN
@		EQ 10MG BASE	A076868	002	Aug 04, 2005	Jul	CAHN
@		EQ 25MG BASE	A076868	003	Aug 04, 2005	Jul	CAHN
@		EQ 50MG BASE	A076868	004	Aug 04, 2005	Jul	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	Apr	NEWA
---	----------------	-------	---------	-----	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

+	SUNOVION PHARMS INC	20MG	N200603	003	Dec 07, 2011	Aug	CRLD
---	---------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Apr	NEWA
		40MG	N200603 001	Oct 28, 2010	Aug	CRLD
+		40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

@	EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004	Jun	DISC
---	------------	------------	-------------	--------------	-----	------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLLON

+	MYLAN LLC	EQ 85MG BASE/GM	N016763 001		Jun	CAHN
---	-----------	-----------------	-------------	--	-----	------

FOR SOLUTION; TOPICAL

SULFAMYLLON

+	MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jun	CAHN
---	-----------	----	-------------	--------------	-----	------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@	SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009	Jun	DISC
---	----------	------------------	-------------	--------------	-----	------

@		343MG;40MG;750MG	N022456 002	Dec 04, 2009	Jun	DISC
---	--	------------------	-------------	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
--	---------	----------------------	-------------	--------------	-----	------

		40GM/1000ML (40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA
--	--	-----------------------	-------------	--------------	-----	------

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
----	------------------	------	-------------	--------------	-----	------

AT	SUVEN LIFE	0.5%	A091559 001	May 23, 2012	May	NEWA
----	------------	------	-------------	--------------	-----	------

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010	May	CAHN
---	---------------	----------------------------	-------------	--------------	-----	------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
----	-----------------	--------	-------------	--------------	-----	------

AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA
----	--	------	-------------	--------------	-----	------

>A>	AA	MYLAN PHARMS INC	12.5MG	A202640 001	Sep 17, 2012	Sep	NEWA
-----	----	------------------	--------	-------------	--------------	-----	------

>A>	AA		25MG	A202640 002	Sep 17, 2012	Sep	NEWA
-----	----	--	------	-------------	--------------	-----	------

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	AA	MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012	Sep	NEWA
-----	----	------------------	------	-------------	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@ TEVA PARENTERAL 150MG/ML

A076552 001 Oct 27, 2004 Apr DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

>A>	AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270 001	Jun 09, 2009	Sep	CAHN
-----	----	---------------------	-------------------	-------------	--------------	-----	------

>D>	AP	SYNERX	EQ 50MG BASE/VIAL	A090270 001	Jun 09, 2009	Sep	CAHN
-----	----	--------	-------------------	-------------	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@ ORCHID HLTHCARE 5MG

A090044 001 Mar 12, 2012 Mar DISC

AB			5MG	A090044 001	Mar 12, 2012	Feb	NEWA
----	--	--	-----	-------------	--------------	-----	------

	@		10MG	A090044 002	Mar 12, 2012	Mar	DISC
--	---	--	------	-------------	--------------	-----	------

AB			10MG	A090044 002	Mar 12, 2012	Feb	NEWA
----	--	--	------	-------------	--------------	-----	------

NAMENDA

FOREST LABS 5MG

N021487 001 Oct 16, 2003 Mar CTEC

AB			5MG	N021487 001	Oct 16, 2003	Feb	CTEC
----	--	--	-----	-------------	--------------	-----	------

	+		10MG	N021487 002	Oct 16, 2003	Mar	CTEC
--	---	--	------	-------------	--------------	-----	------

AB	+		10MG	N021487 002	Oct 16, 2003	Feb	CTEC
----	---	--	------	-------------	--------------	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE CORP	25MG/ML	A080455 007		Sep	CAHN
-----	----	----------------------	---------	-------------	--	-----	------

>D>	AP		50MG/ML	A080455 008		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>D>	AP		75MG/ML	A080455 009		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>D>	AP		100MG/ML	A080455 010		Sep	CAHN
-----	----	--	----------	-------------	--	-----	------

>D>	AP	ELKINS SINN	25MG/ML	A080445 001		Sep	CAHN
-----	----	-------------	---------	-------------	--	-----	------

>D>	AP		50MG/ML	A080445 002		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>D>	AP		75MG/ML	A080445 003		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>D>	AP		100MG/ML	A080445 004		Sep	CAHN
-----	----	--	----------	-------------	--	-----	------

>A>	AP	HIKMA MAPLE	25MG/ML	A080445 001		Sep	CAHN
-----	----	-------------	---------	-------------	--	-----	------

>A>	AP		25MG/ML	A080455 007		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>A>	AP		50MG/ML	A080455 008		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>A>	AP		50MG/ML	A080445 002		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>A>	AP		75MG/ML	A080455 009		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>A>	AP		75MG/ML	A080445 003		Sep	CAHN
-----	----	--	---------	-------------	--	-----	------

>A>	AP		100MG/ML	A080455 010		Sep	CAHN
-----	----	--	----------	-------------	--	-----	------

>A>	AP		100MG/ML	A080445 004		Sep	CAHN
-----	----	--	----------	-------------	--	-----	------

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	BAXTER HLTHCARE CORP	10MG/ML	A081002 001	Jul 30, 1993	Sep	CAHN
-----	----	----------------------	---------	-------------	--------------	-----	------

>A>	AP	HIKMA MAPLE	10MG/ML	A081002 001	Jul 30, 1993	Sep	CAHN
-----	----	-------------	---------	-------------	--------------	-----	------

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@ DENTSPLY PHARM 3%

A088653 001 Aug 21, 1984 May DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@ AQUA PHARMS 2%;0.01%

N020922 001 Dec 10, 1999 Jun DISC

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@ APTALIS PHARMA US 500MG
1GM

N021252 001 Jan 05, 2001 Jul CAHN

N021252 002 Nov 05, 2004 Jul CAHN

ROWASA

@ MEDA PHARMS 500MG

N019919 001 Dec 18, 1990 Jan CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP MYLAN INSTITUTIONAL 100MG/ML

A076488 001 Mar 08, 2012 Feb NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D> AB ALPHAPHARM 500MG

A075969 001 Jan 29, 2002 Sep CAHN

>D> AB 850MG

A075969 002 Jan 29, 2002 Sep CAHN

>D> AB 1GM

A075969 003 Jan 29, 2002 Sep CAHN

AB MARKSANS PHARMA 500MG

A090888 001 Mar 12, 2012 Feb NEWA

AB 850MG

A090888 002 Mar 12, 2012 Feb NEWA

AB 1GM

A090888 003 Mar 12, 2012 Feb NEWA

>A> AB MYLAN PHARMS INC 500MG

A075969 001 Jan 29, 2002 Sep CAHN

>A> AB 850MG

A075969 002 Jan 29, 2002 Sep CAHN

>A> AB 1GM

A075969 003 Jan 29, 2002 Sep CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 AUROBINDO PHARMA LTD 500MG

A079118 001 Jul 20, 2012 Jul NEWA

AB 750MG

A079118 002 Jul 20, 2012 Jul NEWA

AB1 INVENTIA HLTHCARE 500MG

A201991 001 Jan 18, 2012 Jan NEWA

AB2 MYLAN PHARMS INC 500MG

A200690 001 Aug 01, 2012 Jul NEWA

AB 1GM

A200690 002 Aug 01, 2012 Jul NEWA

@ RANBAXY LABS LTD 500MG

A076413 001 Jun 18, 2004 Apr DISC

@ 750MG

A077211 001 Jun 29, 2005 Apr DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB TAKEDA PHARMS USA 500MG;EQ 15MG BASE

N021842 001 Aug 29, 2005 Aug CAHN

AB + 850MG;EQ 15MG BASE

N021842 002 Aug 29, 2005 Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

TAKEDA PHARMS USA 1GM;EQ 15MG BASE

N022024 001 May 12, 2009 Aug CAHN

+ 1GM;EQ 30MG BASE

N022024 002 May 12, 2009 Aug CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

BRISTOL MYERS SQUIBB 500MG;EQ 5MG BASE

N200678 001 Nov 05, 2010 Apr CAIN

1GM;EQ 2.5MG BASE

N200678 003 Nov 05, 2010 Apr CAIN

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

+	BRISTOL MYERS SQUIBB	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAIN
---	----------------------	-----------------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989	001		Mar	CMFD
AA		750MG	A086988	001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	---------	-----	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	AP	+	BIONICHE PHARMA USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Sep	CAHN
>D>	AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Sep	CAHN
	AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Feb	CAHN
>A>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Sep	CAHN
>A>	AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Sep	CAHN
	AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	NEWA
	AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	NEWA
	AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	NEWA
	AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar	NEWA
	AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Mar	NEWA

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

>A>	AA	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012	Sep	NEWA
>A>	AA		5MG	A200602 002	Sep 24, 2012	Sep	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM 2.5MG

N012524 001 Mar DISC

@ 5MG

N012524 004 Mar DISC

METHYCLOTHIAZIDE

AB	+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	---	------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL 50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

>D>	AP	+	NOVARTIS	0.2MG/ML	N006035 004	Sep	CAHN
-----	----	---	----------	----------	-------------	-----	------

>A>	AP	+	US PHARMS HOLDINGS I	0.2MG/ML	N006035 004	Sep	CAHN
-----	----	---	----------------------	----------	-------------	-----	------

TABLET; ORAL

METHERGINE

>D>	AB	+	NOVARTIS	0.2MG	N006035 003	Sep	CAHN
-----	----	---	----------	-------	-------------	-----	------

>A>	AB	+	US PHARMS HOLDINGS I	0.2MG	N006035 003	Sep	CAHN
-----	----	---	----------------------	-------	-------------	-----	------

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS 8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+ 12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS 12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB	UCB INC	10MG	N021259 003	May 27, 2003	Jul	CFTG
----	---------	------	-------------	--------------	-----	------

AB2		20MG	N021259 001	Apr 03, 2001	Jul	CFTG
-----	--	------	-------------	--------------	-----	------

AB2		30MG	N021259 002	Jun 19, 2003	Jul	CFTG
-----	--	------	-------------	--------------	-----	------

AB2		40MG	N021259 004	Feb 19, 2006	Jul	CFTG
-----	--	------	-------------	--------------	-----	------

AB		50MG	N021259 005	Feb 19, 2006	Jul	CFTG
----	--	------	-------------	--------------	-----	------

AB	+	60MG	N021259 006	Feb 19, 2006	Jul	CFTG
----	---	------	-------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

AB1	ACTAVIS	20MG	A078458 001	Dec 01, 2011	Jul	CTEC
-----	---------	------	-------------	--------------	-----	------

AB1		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
-----	--	------	-------------	--------------	-----	------

AB1		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
-----	--	------	-------------	--------------	-----	------

AB1	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jul	CTEC
-----	---------------	------	-------------	--------------	-----	------

AB		20MG	A079031 001	Jul 13, 2012	Jun	NEWA
----	--	------	-------------	--------------	-----	------

AB1		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
-----	--	------	-------------	--------------	-----	------

AB		30MG	A079031 002	Jul 13, 2012	Jun	NEWA
----	--	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	BARR LABS INC	40MG	A079031	003	Jul 13, 2012	Jul	CTEC
AB		40MG	A079031	003	Jul 13, 2012	Jun	NEWA
AB	TEVA PHARMS	10MG	A077707	001	Jul 19, 2012	Jul	NEWA
AB2		20MG	A077707	002	Jul 19, 2012	Jul	NEWA
AB2		30MG	A077707	003	Jul 19, 2012	Jul	NEWA
AB2		40MG	A078873	001	Jul 19, 2012	Jul	NEWA
AB		50MG	A078873	002	Jul 19, 2012	Jul	NEWA
AB		60MG	A078873	003	Jul 19, 2012	Jul	NEWA

RITALIN LA

AB1	NOVARTIS	20MG	N021284	001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284	002	Jun 05, 2002	Jul	CTEC
AB1	+	40MG	N021284	003	Jun 05, 2002	Jul	CTEC

>A> FOR SUSPENSION, EXTENDED RELEASE; ORAL

>A> QUILLIVANT XR

>A> + NEXTWAVE PHARMS 5MG/ML N202100 001 Sep 27, 2012 Sep NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710	002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710	003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@ UCB INC 10MG A040306 001 Oct 20, 1999 Jul DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Aug	CAHN
AP		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Aug	CAHN
	METHYLPREDNISOLONE SODIUM SUCCINATE						
	@ BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007	Jun	DISC
	@	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007	Jun	DISC
	@	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007	Jun	DISC
	@	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007	Jun	DISC
	@	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007	Jun	DISC
	@	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007	Jun	DISC
	@ TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@ TEVA PARENTERAL EQ 5MG BASE/ML A073135 001 Nov 27, 1991 Jan DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617	001	Aug 01, 2012	Jul	NEWA
AB		EQ 50MG TARTRATE	A090617	002	Aug 01, 2012	Jul	NEWA
	@ NESHER PHARMS	EQ 100MG TARTRATE	A076640	002	May 18, 2007	Jun	DISC
	@	EQ 200MG TARTRATE	A076640	001	May 18, 2007	Jun	DISC
AB	REDDYS	EQ 100MG BASE	A078889	001	Aug 15, 2012	Jul	NEWA
AB		EQ 200MG BASE	A078889	002	Aug 15, 2012	Jul	NEWA
	@ SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006	Aug	DISC
	@	EQ 50MG TARTRATE	A076969	002	May 18, 2007	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

@ SANDOZ

EQ 100MG TARTRATE

A076969 003 Mar 20, 2008 Aug DISC

@

EQ 200MG TARTRATE

A076969 004 Mar 20, 2008 Aug DISC

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

>D>	AB	NOVARTIS	50MG	N017963 001		Sep	CAHN
>D>	AB		100MG	N017963 002		Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	50MG	N017963 001		Sep	CAHN
>A>	AB		100MG	N017963 002		Sep	CAHN

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

NORITATE

+		VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN
---	--	--------------	----	-------------	--------------	-----	------

GEL; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE

>D>		@ ELKINS SINN	500MG/100ML	N018907 001	Mar 30, 1984	Sep	CAHN
-----	--	---------------	-------------	-------------	--------------	-----	------

>A>		@ HIKMA MAPLE	500MG/100ML	N018907 001	Mar 30, 1984	Sep	CAHN
-----	--	---------------	-------------	-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+		HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
---	--	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METOPIRONE

		@ HRA PHARMA	250MG	N012911 001		Jun	CAHN
--	--	--------------	-------	-------------	--	-----	------

METYROSINE

CAPSULE; ORAL

DEMSE

+		BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
---	--	----------------------	-------	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
>D>	AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN
>D>	AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
>D>	AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN
	AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
	AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA
>A>	AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
>A>	AP		EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
>A>	AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN
>A>	AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB	SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+	5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB		10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
---	----------------	-------	-------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>D>	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	A075530 001	May 28, 2002	Sep	CAHN
>D>		@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075852 001	May 28, 2002	Sep	CAHN
>A>	AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075530 001	May 28, 2002	Sep	CAHN
>A>		@	EQ 1MG BASE/ML	A075852 001	May 28, 2002	Sep	CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>		@ BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002	Sep	CAHN
>A>		@ HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002	Sep	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
	@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN
AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	RANBAXY LABS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012	Jul	NEWA
		EQ 67.5MG BASE	N201922 002	Jul 11, 2012	Jul	NEWA
		EQ 90MG BASE	N201922 003	Jul 11, 2012	Jul	NEWA
		EQ 112.5MG BASE	N201922 004	Jul 11, 2012	Jul	NEWA
+		EQ 135MG BASE	N201922 005	Jul 11, 2012	Jul	NEWA

INJECTABLE; INJECTION

MINOCIN

+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN
---	------------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

MINOCIN

@	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN
---	------------------	------------------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	BARR LABS INC	EQ 65MG BASE	A065485 004	May 18, 2012	Sep	NEWA
>A>	AB		EQ 115MG BASE	A065485 005	May 18, 2012	Sep	NEWA
>D>	AB	MATRIX LABS LTD	EQ 45MG BASE	A090911 001	Jul 20, 2010	Sep	CAHN
>D>	AB		EQ 90MG BASE	A090911 002	Jul 20, 2010	Sep	CAHN
>D>	AB		EQ 135MG BASE	A090911 003	Jul 20, 2010	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 45MG BASE	A090911 001	Jul 20, 2010	Sep	CAHN
>A>	AB		EQ 90MG BASE	A090911 002	Jul 20, 2010	Sep	CAHN
>A>	AB		EQ 135MG BASE	A090911 003	Jul 20, 2010	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

>D>		MEDICIS	EQ 65MG BASE	N050808 004	Jul 23, 2009	Sep	CFTG
>A>	AB		EQ 65MG BASE	N050808 004	Jul 23, 2009	Sep	CFTG
>D>			EQ 115MG BASE	N050808 005	Jul 23, 2009	Sep	CFTG
>A>	AB		EQ 115MG BASE	N050808 005	Jul 23, 2009	Sep	CFTG

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

		APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA
		+	50MG	N202611 002	Jun 28, 2012	Jun	NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>D>	AB	ALPHAPHARM	15MG	A076176 001	Jun 19, 2003	Sep	CAHN
>D>	AB		30MG	A076176 002	Jun 19, 2003	Sep	CAHN
>D>	AB		45MG	A076176 003	Jun 19, 2003	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	15MG	A076176 001	Jun 19, 2003	Sep	CAHN
>A>	AB		30MG	A076176 002	Jun 19, 2003	Sep	CAHN
>A>	AB		45MG	A076176 003	Jun 19, 2003	Sep	CAHN

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

AB		NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA
AB			0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

		+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
--	--	---	---------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

MITOMYCIN

>D>	AP	BAXTER HLTHCARE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
>D>	AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN
>A>	AP	HIKMA MAPLE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
>A>	AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC
@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC
@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	Jun	CAHN
---	---------------------	----------------	-------------	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

>A>	AB	AUROBINDO PHARMA LTD	100MG	A202566 001	Sep 27, 2012	Sep	NEWA
>A>	AB		200MG	A202566 002	Sep 27, 2012	Sep	NEWA
>A>	AB	HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012	Sep	NEWA
>A>	AB		200MG	A090543 002	Sep 26, 2012	Sep	NEWA
	AB	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012	Jun	NEWA
	AB		200MG	A076594 002	Jul 16, 2012	Jun	NEWA
>A>	AB	ORCHID HLTHCARE	100MG	A078963 001	Sep 26, 2012	Sep	NEWA
>A>	AB		200MG	A078963 002	Sep 26, 2012	Sep	NEWA

PROVIGIL

	AB	CEPHALON	100MG	N020717 001	Dec 24, 1998	Jun	CFTG
	AB	+	200MG	N020717 002	Dec 24, 1998	Jun	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

	AB	+	MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987	Jun	CAHN
--	----	---	-------------------	------	-------------	--------------	-----	------

MOMETASONE FUROATE

	AB	FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN
--	----	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

ELOCON

	AB	+	MERCK SHARP DOHME	0.1%	N019796 001	Mar 30, 1989	Jul	CAHN
--	----	---	-------------------	------	-------------	--------------	-----	------

MOMETASONE FUROATE

	AB	FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN
--	----	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

ELOCON

	AB	+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987	May	CAHN
--	----	---	-------------------	------	-------------	--------------	-----	------

MOMETASONE FUROATE

	AB	FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN
--	----	----------------	------	-------------	--------------	-----	------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

>A>	AB	DR REDDYS LABS LTD	EQ 4MG BASE/PACKET	A202906 001	Sep 17, 2012	Sep	NEWA
	AB	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955 001	Aug 03, 2012	Jul	NEWA

SINGULAIR

	AB	+	MERCK	EQ 4MG BASE/PACKET	N021409 001	Jul 26, 2002	Jul	CFTG
--	----	---	-------	--------------------	-------------	--------------	-----	------

TABLET; ORAL

MONTELUKAST SODIUM

>A>	AB	ACCORD HLTHCARE	EQ 10MG BASE	A202717 001	Sep 21, 2012	Sep	NEWA
	AB	APOTEX CORP	EQ 10MG BASE	A201294 001	Aug 03, 2012	Jul	NEWA
	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468 001	Aug 03, 2012	Jul	NEWA
	AB	DR REDDYS LABS LTD	EQ 10MG BASE	A201582 001	Aug 06, 2012	Jul	NEWA
	AB	ENDO PHARMS	EQ 10MG BASE	A091576 001	Aug 03, 2012	Jul	NEWA
	AB	GLENMARK GENERICS	EQ 10MG BASE	A090926 001	Aug 03, 2012	Jul	NEWA
	AB	KUDCO IRELAND	EQ 10MG BASE	A201522 001	Aug 03, 2012	Jul	NEWA
	AB	MYLAN PHARMS INC	EQ 10MG BASE	A079103 001	Aug 03, 2012	Jul	NEWA
	AB	ROXANE	EQ 10MG BASE	A090655 001	Aug 03, 2012	Jul	NEWA
	AB	SANDOZ INC	EQ 10MG BASE	A200889 001	Aug 03, 2012	Jul	NEWA
	AB	TEVA PHARMS	EQ 10MG BASE	A078605 001	Aug 03, 2012	Jul	NEWA
	AB	TORRENT PHARMS LTD	EQ 10MG BASE	A201515 001	Aug 03, 2012	Jul	NEWA

SINGULAIR

	AB	+	MERCK	EQ 10MG BASE	N020829 002	Feb 20, 1998	Jul	CFTG
--	----	---	-------	--------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	APOTEX INC	EQ 4MG BASE	A201508 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A201508 002	Aug 03, 2012	Jul	NEWA
AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A202096 002	Aug 03, 2012	Jul	NEWA
AB	DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012	Jul	NEWA
AB		EQ 5MG BASE	A201581 002	Aug 06, 2012	Jul	NEWA
AB	ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
AB	KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
AB	ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA
SINGULAIR						
AB	MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

	ACTAVIS ELIZABETH	40MG	N020616 009	Jul 09, 2012	Jul	NEWA
		70MG	N020616 010	Jul 09, 2012	Jul	NEWA
		130MG	N020616 011	Jul 09, 2012	Jul	NEWA
		150MG	N020616 012	Jul 09, 2012	Jul	NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN
INFUMORPH							
+		HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
+			25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

	@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA		PADDOCK LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul	NEWA
----	--	-------------	-----------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>D>	AB	ENDO PHARMS	15MG	A075295 001	Oct 28, 1998	Sep	CAHN
>D>	AB		30MG	A075295 002	Oct 28, 1998	Sep	CAHN
>D>	AB		60MG	A075295 003	Oct 28, 1998	Sep	CAHN
>D>	AB		100MG	A075295 004	Sep 15, 2000	Sep	CAHN
>D>	AB		200MG	A075295 005	Sep 15, 2000	Sep	CAHN
	AB	RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB	RANBAXY LABS LTD	30MG	A078761 002	May 11, 2012	Apr	NEWA
AB		60MG	A078761 003	May 11, 2012	Apr	NEWA
AB		100MG	A078761 004	May 11, 2012	Apr	NEWA
AB		200MG	A078761 005	May 11, 2012	Apr	NEWA
>A>	AB	VINTAGE PHARMS LLC	15MG	A075295 001	Oct 28, 1998	Sep CAHN
>A>	AB		30MG	A075295 002	Oct 28, 1998	Sep CAHN
>A>	AB		60MG	A075295 003	Oct 28, 1998	Sep CAHN
>A>	AB		100MG	A075295 004	Sep 15, 2000	Sep CAHN
>A>	AB		200MG	A075295 005	Sep 15, 2000	Sep CAHN
	ORAMORPH SR					
	@ XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
	@	30MG	N019977 001	Aug 15, 1991	May	DISC
	@	60MG	N019977 002	Aug 15, 1991	May	DISC
	@	100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCI

OINTMENT; TOPICAL

MUPIROCI

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	ENDO PHARMS	250MG	A090111 001	Dec 22, 2009	Sep CAHN
>A>	AB	VINTAGE PHARMS LLC	250MG	A090111 001	Dec 22, 2009	Sep CAHN
>D>	AB	ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009	Sep DISC
>A>	@		250MG	A065433 001	May 04, 2009	Sep DISC

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	ENDO PHARMS	500MG	A090606 001	Jul 16, 2010	Sep CAHN
>A>	AB	VINTAGE PHARMS LLC	500MG	A090606 001	Jul 16, 2010	Sep CAHN
>D>	AB	ZYDUS PHARMS USA INC	500MG	A065477 001	May 04, 2009	Sep DISC
>A>	@		500MG	A065477 001	May 04, 2009	Sep DISC

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB	APOTEX INC	180MG	A091558 001	Aug 21, 2012	Aug	NEWA
	MYFORTIC					
AB	NOVARTIS	180MG	N050791 001	Feb 27, 2004	Aug	CFTG

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB	MATRIX LABS LTD	500MG	A090516 001	Jul 12, 2010	Sep CAHN
>D>	AB		750MG	A090516 002	Jul 12, 2010	Sep CAHN
>A>	AB	MYLAN PHARMS INC	500MG	A090516 001	Jul 12, 2010	Sep CAHN
>A>	AB		750MG	A090516 002	Jul 12, 2010	Sep CAHN
	AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb CMFD
	AB		750MG	A079093 002	Feb 27, 2009	Feb CMFD

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	ANTIBIOTICE	EQ 1GM BASE	A090560 001	Oct 03, 2011	Aug	CAHN
AP		EQ 2GM BASE	A090560 002	Oct 03, 2011	Aug	CAHN
AP	ASTRAL PHARM INDS	EQ 1GM BASE/VIAL	A090582 001	Aug 24, 2012	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A090582 002	Aug 24, 2012	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A090580 001	Aug 24, 2012	Aug	NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	HIKMA MAPLE	0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN

NALOXONE HYDROCHLORIDE

@	HIKMA MAPLE	0.02MG/ML	A071272 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071287 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071273 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071274 001	May 24, 1988	Jun	CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

>D>	AB	ALPHAPHARM	375MG	A075390 001	Apr 19, 2001	Sep	CAHN
>D>	AB		500MG	A075390 002	Apr 19, 2001	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	375MG	A075390 001	Apr 19, 2001	Sep	CAHN
>A>	AB		500MG	A075390 002	Apr 19, 2001	Sep	CAHN

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN
----	-------------------	---------------	-------------	--	-----	------

ANAPROX DS

AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN
----	---	-------------------	---------------	-------------	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
---	--------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
----	------------------	-------------	-------------	--------------	-----	------

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

@ TEVA PHARMS

60MG

A077467 001 Sep 09, 2009 Jul DISC

@

120MG

A077467 002 Sep 09, 2009 Jul DISC

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

AT	+ ALLERGAN	2%	N021009 001	Dec 08, 1999	Aug	CFTG
----	------------	----	-------------	--------------	-----	------

NEDOCROMIL SODIUM

AT	AKORN	2%	A090638 001	Aug 22, 2012	Aug	NEWA
----	-------	----	-------------	--------------	-----	------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA	AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
----	-----------	----------	-------------	--------------	-----	------

VIRAMUNE

AA	+ BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG
----	------------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB	APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
AB	AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
AB	CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
AB	HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
AB	MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
AB	MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
AB	MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
AB	PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
AB	SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May	NEWA
AB	STRIDES	200MG	A078195 001	May 22, 2012	May	NEWA

VIRAMUNE

AB	+ BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May	CFTG
----	------------------------	-------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	ACTAVIS	90MG	A077899 003	May 25, 2012	May	NEWA
-----	---------	------	-------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB	ALMATICA	25MG	N016620 003		Jul	CAHN
AB		50MG	N016620 001		Jul	CAHN
AB	+	100MG	N016620 002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+ ALMATICA	75MG;25MG	N020064 001	Dec 24, 1991	Jul	CAHN
----	------------	-----------	-------------	--------------	-----	------

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ RANBAXY LABS LTD 75MG;25MG

A076951 001 Mar 30, 2005 Apr DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1 MEDICIS 0.1MG/HR

A089771 001 Aug 30, 1996 Jul CAHN

AB1 0.2MG/HR

A089772 001 Aug 30, 1996 Jul CAHN

AB1 0.4MG/HR

A089773 001 Aug 30, 1996 Jul CAHN

AB1 0.6MG/HR

A089774 001 Aug 30, 1996 Jul CAHN

OINTMENT; INTRA-ANAL

RECTIV

+ APTALIS PHARMA 0.4%

N021359 001 Jun 21, 2011 Jan CAHN

NIZATIDINE

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM 150MG

N019508 001 Apr 12, 1988 Mar DISC

@ 300MG

N019508 002 Apr 12, 1988 Mar DISC

NIZATIDINE

@ MYLAN PHARMS INC 150MG

A075934 001 Jul 09, 2002 Apr DISC

@ 300MG

A075934 002 Jul 09, 2002 Apr DISC

AB + 300MG

A075806 002 Jul 05, 2002 Apr CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP CLARIS LIFESCIENCES EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 May CAHN

AP SINTETICA EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 Mar NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB AMNEAL PHARMS 5MG

A200275 001 Jul 30, 2012 Jul NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT FOUGERA PHARMS 100,000 UNITS/GM

A062129 001 Jan CAHN

AT + TARO 100,000 UNITS/GM

A064022 001 Jan 29, 1993 Aug CRLD

OINTMENT; TOPICAL

NYSTATIN

AT + FOUGERA PHARMS 100,000 UNITS/GM

A062124 002 Sep 23, 1982 Jan CAHN

POWDER; TOPICAL

NYSTATIN

@ NESHER PHARMS 100,000 UNITS/GM

A065321 001 Aug 18, 2006 Jun DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062367 001 May 28, 1985 Jun CAHN

OINTMENT; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062733 001 Mar 09, 1987 Jun CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

@ SANDOZ 0.3%

A076848 001 Nov 25, 2008 Aug DISC

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD 200MG

A076220 001 Sep 02, 2003 Apr DISC

@ 300MG

A076220 002 Sep 02, 2003 Apr DISC

@ 400MG

A076220 003 Sep 02, 2003 Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

>A> AP LUITPOLD 10MG/VIAL

A201741 001 Mar 20, 2012 Sep CAHN

>D> AP PHARMAFORCE 10MG/VIAL

A201741 001 Mar 20, 2012 Sep CAHN

AP 10MG/VIAL

A201741 001 Mar 20, 2012 Mar NEWA

AP SANDOZ INC 10MG/VIAL

A201588 001 Oct 24, 2011 Mar CAHN

TABLET; ORAL

OLANZAPINE

AB APOTEX INC 2.5MG

A090798 001 Apr 23, 2012 Apr NEWA

AB 5MG

A090798 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A090798 003 Apr 23, 2012 Apr NEWA

AB 10MG

A090798 004 Apr 23, 2012 Apr NEWA

AB 15MG

A090798 005 Apr 23, 2012 Apr NEWA

AB 20MG

A090798 006 Apr 23, 2012 Apr NEWA

AB AUROBINDO PHARMA LTD 2.5MG

A202050 001 Apr 23, 2012 Apr NEWA

AB 5MG

A202050 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A202050 003 Apr 23, 2012 Apr NEWA

AB 10MG

A202050 004 Apr 23, 2012 Apr NEWA

AB 15MG

A202050 005 Apr 23, 2012 Apr NEWA

AB 20MG

A202050 006 Apr 23, 2012 Apr NEWA

AB DR REDDYS LABS LTD 2.5MG

A076255 001 Apr 23, 2012 Apr NEWA

AB 5MG

A076255 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A076255 003 Apr 23, 2012 Apr NEWA

AB 10MG

A076255 004 Apr 23, 2012 Apr NEWA

AB 15MG

A076133 001 Apr 23, 2012 Apr NEWA

AB MYLAN 2.5MG

A076866 001 Apr 23, 2012 Apr NEWA

AB 5MG

A076866 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A076866 003 Apr 23, 2012 Apr NEWA

AB 10MG

A076866 004 Apr 23, 2012 Apr NEWA

AB 15MG

A076866 005 Apr 23, 2012 Apr NEWA

AB 20MG

A076866 006 Apr 23, 2012 Apr NEWA

AB ORCHID HLTHCARE 2.5MG

A202287 001 Apr 23, 2012 Apr NEWA

AB 5MG

A202287 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A202287 003 Apr 23, 2012 Apr NEWA

AB 10MG

A202287 004 Apr 23, 2012 Apr NEWA

AB 15MG

A202287 005 Apr 23, 2012 Apr NEWA

AB 20MG

A202287 006 Apr 23, 2012 Apr NEWA

AB SUN PHARM INDS 2.5MG

A091038 001 Apr 23, 2012 Apr NEWA

AB 5MG

A091038 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A091038 003 Apr 23, 2012 Apr NEWA

AB 10MG

A091038 004 Apr 23, 2012 Apr NEWA

AB 15MG

A091038 005 Apr 23, 2012 Apr NEWA

AB 20MG

A091038 006 Apr 23, 2012 Apr NEWA

AB TORRENT PHARMS LTD 2.5MG

A091434 001 Apr 23, 2012 Apr NEWA

TABLET; ORAL

OLANZAPINE

AB	TORRENT PHARMS LTD	5MG	A091434 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	JUBILANT ORGANOSYS	5MG	A200221 001	Sep 12, 2012	Aug	NEWA
AB		10MG	A200221 002	Sep 12, 2012	Aug	NEWA
AB		15MG	A200221 003	Sep 12, 2012	Aug	NEWA
AB		20MG	A200221 004	Sep 12, 2012	Aug	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA
AB	SANDOZ	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@	NESHER PHARMS	4MG	A077717 001	Jun 25, 2007	Jun	DISC
@		8MG	A077717 002	Jun 25, 2007	Jun	DISC
@	PAR PHARM	4MG	A076506 001	Dec 26, 2006	Aug	DISC
@		8MG	A076506 002	Dec 26, 2006	Aug	DISC
@		16MG	A077406 001	Dec 26, 2006	Aug	DISC
@		24MG	A077406 002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
	@ SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007	Aug	DISC
	ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER					
AP	+ BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006	Sep	DISC
	@	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006	Sep	DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

>A>	DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006	Sep	NEWA
	@ PAR PHARM	EQ 4MG BASE	A077303 001	Jun 25, 2007	Aug	DISC
	@	EQ 8MG BASE	A077303 002	Jun 25, 2007	Aug	DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

		@ PAR PHARM	EQ 24MG BASE	A077303 004	Jun 25, 2007	Aug	DISC
>D>	AB	WEST WARD	EQ 4MG BASE	A077545 001	Sep 06, 2007	Sep	DISC
>D>	AB		EQ 8MG BASE	A077545 002	Sep 06, 2007	Sep	DISC
>D>	AB		EQ 24MG BASE	A077545 003	Sep 06, 2007	Sep	DISC
>A>		@ WEST WARD PHARM CORP	EQ 4MG BASE	A077545 001	Sep 06, 2007	Sep	DISC
>A>		@	EQ 8MG BASE	A077545 002	Sep 06, 2007	Sep	DISC
>A>		@	EQ 24MG BASE	A077545 003	Sep 06, 2007	Sep	DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB		CNTY LINE PHARMS	100MG	A040249 001	Jan 29, 1999	Jul	CAHN
AB		INVAGEN PHARMS	100MG	A091158 001	Jul 27, 2012	Jul	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+		ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	--	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP		SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP			EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP			EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP		ACTAVIS TOTOWA	50MG/VIAL	A078803 001	Aug 08, 2012	Jul	NEWA
AP			100MG/VIAL	A078803 002	Aug 08, 2012	Jul	NEWA
AP		ONCO THERAPIES LTD	50MG/10ML (5MG/ML)	A091358 001	Aug 07, 2012	Jul	NEWA
AP			50MG/VIAL	A200979 001	Aug 08, 2012	Jul	NEWA
AP			100MG/VIAL	A200979 002	Aug 08, 2012	Jul	NEWA
AP			100MG/20ML (5MG/ML)	A091358 002	Aug 07, 2012	Jul	NEWA
AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+		100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB		AMNEAL PHARMS	300MG/5ML	A202961 001	Sep 17, 2012	Aug	NEWA
>A>	AB	ROXANE	300MG/5ML	A201193 001	Oct 03, 2012	Sep	NEWA

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+		FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	--	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+		WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
+			600MG	A086742 001		Jun	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
ANTUROL

+	ARROW INTL	3%	N202513	001	Dec 07, 2011	Apr	CAHN
+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS 5MG

N017577 001 Mar DISC

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079	001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Mar	NEWA
----	--	------------------	------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB		COASTAL PHARMS	5MG	A203107	001	Jul 26, 2012	Jul	NEWA
----	--	----------------	-----	---------	-----	--------------	-----	------

AB	+	LEHIGH VALLEY	5MG	N200534	001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----	---------	-----	--------------	-----	------

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535	001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----------	---------	-----	--------------	-----	------

+	VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jan	NEWA
---	------------	---------	---------	-----	--------------	-----	------

AA			100MG/5ML	A202537	001	Jul 30, 2012	Jul	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758	003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS 5MG

N021610 001 Jun 22, 2006 May DISC

@ 10MG

N021610 002 Jun 22, 2006 May DISC

@ 20MG

N021610 003 Jun 22, 2006 May DISC

@ 30MG

N021610 007 Feb 29, 2008 May DISC

+		40MG	N201655	007	Dec 09, 2011	Aug	CRLD
---	--	------	---------	-----	--------------	-----	------

@ 40MG

N021610 004 Jun 22, 2006 May DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS 5MG

A079087 001 Jun 14, 2010 May CTEC

10MG

A079087 003 Jun 14, 2010 May CTEC

20MG

A079087 005 Jun 14, 2010 May CTEC

30MG

A079087 006 Jul 22, 2010 May CTEC

40MG

A079087 007 Jun 14, 2010 May CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL 10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 Jan DISC

@ 100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 Mar DISC

PITOCIN

JHP PHARMS 500USP UNITS/50ML (10USP UNITS/ML)

N018261 003 Sep 05, 2012 Aug NEWA

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA

6MG/ML

N020262 001 Dec 29, 1992 Mar CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991 Mar DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

15,000USP UNITS;3,000USP
UNITS;9,500USP UNITS

N020725 004 Jul 12, 2011 Jun NEWA

30,000USP UNITS;6,000USP
UNITS;19,000USP UNITS

N020725 001 Apr 30, 2009 Feb CAHN

60,000USP UNITS;12,000USP
UNITS;38,000USP UNITS

N020725 002 Apr 30, 2009 Feb CAHN

+ 120,000USP UNITS;24,000USP
UNITS;76,000USP UNITS

N020725 003 Apr 30, 2009 Feb CAHN

PERTZYE

DIGESTIVE CARE INC

30,250USP/UNITS;8,000USP/UNITS;28
,750USP/UNITS

N022175 001 May 17, 2012 May NEWA

+ 60,500USP/UNITS;16,000USP/UNITS;5
7,500USP/UNITS

N022175 002 May 17, 2012 May NEWA

ULTRESA

APTALIS PHARMA US

27,600USP UNITS;13,800USP
UNITS;27,600USP UNITS

N022222 001 Mar 01, 2012 Mar NEWA

41,400USP UNITS;20,700USP
UNITS;41,400USP UNITS

N022222 002 Mar 01, 2012 Mar NEWA

+ 46,000USP UNITS;23,000USP
UNITS;46,000USP UNITS

N022222 003 Mar 01, 2012 Mar NEWA

ZENPEP

APTALIS PHARMA US

16,000USP UNITS;3,000USP
UNITS;10,000USP UNITS

N022210 005 Jun 15, 2011 Apr NEWA

109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009 Apr CRLD

+ 136,000USP UNITS;25,000USP
UNITS;85,000USP UNITS

N022210 006 Jul 13, 2011 Apr NEWA

TABLET; ORAL

VIOKACE

APTALIS PHARMA US

39,150USP UNITS;10,440USP
UNITS;39,150USP UNITS

N022542 001 Mar 01, 2012 Mar NEWA

+ 78,300USP UNITS;20,880USP
UNITS;78,300USP UNITS

N022542 002 Mar 01, 2012 Mar NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB APOTEX INC

EQ 20MG BASE

A090807 001 May 02, 2012 Apr NEWA

AB

EQ 40MG BASE

A090807 002 May 02, 2012 Apr NEWA

>A> AB AUROBINDO PHARMA LTD

EQ 20MG BASE

A202038 001 Sep 28, 2012 Sep NEWA

>A> AB

EQ 40MG BASE

A202038 002 Sep 28, 2012 Sep NEWA

AB MACLEODS PHARMS LTD

EQ 20MG BASE

A200821 001 Feb 16, 2012 Jan NEWA

AB

EQ 40MG BASE

A200821 002 Feb 16, 2012 Jan NEWA

>D> AB MATRIX LABS LTD

EQ 20MG BASE

A090970 001 Jan 19, 2011 Sep CAHN

>D> AB

EQ 40MG BASE

A090970 002 Jan 19, 2011 Sep CAHN

>A> AB MYLAN PHARMS INC

EQ 20MG BASE

A090970 001 Jan 19, 2011 Sep CAHN

>A> AB

EQ 40MG BASE

A090970 002 Jan 19, 2011 Sep CAHN

AB RANBAXY LABS LTD

EQ 20MG BASE

A200794 001 May 02, 2012 Apr NEWA

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	RANBAXY LABS LTD	EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA
----	------------------	--------------	-------------	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
	AB		EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
>D>	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
>D>	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
>D>	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN
	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD
>D>	AB	ALPHAPHARM	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
>D>	AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
>D>	AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
>D>	AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
>A>	AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
>A>	AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
>A>	AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
>A>	AB	PROSAM LABS	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
>A>	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
>A>	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
>A>	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

>D>	AP	APP PHARMS	5,000,000 UNITS/VIAL	A065448 001	Aug 18, 2009	Sep	CAHN
>D>	AP		20,000,000 UNITS/VIAL	A065448 002	Aug 18, 2009	Sep	CAHN
>A>	AP	IBI	5,000,000 UNITS/VIAL	A065448 001	Aug 18, 2009	Sep	CAHN

		INJECTABLE; INJECTION							
		PENICILLIN G POTASSIUM							
>A>	AP	IBI	20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Sep	CAHN	
		<u>PENTOBARBITAL SODIUM</u>							
		INJECTABLE; INJECTION							
		NEMBUTAL SODIUM							
	+	OAK PHARMS	50MG/ML	A083246	001		Feb	CAHN	
		<u>PERINDOPRIL ERBUMINE</u>							
		TABLET; ORAL							
		ACEON							
AB		XOMA	2MG	N020184	001	Dec 30, 1993	Jan	CAHN	
AB			4MG	N020184	002	Dec 30, 1993	Jan	CAHN	
AB	+		8MG	N020184	003	Dec 30, 1993	Jan	CAHN	
		<u>PERMETHRIN</u>							
		CREAM; TOPICAL							
		ELIMITE							
AB	+	RENAISSANCE PHARMA	5%	N019855	001	Aug 25, 1989	May	CAHN	
		<u>PHENOXYBENZAMINE HYDROCHLORIDE</u>							
		CAPSULE; ORAL							
		DIBENZYLINE							
AB	+	WELLSPRING PHARM	10MG	N008708	001		Jun	CFTG	
		PHENOXYBENZAMINE HYDROCHLORIDE							
AB		ROXANE	10MG	A201050	001	Jul 16, 2012	Jun	NEWA	
		<u>PHENTERMINE HYDROCHLORIDE</u>							
		CAPSULE; ORAL							
		PHENTERMINE HYDROCHLORIDE							
>A>	AA	ELITE LABS	15MG	A202248	001	Sep 28, 2012	Sep	NEWA	
>A>	AA		30MG	A202248	002	Sep 28, 2012	Sep	NEWA	
AA		LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	NEWA	
	@	MIKAH PHARMA	15MG	A040460	001	Jan 14, 2003	Jul	CAHN	
	@		30MG	A040227	001	Jun 18, 1997	Jul	CAHN	
	@		30MG	A040448	001	Jan 22, 2003	Jul	CAHN	
	@		37.5MG	A040228	001	Jun 19, 1997	Jul	CAHN	
		TABLET; ORAL							
		PHENTERMINE HYDROCHLORIDE							
	@	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	Jul	CAHN	
>A>	AA	MIRROR PHARMS	37.5MG	A091451	001	Sep 21, 2012	Sep	NEWA	
	@	SANDOZ INC	30MG	A088605	001	Sep 28, 1987	Feb	DISC	
		TABLET, ORALLY DISINTEGRATING; ORAL							
		SUPRENZA							
		CITIUS PHARMS	30MG	N202088	002	Jun 13, 2011	Apr	CRLD	
	+		37.5MG	N202088	003	Mar 27, 2012	Apr	CRLD	
			37.5MG	N202088	003	Mar 27, 2012	Mar	NEWA	
		<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE</u>							
		CAPSULE, EXTENDED RELEASE; ORAL							
		QSYMIA							
		VIVUS							
			EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jul	NEWA	
			EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jul	NEWA	
			EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jul	NEWA	
	+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jul	NEWA	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+ LANNETT HOLDINGS INC EQ 15MG BASE

A040872 001 Jul 28, 2011 Jan CRLD

+ EQ 30MG BASE

A040872 002 Jul 28, 2011 Jan CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP + HIKMA MAPLE 50MG/ML

A084307 001

Jun CAHN

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP + INTL MEDICATION 1MG/0.5ML

A083722 001

Feb CRLD

TABLET; ORAL

MEPHYTON

+ VALEANT PHARMS 5MG

N010104 003

Jun CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

@ MYLAN PHARMS INC 5MG

A074013 001 Sep 24, 1992 May CAHN

@ 10MG

A074018 001 Sep 24, 1992 May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB TAKEDA PHARMS USA EQ 15MG BASE

N021073 001 Jul 15, 1999 Aug CFTG

EQ 15MG BASE

N021073 001 Jul 15, 1999 Mar CAHN

AB EQ 30MG BASE

N021073 002 Jul 15, 1999 Aug CFTG

EQ 30MG BASE

N021073 002 Jul 15, 1999 Mar CAHN

AB + EQ 45MG BASE

N021073 003 Jul 15, 1999 Aug CFTG

+ EQ 45MG BASE

N021073 003 Jul 15, 1999 Mar CAHN

PIOGLITAZONE HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 15MG BASE

A076801 001 Aug 17, 2012 Aug NEWA

AB EQ 30MG BASE

A076801 002 Aug 17, 2012 Aug NEWA

AB EQ 45MG BASE

A076801 003 Aug 17, 2012 Aug NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

>D> AA PADDOCK LLC 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT A090769 001 Jun 07, 2010 Sep DISC

>A> @ 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT A090769 001 Jun 07, 2010 Sep DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

>D> AA PADDOCK LLC 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT A090712 001 Feb 25, 2010 Sep DISC

>A> @ 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT A090712 001 Feb 25, 2010 Sep DISC

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

@ FUTURE PAK 10MEQ A070999 001 Oct 22, 1987 Mar DISC

KAON CL-10

@ SAVAGE LABS 10MEQ N017046 002 Mar DISC

KLOR-CON M20

AB + UPSHER SMITH LABS 20MEQ A074726 001 Nov 20, 1998 Mar CRLD

KLOTRIX

@ APOTHECON 10MEQ N017850 001 Mar DISC

POTASSIUM CHLORIDE

@ NESHER PHARMS 20MEQ A076044 001 Apr 05, 2002 Mar DISC

@ SCHERING 10MEQ N019439 002 Jun 13, 1986 Mar DISC

@ 20MEQ N019439 001 Jun 13, 1986 Mar DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

@ NOVA K 10MEQ/PACKET N019647 002 Oct 13, 1988 Feb CAHN

@ 20MEQ/PACKET N019647 001 Oct 13, 1988 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB APOTEX INC 0.125MG A090151 001 Apr 30, 2012 Apr NEWA

AB 0.25MG A090151 002 Apr 30, 2012 Apr NEWA

AB 0.5MG A090151 003 Apr 30, 2012 Apr NEWA

AB 0.75MG A090151 006 Apr 30, 2012 Apr NEWA

AB 1MG A090151 004 Apr 30, 2012 Apr NEWA

AB 1.5MG A090151 005 Apr 30, 2012 Apr NEWA

>A> AB MACLEODS PHARMS LTD 0.125MG A202164 001 Sep 20, 2012 Sep NEWA

>A> AB 0.25MG A202164 002 Sep 20, 2012 Sep NEWA

>A> AB 0.5MG A202164 003 Sep 20, 2012 Sep NEWA

>A> AB 1MG A202164 004 Sep 20, 2012 Sep NEWA

>A> AB 1.5MG A202164 005 Sep 20, 2012 Sep NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

@ PLIVA HRVATSKA DOO 10MG A077730 001 Nov 21, 2006 Jun DISC

@ 20MG A077730 002 Nov 21, 2006 Jun DISC

@ 30MG A077730 003 Nov 21, 2006 Jun DISC

@ 40MG A077730 005 Nov 21, 2006 Jun DISC

@ RANBAXY LABS LTD 10MG A076445 001 Apr 23, 2007 Apr DISC

@ 20MG A076445 002 Apr 23, 2007 Apr DISC

@ 40MG A076445 003 Apr 23, 2007 Apr DISC

@ 80MG A076445 004 Apr 23, 2007 Apr DISC

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB FOUGERA PHARMS 0.1% A077287 001 Sep 19, 2006 Jan CAHN

OINTMENT; TOPICAL

PREDNICARBATE

AB FOUGERA PHARMS 0.1% A077236 001 Mar 09, 2007 Jan CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	+	HI TECH PHARMA CO	15MG/5ML	A040401	001	Feb 27, 2003	Jul	CRLD
		@ NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001	Jun	DISC
		@	15MG/5ML	A040364	001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

>A>	AA	+	SETON PHARM	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Sep	CAHN
>D>	AA	+	UCB INC	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Sep	CAHN
			PREDNISOLONE SODIUM PHOSPHATE						
		+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jul	CAHN
		@	NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005	Jun	DISC

PREDNISONE

TABLET, DELAYED RELEASE; ORAL

RAYOS

			HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Jul	NEWA
				2MG	N202020	002	Jul 26, 2012	Jul	NEWA
		+		5MG	N202020	003	Jul 26, 2012	Jul	NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB			PF PRISM	25MG	N021446	001	Dec 30, 2004	Jun	CFTG
				25MG	N021446	001	Dec 30, 2004	Jan	CAHN
AB				50MG	N021446	002	Dec 30, 2004	Jun	CFTG
				50MG	N021446	002	Dec 30, 2004	Jan	CAHN
AB				75MG	N021446	003	Dec 30, 2004	Jun	CFTG
				75MG	N021446	003	Dec 30, 2004	Jan	CAHN
				100MG	N021446	004	Dec 30, 2004	Jan	CAHN
AB				150MG	N021446	005	Dec 30, 2004	Jun	CFTG
				150MG	N021446	005	Dec 30, 2004	Jan	CAHN
AB				200MG	N021446	006	Dec 30, 2004	Jun	CFTG
				200MG	N021446	006	Dec 30, 2004	Jan	CAHN
AB				225MG	N021446	007	Dec 30, 2004	Jun	CFTG
				225MG	N021446	007	Dec 30, 2004	Jan	CAHN
AB	+			300MG	N021446	008	Dec 30, 2004	Jun	CFTG
	+			300MG	N021446	008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB			LUPIN LTD	25MG	A091040	001	Jul 03, 2012	Jun	NEWA
AB				50MG	A091040	002	Jul 03, 2012	Jun	NEWA
AB				75MG	A091040	003	Jul 03, 2012	Jun	NEWA
AB				100MG	A091040	004	Jul 03, 2012	Jun	NEWA
AB				150MG	A091040	005	Jul 03, 2012	Jun	NEWA
AB				200MG	A091040	006	Jul 03, 2012	Jun	NEWA
AB				225MG	A091040	007	Jul 03, 2012	Jun	NEWA
AB				300MG	A091040	008	Jul 03, 2012	Jun	NEWA
AB			TEVA PHARMS	25MG	A091219	001	Jul 03, 2012	Jun	NEWA
AB				50MG	A091219	002	Jul 03, 2012	Jun	NEWA
AB				75MG	A091224	001	Jul 03, 2012	Jun	NEWA
AB				100MG	A091224	002	Jul 03, 2012	Jun	NEWA
AB				150MG	A091224	003	Jul 03, 2012	Jun	NEWA

CAPSULE; ORAL

PREGABALIN

AB	TEVA PHARMS	200MG	A091224 004	Jul 03, 2012	Jun	NEWA
AB		225MG	A091224 005	Jul 03, 2012	Jun	NEWA
AB		300MG	A091224 006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG	A091221 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091221 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091221 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091221 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091221 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091221 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091221 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091221 008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN
---	----------	---------	-------------	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

@	DENTSPLY PHARM	4%	N021382 001		May	DISC
---	----------------	----	-------------	--	-----	------

PRILOCAINE HYDROCHLORIDE

+	SEPTODONT INC	4%	A079235 001	Sep 29, 2010	May	CRLD
---	---------------	----	-------------	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

@	HIKMA MAPLE	100MG/ML	A089029 001	Apr 17, 1986	Jun	CAHN
---	-------------	----------	-------------	--------------	-----	------

@		500MG/ML	A089030 001	Apr 17, 1986	Jun	CAHN
---	--	----------	-------------	--------------	-----	------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	HIKMA MAPLE	EQ 5MG BASE/ML	A089903 001	Aug 29, 1989	Jun	CAHN
----	---	-------------	----------------	-------------	--------------	-----	------

@		EQ 5MG BASE/ML	A089523 001	May 03, 1988	Jun	CAHN
---	--	----------------	-------------	--------------	-----	------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

>A>	AB	SOFGEN PHARMS	100MG	A200456 001	Sep 28, 2012	Sep	NEWA
-----	----	---------------	-------	-------------	--------------	-----	------

>A>	AB		200MG	A200456 002	Sep 28, 2012	Sep	NEWA
-----	----	--	-------	-------------	--------------	-----	------

	AB	TEVA PHARMS	100MG	A202121 001	Feb 29, 2012	Feb	NEWA
--	----	-------------	-------	-------------	--------------	-----	------

	AB		200MG	A202121 002	Feb 29, 2012	Feb	NEWA
--	----	--	-------	-------------	--------------	-----	------

PROMETRIUM

	AB	ABBOTT LABS	100MG	N019781 001	May 14, 1998	Feb	CFTG
--	----	-------------	-------	-------------	--------------	-----	------

	AB	+	200MG	N019781 002	Oct 15, 1999	Feb	CFTG
--	----	---	-------	-------------	--------------	-----	------

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		TRIS PHARMA INC	6.25MG/5ML	A091675 001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	------------	-------------	--------------	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Jun	DISC
---	---------------	-------	-------------	--------------	-----	------

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ NESHER PHARMS 225MG
@ 300MG

A076193 002 Feb 07, 2002 Jun DISC
A076193 003 Feb 07, 2002 Jun DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

>A> AB APTALIS PHARMATECH 60MG
>A> AB 80MG
>A> AB 120MG
>A> AB 160MG
>D> AB GLAXOSMITHKLINE 60MG
>D> AB 80MG
>D> AB 120MG
>D> AB 160MG

A078703 001 Jul 15, 2011 Sep CAHN
A078703 002 Jul 15, 2011 Sep CAHN
A078703 003 Jul 15, 2011 Sep CAHN
A078703 004 Jul 15, 2011 Sep CAHN
A078703 001 Jul 15, 2011 Sep CAHN
A078703 002 Jul 15, 2011 Sep CAHN
A078703 003 Jul 15, 2011 Sep CAHN
A078703 004 Jul 15, 2011 Sep CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@ TEVA WOMENS R AND D 5MG
@ 10MG

N016012 001 Jul CAHN
N016012 002 Jul CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB + VALEANT PHARMS LLC 60MG

N009829 002 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+ VALEANT PHARMS LLC 180MG

N011665 001 Jun CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB ACCORD HLTHCARE INC EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 100MG BASE
AB EQ 200MG BASE
AB EQ 300MG BASE
AB EQ 400MG BASE
AB APOTEX INC EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 100MG BASE
AB EQ 200MG BASE
AB EQ 300MG BASE
AB EQ 400MG BASE
AB AUROBINDO PHARMA LTD EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 100MG BASE
AB EQ 150MG BASE
AB EQ 200MG BASE
AB EQ 300MG BASE
AB EQ 400MG BASE
AB DR REDDYS LABS LTD EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 100MG BASE

A202152 001 Mar 27, 2012 Mar NEWA
A202152 002 Mar 27, 2012 Mar NEWA
A202152 003 Mar 27, 2012 Mar NEWA
A202152 004 Mar 27, 2012 Mar NEWA
A202152 005 Mar 27, 2012 Mar NEWA
A202152 006 Mar 27, 2012 Mar NEWA
A090960 001 Mar 27, 2012 Mar NEWA
A090960 002 Mar 27, 2012 Mar NEWA
A090960 003 Mar 27, 2012 Mar NEWA
A090960 004 Mar 27, 2012 Mar NEWA
A090960 005 Mar 27, 2012 Mar NEWA
A090960 006 Mar 27, 2012 Mar NEWA
A091388 001 Mar 27, 2012 Mar NEWA
A091388 002 Mar 27, 2012 Mar NEWA
A091388 003 Mar 27, 2012 Mar NEWA
A091388 004 Mar 27, 2012 Mar NEWA
A091388 005 Mar 27, 2012 Mar NEWA
A091388 006 Mar 27, 2012 Mar NEWA
A091388 007 Mar 27, 2012 Mar NEWA
A077380 001 Mar 27, 2012 Mar NEWA
A077380 002 Mar 27, 2012 Mar NEWA
A077380 003 Mar 27, 2012 Mar NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	DR REDDYS LABS LTD	EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA
SEROQUEL						
AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
@		EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
@		EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
@		EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

>D>	+	AR HOLDING CO INC	324MG	N021799 001	Aug 12, 2005	Sep	CFTG
>A>	AB	+	324MG	N021799 001	Aug 12, 2005	Sep	CFTG
>A>		QUININE SULFATE					
>A>	AB	TEVA PHARMS	324MG	A091661 001	Sep 28, 2012	Sep	NEWA

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
---	-------------------	-----	-------------	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009 Apr DISC

@

10MG

A078849 002 Mar 06, 2009 Apr DISC

TABLET; ORAL

ALTACE

@ KING PFIZER

1.25MG

N022021 001 Feb 27, 2007 Jan DISC

@

2.5MG

N022021 002 Feb 27, 2007 Jan DISC

@

5MG

N022021 003 Feb 27, 2007 Jan DISC

@

10MG

N022021 004 Feb 27, 2007 Jan DISC

RAMIPRIL

>D>	AB	MATRIX LABS LTD	1.25MG	A090650 001	Jun 30, 2011	Sep	CAHN
>D>	AB		2.5MG	A090650 002	Jun 30, 2011	Sep	CAHN
>D>	AB		5MG	A090650 003	Jun 30, 2011	Sep	CAHN
>D>	AB		10MG	A090650 004	Jun 30, 2011	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011	Sep	CAHN
>A>	AB		2.5MG	A090650 002	Jun 30, 2011	Sep	CAHN
>A>	AB		5MG	A090650 003	Jun 30, 2011	Sep	CAHN
>A>	AB		10MG	A090650 004	Jun 30, 2011	Sep	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
----	---	--------------	-----------------	-------------	--------------	-----	------

ZANTAC IN PLASTIC CONTAINER

+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
---	--------------	----------------	-------------	--------------	-----	------

@

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986 Mar CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA	RANBAXY	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007	Sep	DISC
>A>		@	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007	Sep	DISC

>A> REGORAFENIB

>A> TABLET; ORAL

>A> STIVARGA

>A>	+	BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012	Sep	NEWA
-----	---	----------------	------	-------------	--------------	-----	------

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB		PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	--	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
	@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
	+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN
---	---------------------	------	-------------	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

	NOVARTIS	13.3MG/24HR	N022083 005	Aug 31, 2012	Aug	NEWA
--	----------	-------------	-------------	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012	Aug	NEWA
AP		100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012	Aug	NEWA
>D>	AP	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008	Sep
>D>	AP		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008	Sep
>A>	AP	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008	Sep
>A>	AP		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008	Sep

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB		EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB		EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB		EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB		EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA
AB	WOCKHARDT LTD	EQ 2MG BASE	A091395 001	Aug 27, 2012	Aug	NEWA
AB		EQ 4MG BASE	A091395 002	Aug 27, 2012	Aug	NEWA
AB		EQ 6MG BASE	A091395 003	Aug 27, 2012	Aug	NEWA
AB		EQ 8MG BASE	A091395 004	Aug 27, 2012	Aug	NEWA
AB		EQ 12MG BASE	A091395 005	Aug 27, 2012	Aug	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC

	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
	2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
	3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
	4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
	6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+	8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ JAZZ EUSA PHARMA 50mCi/ML

N020570 001 Mar 28, 1997 Jul CAHN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

>D> @ ENDO PHARMS 5MG

A074565 001 Aug 02, 1996 Sep CAHN

>A> @ VINTAGE PHARMS LLC 5MG

A074565 001 Aug 02, 1996 Sep CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+ VALEANT INTL 2%

N021385 001 Dec 10, 2003 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 20MG BASE/ML

A078053 001 Feb 05, 2007 Aug DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D> AB MATRIX LABS LTD EQ 25MG BASE

A078626 001 Jan 31, 2008 Sep CAHN

>D> AB EQ 50MG BASE

A078626 002 Jan 31, 2008 Sep CAHN

>D> AB EQ 100MG BASE

A078626 003 Jan 31, 2008 Sep CAHN

>A> AB MYLAN PHARMS INC EQ 25MG BASE

A078626 001 Jan 31, 2008 Sep CAHN

>A> AB EQ 50MG BASE

A078626 002 Jan 31, 2008 Sep CAHN

>A> AB EQ 100MG BASE

A078626 003 Jan 31, 2008 Sep CAHN

AB PROSAM LABS EQ 25MG BASE

A078175 001 Jul 21, 2010 Feb CMFD

AB EQ 50MG BASE

A078175 002 Jul 21, 2010 Feb CMFD

AB EQ 100MG BASE

A078175 003 Jul 21, 2010 Feb CMFD

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER 10MG/ML

N203109 001 Aug 30, 2012 Aug NEWA

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB THEPHARMANETWORK LLC 1%

N018810 001 Dec 23, 1985 Jun CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>D> AB MATRIX LABS LTD 5MG

A090868 001 Jun 08, 2010 Sep CAHN

>D> AB 10MG

A090868 002 Jun 08, 2010 Sep CAHN

>D> AB 20MG

A090868 003 Jun 08, 2010 Sep CAHN

>D> AB 40MG

A090868 004 Jun 08, 2010 Sep CAHN

>D> AB 80MG

A090868 005 Jun 08, 2010 Sep CAHN

>A> AB MYLAN PHARMS INC 5MG

A090868 001 Jun 08, 2010 Sep CAHN

>A> AB 10MG

A090868 002 Jun 08, 2010 Sep CAHN

>A> AB 20MG

A090868 003 Jun 08, 2010 Sep CAHN

>A> AB 40MG

A090868 004 Jun 08, 2010 Sep CAHN

>A> AB 80MG

A090868 005 Jun 08, 2010 Sep CAHN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

>A>	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343 004	Sep 18, 2012	Sep	NEWA
>A>		20MG;EQ 50MG BASE	N202343 005	Sep 18, 2012	Sep	NEWA
>A>		40MG;EQ 50MG BASE	N202343 006	Sep 18, 2012	Sep	NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
+		EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	@ MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--	--------------------	-------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

	@ BRACCO	200uCi/ML	N013993 001		Jun	DISC
--	----------	-----------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

	@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
--	-----------------	--------	-------------	--	-----	------

SOLUTION; ORAL

SODIUM IODIDE I 123

	@ GE HEALTHCARE	2mCi/ML	N017630 002		Jul	DISC
--	-----------------	---------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

	JUBILANT DRAXIMAGE	9-100mCi	N021305 006	May 19, 2005	Feb	CAHN
--	--------------------	----------	-------------	--------------	-----	------

CAPSULE; ORAL

SODIUM IODIDE I-131

@ JUBILANT DRAXIMAGE 2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE 1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

@ 1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@ 1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

+ 250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS 500MG/ML

N021196 001 Jul 17, 2002 Jun CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHARMA 454GM/BOT

A040909 001 Dec 03, 2008 Jun DISC

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS 12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012 Feb NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK INC 5MG/1.5ML

N021148 001 Jun 20, 2000 Jul DISC

@ 10MG/1.5ML

N021148 002 Jun 20, 2000 Jul DISC

@ 15MG/1.5ML

N021148 003 Jun 20, 2000 Jul DISC

>D> NORDITROPIN NORDIFLEX

>D> BX NOVO NORDISK INC 5MG/1.5ML

N021148 004 Oct 01, 2004 Sep DISC

>A> @ 5MG/1.5ML

N021148 004 Oct 01, 2004 Sep DISC

>D> BX 10MG/1.5ML

N021148 005 Oct 01, 2004 Sep DISC

>A> @ 10MG/1.5ML

N021148 005 Oct 01, 2004 Sep DISC

>D> 15MG/1.5ML

N021148 006 Oct 01, 2004 Sep DISC

>A> @ 15MG/1.5ML

N021148 006 Oct 01, 2004 Sep DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2 EPIC PHARMA INC 80MG

A077070 001 Nov 04, 2005 Jun CAHN

AB2 120MG

A077070 002 Nov 04, 2005 Jun CAHN

AB2 160MG

A077070 003 Nov 04, 2005 Jun CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+ PARAPRO LLC 0.9%

N022408 001 Jan 18, 2011 May CAHN

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK LLC	100MG	N019998 002	Jan 30, 1991	Mar	CAHN
---	--------------	-------	-------------	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	-------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFATRIM

@ STI PHARMA LLC 200MG/5ML;40MG/5ML

N018615 002	Jan 07, 1983	Aug	CAHN
-------------	--------------	-----	------

SULFATRIM PEDIATRIC

AB	STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615 001	Jan 07, 1983	Aug	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	JAZZ PHARMS COMMERCL	15%	N006530 003	Jan 27, 1987	Mar	CAHN
---	----------------------	-----	-------------	--------------	-----	------

+	JAZZ PHARMS II	15%	N006530 003	Jan 27, 1987	Jul	CAHN
---	----------------	-----	-------------	--------------	-----	------

+	JAZZ PHARMS III	15%	N006530 003	Jan 27, 1987	Jun	CAHN
---	-----------------	-----	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

AVC

@	JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
---	----------------------	--------	-------------	--------------	-----	------

@	JAZZ PHARMS II	1.05GM	N006530 004	Jan 27, 1987	Jul	CAHN
---	----------------	--------	-------------	--------------	-----	------

@	JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN
---	-----------------	--------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD
----	----------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN
----	------------	-------------------------------------	-------------	--------------	-----	------

SUMAVEL DOSEPRO

BX	+ ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC
----	---------------	-------------------------------------	-------------	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263 001	Jun 19, 2012	Jun	NEWA
----	------------	--------------	-------------	--------------	-----	------

AB		EQ 50MG BASE	A200263 002	Jun 19, 2012	Jun	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 100MG BASE	A200263 003	Jun 19, 2012	Jun	NEWA
----	--	---------------	-------------	--------------	-----	------

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

>D>	AB	ACCORD HLTHCARE	0.5MG	A091195 001	Aug 31, 2011	Sep	CPOT
-----	----	-----------------	-------	-------------	--------------	-----	------

>A>	AB		EQ 0.5MG BASE	A091195 001	Aug 31, 2011	Sep	CPOT
-----	----	--	---------------	-------------	--------------	-----	------

>D>	AB		1MG	A091195 002	Aug 31, 2011	Sep	CPOT
-----	----	--	-----	-------------	--------------	-----	------

>A>	AB		EQ 1MG BASE	A091195 002	Aug 31, 2011	Sep	CPOT
-----	----	--	-------------	-------------	--------------	-----	------

>D>	AB		5MG	A091195 003	Aug 31, 2011	Sep	CPOT
-----	----	--	-----	-------------	--------------	-----	------

>A>	AB		EQ 5MG BASE	A091195 003	Aug 31, 2011	Sep	CPOT
-----	----	--	-------------	-------------	--------------	-----	------

>A>	AB	PANACEA BIOTEC LTD	EQ 0.5MG BASE	A090802 001	Sep 28, 2012	Sep	NEWA
-----	----	--------------------	---------------	-------------	--------------	-----	------

CAPSULE; ORAL

TACROLIMUS

>A>	AB	PANACEA BIOTEC LTD	EQ 1MG BASE	A090802 002	Sep 28, 2012	Sep	NEWA
>A>	AB		EQ 5MG BASE	A090802 003	Sep 28, 2012	Sep	NEWA

TAFILUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

ONCOGENERIX PHARMS

EQ 10MG BASE/5ML

N021807 001	Oct 29, 2005	Aug	CMFD
-------------	--------------	-----	------

TABLET; ORAL

TAMOXIFEN CITRATE

@ AEGIS PHARMS

EQ 10MG BASE

A076398 001	Mar 31, 2003	Jun	DISC
-------------	--------------	-----	------

@

EQ 20MG BASE

A076398 002	Mar 31, 2003	Jun	DISC
-------------	--------------	-----	------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@ JUBILANT DRAXIMAGE

N/A

N018035 001		May	CAHN
-------------	--	-----	------

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--------------------	-----	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA
----	--	--------	-------------	--------------	-----	------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
----	-------------------	-----	-------------	--------------	-----	------

AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
----	--	------	-------------	--------------	-----	------

AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN
----	---	-------	-------------	--------------	-----	------

POWDER; INTRAVENOUS

TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
---	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SC00PFUL	N022577	001	Jan 18, 2012	Jan	NEWA
---	---------------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL

VIREAD

	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Apr	NEWA
		200MG	N021356	003	Jan 18, 2012	Apr	NEWA
		250MG	N021356	004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@	RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002	Apr	DISC
@		EQ 2MG BASE	A076021	002	Aug 22, 2002	Apr	DISC
@		EQ 5MG BASE	A076021	003	Aug 22, 2002	Apr	DISC
@		EQ 10MG BASE	A076021	004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	TEVA PARENTERAL	1MG/ML	A076853	001	Jul 20, 2004	Jan	DISC
---	-----------------	--------	---------	-----	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712	001	Feb 18, 2005	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

>A> TERIFLUNOMIDE

>A> TABLET; ORAL

>A> AUBAGIO

>A>	SANOFI AVENTIS US	7MG	N202992	001	Sep 12, 2012	Sep	NEWA
-----	-------------------	-----	---------	-----	--------------	-----	------

>A>	+	14MG	N202992	002	Sep 12, 2012	Sep	NEWA
-----	---	------	---------	-----	--------------	-----	------

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

@	EMD SERONO	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Jun	DISC
+		EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Jun	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Feb	CPOT
			1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Feb	CPOT

>A>		ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Sep	NEWA
-----	--	--------	-------------------------------	---------	-----	--------------	-----	------

>A>	+		1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Sep	NEWA
-----	---	--	-----------------------------	---------	-----	--------------	-----	------

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001	Oct 31, 2002	Feb	CPOT
----	---	-----------------	----------------------	---------	-----	--------------	-----	------

TESTOSTERONE

		TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA
--	--	-------------	-------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTIONTHEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC
@		40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC
@		80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC
@		160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC
@		200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC
@		320MG/100ML	N018649	006	Nov 13, 1985	Mar	DISC
@		400MG/100ML	N018649	005	Jul 26, 1982	Mar	DISC

SOLUTION; ORALTHEOPHYLLINE

AA	+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Jun	CTEC
AA		TRIS PHARMA INC	80MG/15ML	A091586	001	Jun 15, 2012	Jun	NEWA

TABLET; ORALTHEOLAIR

+	MEDICIS	125MG	A086399	001		Jul	CAHN
+		250MG	A086399	002		Jul	CAHN

TABLET, EXTENDED RELEASE; ORALUNIPHYL

>D>	@	PURDUE PHARM PRODS	400MG	A087571	001	Sep 01, 1982	Sep	CAHN
>D>	@		600MG	A040086	001	Apr 15, 1996	Sep	CAHN
>A>	@	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Sep	CAHN
>A>	@		600MG	A040086	001	Apr 15, 1996	Sep	CAHN

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTIONTHIAMINE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	100MG/ML	A091623	001	Jun 25, 2012	Jun	NEWA
----	--	---------------------	----------	---------	-----	--------------	-----	------

TIAGABINE HYDROCHLORIDETABLET; ORALGABITRIL

@	CEPHALON	6MG	N020646	006	Nov 29, 2005	Jan	DISC
@		8MG	N020646	007	Nov 29, 2005	Jan	DISC
@		10MG	N020646	008	Nov 29, 2005	Jan	DISC

TINIDAZOLETABLET; ORALTINDAMAX

AB		MISSION PHARMA	250MG	N021618	001	May 17, 2004	Apr	CFTG
AB	+		500MG	N021618	002	May 17, 2004	Apr	CFTG

TINIDAZOLE

AB		NOVEL LABS INC	250MG	A202044	001	Apr 30, 2012	Apr	NEWA
AB			500MG	A202044	002	Apr 30, 2012	Apr	NEWA
AB		ROXANE	250MG	A201172	001	Apr 30, 2012	Apr	NEWA
AB			500MG	A201172	002	Apr 30, 2012	Apr	NEWA

TINZAPARIN SODIUMINJECTABLE; INJECTIONINNOHEP

@	LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000	Jun	DISC
---	---------------	--------------	---------	-----	--------------	-----	------

TIZANIDINE HYDROCHLORIDECAPSULE; ORALTIZANIDINE HYDROCHLORIDE

AB		APOTEX INC	EQ 2MG BASE	A078868	001	Feb 03, 2012	Jan	NEWA
----	--	------------	-------------	---------	-----	--------------	-----	------

CAPSULE; ORALTIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
<u>ZANAFLEX</u>						
AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORALTIZANIDINE HYDROCHLORIDE

>D>	AB	ALPHAPHARM	EQ 2MG BASE	A076282 001	Dec 16, 2003	Sep	CAHN
>D>	AB		EQ 4MG BASE	A076282 002	Dec 16, 2003	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003	Sep	CAHN
>A>	AB		EQ 4MG BASE	A076282 002	Dec 16, 2003	Sep	CAHN
	AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
	AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
	AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOBRAMYCIN SULFATEINJECTABLE; INJECTIONTOBRAMYCIN SULFATE

>D>	AP	AKORN STRIDES	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN
>D>	AP	APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
>A>		@	EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
>A>	AP	PFIZER	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN

TOLBUTAMIDETABLET; ORALTOLBUTAMIDE

	+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
		@ WATSON LABS	500MG	A087318 001		Mar	DISC
		@	500MG	A086109 001		Mar	DISC

TOLCAPONETABLET; ORALTASMAR

	+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
		@	200MG	N020697 002	Jan 29, 1998	May	CAHN

TOLTERODINE TARTRATETABLET; ORALDETROL

>D>		PHARMACIA AND UPJOHN	1MG	N020771 001	Mar 25, 1998	Sep	CFTG
>A>	AB		1MG	N020771 001	Mar 25, 1998	Sep	CFTG
>D>		+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG
>A>	AB	+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG
>A>		TOLTERODINE TARTRATE					
>A>	AB	APOTEX CORP	1MG	A200164 001	Sep 25, 2012	Sep	NEWA
>A>	AB		2MG	A200164 002	Sep 25, 2012	Sep	NEWA

TOPOTECAN HYDROCHLORIDEINJECTABLE; INJECTIONTOPOTECAN HYDROCHLORIDE

AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
AP	ONCO THERAPIES LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012	Aug	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB	ALPHAPHARM	50MG	A075980	001	Nov 21, 2002	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002	Sep	CAHN
		@ SANDOZ	50MG	A075968	001	Jun 25, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2		ACTAVIS	100MG	A091609	001	Jun 27, 2012	Jun	NEWA
AB2			200MG	A091609	002	Jun 27, 2012	Jun	NEWA
AB2			300MG	A091609	003	Jun 27, 2012	Jun	NEWA
AB2		ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Jun	NEWA
AB2			200MG	A200491	002	Jun 27, 2012	Jun	NEWA
AB2			300MG	A200491	003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693	001	May 05, 2005	Mar	CTNA
---	--------------	------	---------	-----	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP		APP PHARMS LLC	100MG/ML	A091596	001	Mar 02, 2012	May	CAHN
>A>	AP	LUITPOLD	100MG/ML	A201885	001	Aug 10, 2011	Sep	CAHN
AP		NEXUS PHARMS	100MG/ML	A091596	001	Mar 02, 2012	Feb	NEWA
>D>	AP	PHARMAFORCE	100MG/ML	A201885	001	Aug 10, 2011	Sep	CAHN

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

>D>	AB	MATRIX LABS LTD	50MG	A090514	001	Jun 02, 2009	Sep	CAHN
>D>	AB		100MG	A090514	002	Jun 02, 2009	Sep	CAHN
>D>	AB		150MG	A090514	003	Jun 02, 2009	Sep	CAHN
>D>	AB		300MG	A090514	004	Jun 02, 2009	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	Sep	CAHN
>A>	AB		100MG	A090514	002	Jun 02, 2009	Sep	CAHN
>A>	AB		150MG	A090514	003	Jun 02, 2009	Sep	CAHN
>A>	AB		300MG	A090514	004	Jun 02, 2009	Sep	CAHN

TRETINOIN

CREAM; TOPICAL

AVITA

AB		MYLAN PHARMS INC	0.025%	N020404	003	Jan 14, 1997	Jun	CAHN
----	--	------------------	--------	---------	-----	--------------	-----	------

RENOVA

+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Jan	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

AB2	+		0.05%	N019963	001	Dec 29, 1995	Jan	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN
----	---	--------------	--------	---------	-----	--------------	-----	------

AB1	+		0.05%	N017522	001		Jan	CAHN
-----	---	--	-------	---------	-----	--	-----	------

AB	+		0.1%	N017340	001		Jan	CAHN
----	---	--	------	---------	-----	--	-----	------

CREAM; TOPICAL

TRETINOIN

AB	PRECISION DERMAT	0.025%	A075264	001	Dec 24, 1998	May	CAHN
	+	0.0375%	A090098	001	Mar 22, 2010	May	CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	May	CAHN
>A>		0.075%	A202209	001	Oct 11, 2012	Sep	NEWA
AB		0.1%	A075213	001	Dec 24, 1998	May	CAHN
AB2	SUNEVA MEDCL	0.05%	A076498	001	Sep 15, 2005	May	CAHN

GEL; TOPICAL

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955	001		Jan	CAHN
AB	+		0.025%	N017579	002		Jan	CAHN

TRETINOIN

AB	PRECISION DERMAT	0.01%	A075589	001	Jun 11, 2002	May	CAHN
AB		0.025%	A075529	001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	VALEANT INTL	0.05%	N016921	001		Jan	CAHN
----	---	--------------	-------	---------	-----	--	-----	------

SWAB; TOPICAL

RETIN-A

	@	VALEANT INTL	0.05%	N016921	002		Jan	CAHN
--	---	--------------	-------	---------	-----	--	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

	@	ABBOTT	0.1MG/INH	N018117	001	Apr 23, 1982	May	DISC
--	---	--------	-----------	---------	-----	--------------	-----	------

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085692	001		Jan	CAHN
AT		0.1%	A085692	003		Jan	CAHN
AT	+	0.5%	A085692	002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003	Jan	CAHN
AT		0.1%	A040467	002	Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085691	001		Jan	CAHN
AT		0.1%	A085691	003		Jan	CAHN
AT		0.5%	A085691	002		Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

AB	TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN
----	-------------	---------------	---------	-----	--------------	-----	------

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

>D>	AB	ALPHAPHARM	0.125MG	A074031	001	Mar 25, 1994	Sep	CAHN
>D>	AB		0.25MG	A074031	002	Mar 25, 1994	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Sep	CAHN
>A>	AB		0.25MG	A074031	002	Mar 25, 1994	Sep	CAHN

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

>D>	AT	ALCON	1%	A074311	001	Oct 06, 1995	Sep	CAHN
-----	----	-------	----	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

>A>	AT	ALCON PHARMS LTD	1%	A074311	001	Oct 06,	1995	Sep	CAHN
-----	----	------------------	----	---------	-----	---------	------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

@ HOSPIRA 100MG/ML

A088804	001	Apr 03,	1987	Jun	DISC
---------	-----	---------	------	-----	------

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

>D>	+	ALLERGAN	60MG	N022103	001	Aug 03,	2007	Sep	CFTG
-----	---	----------	------	---------	-----	---------	------	-----	------

>A>	AB	+	60MG	N022103	001	Aug 03,	2007	Sep	CFTG
-----	----	---	------	---------	-----	---------	------	-----	------

>A>		TROSPIUM CHLORIDE							
-----	--	-------------------	--	--	--	--	--	--	--

>A>	AB	WATSON LABS INC FL	60MG	A091289	001	Oct 12,	2012	Sep	NEWA
-----	----	--------------------	------	---------	-----	---------	------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03,	2012	Mar	NEWA
----	--------------------	---------------	---------	-----	---------	------	-----	------

AB		EQ 1GM BASE	A201506	002	Apr 03,	2012	Mar	NEWA
----	--	-------------	---------	-----	---------	------	-----	------

>D>	AB	MATRIX LABS LTD	EQ 500MG BASE	A078518	001	May 24,	2010	Sep	CAHN
-----	----	-----------------	---------------	---------	-----	---------	------	-----	------

>D>	AB		EQ 1GM BASE	A078518	002	May 24,	2010	Sep	CAHN
-----	----	--	-------------	---------	-----	---------	------	-----	------

>A>	AB	MYLAN PHARMS INC	EQ 500MG BASE	A078518	001	May 24,	2010	Sep	CAHN
-----	----	------------------	---------------	---------	-----	---------	------	-----	------

>A>	AB		EQ 1GM BASE	A078518	002	May 24,	2010	Sep	CAHN
-----	----	--	-------------	---------	-----	---------	------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28,	2009	May	CAHN
---	-------------------	---------	---------	-----	---------	------	-----	------

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29,	2001	May	CAHN
---	-------------------	---------------	---------	-----	---------	------	-----	------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15,	1986	Mar	CFTG
----	------------	---------------	---------	-----	---------	------	-----	------

AB	+	EQ 250MG BASE	N050606	002	Apr 15,	1986	Mar	CFTG
----	---	---------------	---------	-----	---------	------	-----	------

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478	001	Apr 09,	2012	Mar	NEWA
----	-------	---------------	---------	-----	---------	------	-----	------

AB		EQ 250MG BASE	A065478	002	Apr 09,	2012	Mar	NEWA
----	--	---------------	---------	-----	---------	------	-----	------

AB	APP PHARMS LLC	EQ 125MG BASE	A065453	001	Jun 18,	2012	Jun	NEWA
----	----------------	---------------	---------	-----	---------	------	-----	------

AB		EQ 250MG BASE	A065453	002	Jun 18,	2012	Jun	NEWA
----	--	---------------	---------	-----	---------	------	-----	------

AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09,	2012	Mar	NEWA
----	---------------------	---------------	---------	-----	---------	------	-----	------

AB		EQ 250MG BASE	A065490	002	Apr 09,	2012	Mar	NEWA
----	--	---------------	---------	-----	---------	------	-----	------

AB	WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09,	2012	Mar	NEWA
----	-------------	---------------	---------	-----	---------	------	-----	------

AB		EQ 250MG BASE	A065510	002	Apr 09,	2012	Mar	NEWA
----	--	---------------	---------	-----	---------	------	-----	------

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837	001	Aug 10,	2012	Jul	NEWA
----	---------------	------------------	---------	-----	---------	------	-----	------

AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10,	2012	Jul	NEWA
----	------------	------------------	---------	-----	---------	------	-----	------

AP		EQ 10GM BASE/VIAL	A201048	002	Aug 10,	2012	Jul	NEWA
----	--	-------------------	---------	-----	---------	------	-----	------

VANDETANIB

TABLET; ORAL

CAPRELSA

IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
+	300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD	
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD	
AP	+	SUN PHARMA GLOBAL	10MG/VIAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP	+		20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+ LUNDBECK LLC 500MG/PACKET N022006 001 Aug 21, 2009 Apr CAHN

TABLET; ORAL

SABRIL

+ LUNDBECK LLC 500MG N020427 001 Aug 21, 2009 Apr CAHN

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+ FOREST LABS INC 10MG N022567 001 Jan 21, 2011 Apr CRLD

40MG N022567 003 Jan 21, 2011 Apr CRLD

VINCRISTINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+ TALON THERAP 5MG/5ML (1MG/ML) N202497 001 Aug 09, 2012 Aug NEWA

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

AP ONCO THERAPIES LTD EQ 10MG BASE/ML A200148 001 Aug 31, 2012 Aug NEWA

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>A> AP JIANGSU HANSON PHARM EQ 10MG BASE/ML A091106 001 Sep 26, 2012 Sep NEWA

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ GENENTECH 150MG N203388 001 Jan 30, 2012 Jan NEWA

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP + PFIZER 200MG/VIAL N021267 001 May 24, 2002 May CFTG

VORICONAZOLE

AP SANDOZ INC 200MG/VIAL A090862 001 May 30, 2012 May NEWA

TABLET; ORAL

VORICONAZOLE

AB TEVA PHARMS 50MG A091658 001 Apr 06, 2012 Mar NEWA

AB 200MG A091658 002 Apr 06, 2012 Mar NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@ JAZZ PHARMS COMMERCL 200MCG/2ML (100MCG/ML) N021060 003 Dec 28, 2004 Mar CAHN

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML) N021060 003 Dec 28, 2004 Jun CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+ JAZZ PHARMS COMMERCL 100MCG/1ML (100MCG/ML) N021060 002 Dec 28, 2004 Mar CAHN

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	500MCG/5ML (100MCG/ML)	N021060	004	Dec 28,	2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28,	2004	Mar	CAHN
+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28,	2004	Jun	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28,	2004	Jun	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28,	2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

>D>	AB	MATRIX LABS LTD	300MG	A078922	001	Feb 14,	2008	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	300MG	A078922	001	Feb 14,	2008	Sep	CAHN
		@ RANBAXY LABS LTD	300MG	A077327	001	Sep 19,	2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05,	2001	Feb	CFTG
AB			EQ 40MG BASE	N020825	002	Feb 05,	2001	Feb	CFTG
AB			EQ 60MG BASE	N020825	003	Feb 05,	2001	Feb	CFTG
AB			EQ 80MG BASE	N020825	004	Feb 05,	2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02,	2012	Feb	NEWA
AB			EQ 40MG BASE	A077561	002	Mar 02,	2012	Feb	NEWA
AB			EQ 60MG BASE	A077561	003	Mar 02,	2012	Feb	NEWA
AB			EQ 80MG BASE	A077561	004	Mar 02,	2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02,	2012	Feb	NEWA
AB			EQ 40MG BASE	A077565	002	Mar 02,	2012	Feb	NEWA
AB			EQ 60MG BASE	A077565	003	Mar 02,	2012	Feb	NEWA
AB			EQ 80MG BASE	A077565	004	Mar 02,	2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02,	2012	Feb	NEWA
AB			EQ 40MG BASE	A077560	002	Mar 02,	2012	Feb	NEWA
AB			EQ 60MG BASE	A077560	003	Mar 02,	2012	Feb	NEWA
AB			EQ 80MG BASE	A077560	004	Mar 02,	2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562	001	Jun 01,	2012	May	NEWA
AB			EQ 40MG BASE	A077562	002	Jun 01,	2012	May	NEWA
AB			EQ 60MG BASE	A077562	003	Jun 01,	2012	May	NEWA
AB			EQ 80MG BASE	A077562	004	Jun 01,	2012	May	NEWA
AB		WOCKHARDT LTD	EQ 20MG BASE	A090348	001	Sep 05,	2012	Aug	NEWA
AB			EQ 40MG BASE	A090348	002	Sep 05,	2012	Aug	NEWA
AB			EQ 60MG BASE	A090348	003	Sep 05,	2012	Aug	NEWA
AB			EQ 80MG BASE	A090348	004	Sep 05,	2012	Aug	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB		CIPLA LTD	5MG	A077388	001	Jul 30,	2012	Jul	NEWA
AB			10MG	A077388	002	Jul 30,	2012	Jul	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

>D>	AB	ALPHAPHARM	25MG	A077647	001	Dec 22,	2005	Sep	CAHN
>D>	AB		50MG	A077647	002	Dec 22,	2005	Sep	CAHN
>D>	AB		100MG	A077647	003	Dec 22,	2005	Sep	CAHN

CAPSULE; ORAL

ZONISAMIDE

>A>	AB	MYLAN PHARMS INC	25MG	A077647 001	Dec 22, 2005	Sep	CAHN
>A>	AB		50MG	A077647 002	Dec 22, 2005	Sep	CAHN
>A>	AB		100MG	A077647 003	Dec 22, 2005	Sep	CAHN

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
---	-------------	------------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Jul	DISC
---	------------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Jul	DISC
---	------------------	---------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012	Sep	NEWA
-----	--------------------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCRUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

CHLORASCRUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCRUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA
-----------------	-----------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA
---------------------	--	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@	MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
---	-------------	------	---------	-----	--------------	-----	------

+		20MG	N020801	002	Dec 17, 2007	Mar	CAHN
---	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

PEPCID AC

MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
-------------	------	---------	-----	--------------	-----	------

+		20MG	N020325	002	Sep 23, 2003	Mar	CAHN
---	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

PEPCID AC (GELTAB)

MCNEIL CONS 10MG

N020902 001 Aug 05, 1999 Mar CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS 30MG

A091567 002 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 30MG

A079112 002 Feb 08, 2012 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS 30MG

A091567 001 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 30MG

A079112 001 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS 60MG

A091567 004 Feb 06, 2012 Jan NEWA

180MG

A091567 006 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 60MG

A079112 004 Feb 08, 2012 Jan NEWA

180MG

A079112 006 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS 60MG

A091567 003 Feb 06, 2012 Jan NEWA

180MG

A091567 005 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 60MG

A079112 003 Feb 08, 2012 Jan NEWA

180MG

A079112 005 Feb 08, 2012 Jan NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009 Jan CAHN

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+ PFIZER CONS HLTHCARE EQ 200MG BASE

N201803 001 Jun 12, 2012 Jun NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD 15MG

A202194 001 May 18, 2012 Apr NEWA

PERRIGO R AND D 15MG

A202319 001 May 18, 2012 Apr NEWA

WOCKHARDT LTD 15MG

A202727 001 May 18, 2012 Apr NEWA

PREVACID 24 HR

+ NOVARTIS 15MG

N022327 001 May 18, 2009 Apr CFTG

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

WATSON LABS INC 1.5MG

A200670 001 Jul 12, 2012 Jun NEWA

PLAN B

+ TEVA BRANDED PHARM 0.75MG

N021045 002 Aug 24, 2006 May CAHN

PLAN B ONE-STEP

+ DURAMED 1.5MG

N021998 001 Jul 10, 2009 Jun CFTG

LORATADINE

SYRUP; ORAL

LORATADINE

@ RANBAXY LABS LTD 1MG/ML

A076529 001 Aug 20, 2004 Jul DISC

NICOTINEFILM, EXTENDED RELEASE; TRANSDERMAL
NICOTINE

AVEVA	7MG/24HR	A074612 002	Jul 28, 2003	Apr	NEWA
	14MG/24HR	A074612 003	Oct 20, 1997	Apr	NEWA

NICOTINE POLACRILEXTROCHE/LOZENGE; ORAL
NICOTINE POLACRILEX

>A>	PERRIGO R AND D	EQ 2MG BASE	A203690 001	Oct 09, 2012	Sep	NEWA
>A>		EQ 4MG BASE	A203690 002	Oct 09, 2012	Sep	NEWA

POLYETHYLENE GLYCOL 3350FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

>D>	PADDOCK LLC	17GM/SC00PFUL	A090567 001	Oct 15, 2009	Sep	DISC
>A>	@	17GM/SC00PFUL	A090567 001	Oct 15, 2009	Sep	DISC

RANITIDINE HYDROCHLORIDETABLET; ORAL
RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172 001	May 31, 2012	May	NEWA
SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2012

NO SEPTEMBER 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2012 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 32ND EDITION

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

A - 1

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A091294 001					>A> PC	Dec 16, 2012
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	RE42462	Jul 29, 2018	DS			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	8216289	May 01, 2018	U-289			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>APREPITANT - EMEND</u>						
N021549 001	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 002	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 003	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1282			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
	>A> 8263054	Aug 25, 2023	U-1277			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	>A> 8278353	Mar 16, 2025	DP			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 001	>A> 6002008	Mar 27, 2018	DS DP U-1284		>A> NCE	Sep 04, 2017
	>A> 7417148	Jan 23, 2026	U-1283		>A> ODE	Sep 04, 2019
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7919625	Dec 11, 2025	DP			
	>A> RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 002	>A> 6002008	Mar 27, 2018	DS DP U-1284		>A> NCE	Sep 04, 2017
	>A> 7417148	Jan 23, 2026	U-1283		>A> ODE	Sep 04, 2019
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7919625	Dec 11, 2025	DP			
	>A> RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003					NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004					NDF	Aug 30, 2013
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001	>A> 8263580	May 26, 2026	DP U-1280		>A> I-657	Sep 27, 2015
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	>A> 8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	>A> 8247400	Feb 10, 2031	DP U-282			
<u>CEVIMELINE HYDROCHLORIDE - CEVIMELINE</u>						
A091260 001					>A> PC	Apr 06, 2013
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N203155 001					>A> NCE >A> W	Sep 12, 2017 Sep 12, 2017
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	>A> 5814639	Sep 29, 2015	DS DP			
	>A> 5914331	Jul 02, 2017	DS			
	>A> 5922695	Jul 25, 2017	DS U-257			
	>A> 5935946	Jul 25, 2017	DS DP U-257			
	>A> 5977089	Jul 25, 2017	DS DP U-257			
	>A> 6043230	Jul 25, 2017	U-257			
	>A> 6642245	Nov 04, 2020	U-257			
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 7176220	Nov 20, 2023	DS DP U-257			
	>A> 7635704	Jan 12, 2026	DS DP U-257			
	>A> 8148374	Sep 03, 2029	DS DP U-1279			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	8217057	Nov 06, 2029	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	>A> 8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	>A> 8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	>A> 8101582	Dec 19, 2027	DP U-1082			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N021394 001	>A> 8263647	May 30, 2022	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2013	DS DP U-992			
	5223510	Jul 26, 2013	DS DP U-1261			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7160870	Nov 20, 2022	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	7160870	Nov 20, 2022	DS DP U-930			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001	>A> 7709517	Aug 13, 2027	DS DP		NCE	Aug 31, 2017
	>A> 8183274	May 15, 2026	U-1281			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESZOPICLONE - LUNESTA							
N021476 001	6319926	Jan	16, 2012	U-620			
	6319926*PED	Jul	16, 2012				
	6444673	Feb	14, 2014	DS DP			
	6444673*PED	Aug	14, 2014				
	6864257	Aug	30, 2012	U-629			
	6864257*PED	Mar	02, 2013				
	7381724	Jan	16, 2012	DS DP U-629			
	7381724*PED	Jul	16, 2012				
ESZOPICLONE - LUNESTA							
N021476 002	6319926	Jan	16, 2012	U-620			
	6319926*PED	Jul	16, 2012				
	6444673	Feb	14, 2014	DS DP			
	6444673*PED	Aug	14, 2014				
	6864257	Aug	30, 2012	U-629			
	6864257*PED	Mar	02, 2013				
	7381724	Jan	16, 2012	DS DP U-629			
	7381724*PED	Jul	16, 2012				
ESZOPICLONE - LUNESTA							
N021476 003	6319926	Jan	16, 2012	U-620			
	6319926*PED	Jul	16, 2012				
	6444673	Feb	14, 2014	DS DP			
	6444673*PED	Aug	14, 2014				
	6864257	Aug	30, 2012	U-629			
	6864257*PED	Mar	02, 2013				
	7381724	Jan	16, 2012	DS DP U-629			
	7381724*PED	Jul	16, 2012				
ETONOGESTREL - NEXPLANON							
N021529 002						NP	May 31, 2014
ETRAVIRINE - INTELENCE							
N022187 001	6878717	Nov	05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov	05, 2019	U-1237			
	6878717	Nov	05, 2019	U-1016			
	7037917	Dec	13, 2020	DS DP U-256			
	7037917	Dec	13, 2020	DS DP U-1237			
	7037917	Dec	13, 2020	DS DP U-1016			
ETRAVIRINE - INTELENCE							
N022187 002	6878717	Nov	05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov	05, 2019	U-1237			
	6878717	Nov	05, 2019	U-1016			
	7037917	Dec	13, 2020	DS DP U-256			
	7037917	Dec	13, 2020	DS DP U-1237			
	7037917	Dec	13, 2020	DS DP U-1016			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
N022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001	>A> 5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	>A> 5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	>A> 6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	>A> 7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	>A> 7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002	>A> 5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	>A> 5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	>A> 6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	>A> 7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	>A> 7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003	>A> 5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	>A> 5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	>A> 6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	>A> 7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	>A> 7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004					M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	>A> 8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8062264	Apr 05, 2026	DP			
	8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
	>A> 8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
	>A> 8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 001					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 002					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 003					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 004					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 005					>A> PC	Mar 20, 2013
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 004	5702725	Jul 07, 2014	DP U-1043		>A> NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8188146	Jan 27, 2020	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	8236816	Dec 11, 2029	U-68			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	8222270	Dec 11, 2029	U-68			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>IRON SUCROSE - VENOFER</u>						
N021135 001					>A> NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 002					>A> NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 004					>A> NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024	U-1251			
	8207215*PED	Nov 28, 2024				
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LEVETIRACETAM - KEPRA</u>						
N021035 001					NPP PED	Dec 16, 2014 Jun 16, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPRA</u>						
N021035	002				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035	003				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035	004				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021505	001				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064	001	>A> 5698558	Jul 26, 2013	U-812		
		>A> 5698558*PED	Jan 26, 2014			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157	001	>A> 5698558	Jul 26, 2013	U-852		
		>A> 5698558*PED	Jan 26, 2014			
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623	001	6465709	Jul 07, 2020	DP		
<u>LINACLOTIDE - LINZESS</u>						
N202811	001	>A> 7304036	Jan 28, 2024	DS DP	U-1278	NCE Aug 30, 2017
		>A> 7371727	Jan 28, 2024	DS		
		>A> 7704947	Jan 28, 2024	DS DP		
		>A> 7745409	Jan 28, 2024	DS DP		
		>A> 8080526	Jan 28, 2024	DS DP		
		>A> 8110553	Jan 28, 2024		U-1278	
<u>LINACLOTIDE - LINZESS</u>						
N202811	002	>A> 7304036	Jan 28, 2024	DS DP	U-1278	NCE Aug 30, 2017
		>A> 7371727	Jan 28, 2024	DS		
		>A> 7704947	Jan 28, 2024	DS DP		
		>A> 7745409	Jan 28, 2024	DS DP		
		>A> 8080526	Jan 28, 2024	DS DP		
		>A> 8110553	Jan 28, 2024		U-1278	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		M-121	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-118	Aug 13, 2015
	6890898	Feb 02, 2019	U-493			
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LOPINAVIR; RITONAVIR - KALETRA						
N021906 001	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2025				
LOPINAVIR; RITONAVIR - KALETRA						
N021906 002	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2025				
LORCASERIN HYDROCHLORIDE - BELVIQ						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1255			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
LUBIPROSTONE - AMITIZA						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 001					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 002					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 001	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 002	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 003	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	>A> 6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	>A> 6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	>A> 6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	>A> 6602911	Jan 14, 2023	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	>A> 8282966	Jun 30, 2029	U-1286			
	>A> 8282966*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	>A> 8282966	Jun 30, 2029	U-1286			
	>A> 8282966*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001					M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002					M-119	Aug 29, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003					M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004					M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005					M-119	Aug 29, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	>A> 8263600	Apr 01, 2022	DP			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 003	8168218	Jan 07, 2028	DP U-1269			
<u>PREGABALIN - LYRICA</u>						
N021446 001	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 002	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
PREGABALIN - LYRICA								
N021446 005	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 006	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 007	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 008	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N022488 001	6001876	Dec	30, 2018	U-819	Y			
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL								
N021438 001	6500454	Oct	04, 2021	DP				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL								
N021438 002	6500454	Oct	04, 2021	DP				
RALTEGRAVIR POTASSIUM - ISENTRESS								
N022145 001						M-114	Mar	28, 2015
RALTEGRAVIR POTASSIUM - ISENTRESS								
N203045 001	7169780	Oct	03, 2023	DS DP		M-114	Mar	28, 2015
	7217713	Oct	21, 2022	U-257				
	7435734	Oct	21, 2022	U-257				
	7754731	Mar	11, 2029	DS DP U-257				
RALTEGRAVIR POTASSIUM - ISENTRESS								
N203045 002	7169780	Oct	03, 2023	DS DP		M-114	Mar	28, 2015
	7217713	Oct	21, 2022	U-257				
	7435734	Oct	21, 2022	U-257				
	7754731	Mar	11, 2029	DS DP U-257				
REGADENOSON - LEXISCAN								
N022161 001	8106029	Jun	22, 2019	U-1042				
	8106183	Feb	02, 2027	DS				
	8133879	Jun	22, 2019	DP				
	8183226	Jun	22, 2019	U-116				
REGORAFENIB - STIVARGA								
N203085 001						>A> NCE	Sep	27, 2017
REPAGLINIDE - PRANDIN								
N020741 001	6677358	Jun	12, 2018	DS DP U-1265				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N020222 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	8246989	Jan 16, 2026	DP			
<u>RITONAVIR - NORVIR</u>						
N022417 001	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2925				
<u>RIVASTIGMINE - EXELON</u>						
N022083 005	>A> 5602176	Feb 11, 2014	DS DP U-322		>A> NS	Aug 31, 2015
	>A> 6316023	Jan 08, 2019	DP			
	>A> 6335031	Jan 08, 2019	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			M-61 PED PED	Aug 30, 2015 Mar 01, 2016 Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF PED PED	Nov 20, 2012 Mar 01, 2016 May 20, 2013
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109 001					NDF PED	Aug 30, 2015 Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SILDENAFIL CITRATE - VIAGRA						
N020895 002	5250534	Mar 27, 2012	U-155			
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019				
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 003	5250534	Mar 27, 2012	U-155			
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019				
	6469012*PED	Apr 22, 2020				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 001	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 002	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 003	8168637	Jun 26, 2022	DP U-1188			
SODIUM NITRITE - SODIUM NITRITE						
N203922 001					ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM						
N021196 001	>A> 8263650	Dec 22, 2019	DP U-1102			
	>A> 8263650	Dec 22, 2019	DP U-1101			
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N203923 001					ODE	Jan 14, 2018
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	7776007	Nov 22, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	>A> 8267903	Mar 18, 2023	DP			
TAFLUPROST - ZIOPTAN						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
TALIGLUCERASE ALFA - ELELYSO						
N022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
TAPENTADOL HYDROCHLORIDE - NUCYNТА ER						
N200533 001	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N200533 002	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N200533 003	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N200533 004	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N200533 005	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858 001					ODE	Aug 13, 2019
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2015
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-1275			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 004	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
					PED	Jul 18, 2015
					PED	Apr 01, 2014
					PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-999			
	>A> 5935946	Jul 25, 2017	DS DP U-1275			
	>A> 5935946	Jul 25, 2017	DS DP U-248			
	>A> 5935946	Jul 25, 2017	DS DP U-250			
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 001	>A> 5459163	Oct 17, 2012	DP		>A> NCE	Sep 12, 2017
	>A> 5679709	Oct 21, 2014	DP U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 002	>A> 5459163	Oct 17, 2012	DP		>A> NCE	Sep 12, 2017
	>A> 5679709	Oct 21, 2014	DP U-1285			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002	>A> 5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	>A> 6020311	May 26, 2015	DS DP U-1100			
	>A> 7144577	Jul 14, 2020	U-1100			
	>A> 7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 002					>A> NP	Apr 29, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 003					>A> NP	Apr 29, 2014
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	6455557	Nov 28, 2021		Y		
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	>A> 8273795	May 20, 2026	U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	>A> 8268299	Oct 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1258			
	8211880	Mar 10, 2029	U-1257			
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		>A> ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020	U-1271			
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	------------------------	-----------------------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>